

STN Columbus

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAR 31 IFICDB, IFIPAT, and IFIUIDB enhanced with new custom
IPC display formats
NEWS 3 MAR 31 CAS REGISTRY enhanced with additional experimental
spectra
NEWS 4 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.
applications updated
NEWS 5 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 6 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 7 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 8 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
predefined hit display formats
NEWS 9 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 10 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 11 MAY 30 INPAFAMDB now available on STN for patent family
searching
NEWS 12 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology
sequence search option
NEWS 13 JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 14 JUN 06 KOREAPAT updated with 41,000 documents
NEWS 15 JUN 13 USPATFULL and USPAT2 updated with 11-character
patent numbers for U.S. applications
NEWS 16 JUN 19 CAS REGISTRY includes selected substances from
web-based collections
NEWS 17 JUN 25 CA/CAPLUS and USPAT databases updated with IPC
reclassification data
NEWS 18 JUN 30 AEROSPACE enhanced with more than 1 million U.S.
patent records
NEWS 19 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
options to display authors and affiliated
organizations
NEWS 20 JUN 30 STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in
NEWS 21 JUN 30 STN AnaVist enhanced with database content from EPFULL
NEWS 22 JUL 28 CA/CAPLUS patent coverage enhanced
NEWS 23 JUL 28 EPFULL enhanced with additional legal status
information from the epline Register
NEWS 24 JUL 28 IFICDB, IFIPAT, and IFIUIDB reloaded with enhancements
NEWS 25 JUL 28 STN Viewer performance improved
NEWS 26 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 27 AUG 13 CA/CAPLUS enhanced with printed Chemical Abstracts
page images from 1967-1998

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 01:39:32 ON 15 AUG 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	1.68	1.68

FILE 'REGISTRY' ENTERED AT 01:44:03 ON 15 AUG 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 13 AUG 2008 HIGHEST RN 1040889-91-5
 DICTIONARY FILE UPDATES: 13 AUG 2008 HIGHEST RN 1040889-91-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> e cgp57148b/cn

E1	1	CGP-50281/CN
E2	1	CGP28,237/CN
E3	0 -->	CGP57148B/CN
E4	1	CGP60536B/CN
E5	1	CGPM 9/CN
E6	1	CGPS 910/CN
E7	2	CGR/CN
E8	1	CGR (RESIST)/CN
E9	1	CGR (STABILIZER)/CN
E10	1	CGR 2205/CN
E11	1	CGR 248/CN
E12	1	CGR 811/CN

=> e cgp 57148b/cn

E1	1	CGP 57108/CN
E2	1	CGP 57148/CN
E3	1 -->	CGP 57148B/CN
E4	1	CGP 57250/CN
E5	1	CGP 57380/CN
E6	1	CGP 57418B/CN
E7	1	CGP 57604/CN
E8	1	CGP 57698/CN
E9	1	CGP 57700/CN
E10	1	CGP 57813/CN
E11	1	CGP 57976/CN
E12	1	CGP 58238/CN

=> s e3

L1 1 "CGP 57148B"/CN


=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
 RN 220127-57-1 REGISTRY
 ED Entered STN: 03 Mar 1999
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, methanesulfonate (1:1) (CA INDEX
 NAME)
 OTHER CA INDEX NAMES:
 CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-
 pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI)
 OTHER NAMES:

CN **CGP 57148B**
 CN Gleevac
 CN Gleevec
 CN Glivec
 CN Imatinib mesilate
 CN Imatinib mesylate
 CN STI 571
 MF C29 H31 N7 O . C H4 O3 S
 CI COM
 SR CA
 LC STN Files: ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CHEMCATS,
 CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSPATENTS, IMSRESEARCH, IPA, MRCK*,
 PATDPASPC, PHAR, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USPAT2,
 USPATFULL
 (*File contains numerically searchable property data)


CM 1

CRN 152459-95-5
 CMF C29 H31 N7 O



CM 2

CRN 75-75-2
 CMF C H4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2285 REFERENCES IN FILE CA (1907 TO DATE)
 24 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2305 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file merck
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
8.07	9.75

FILE 'MRCK' ENTERED AT 01:45:00 ON 15 AUG 2008
 COPYRIGHT (C) 2008 Merck & Co., Inc., Whitehouse Station, New Jersey, USA. All Rights Reserved
 FILE COVERS FROM LATE 19TH CENTURY TO PRESENT. LAST UPDATE: AUGUST 2008


THE MERCK INDEX ONLINE is a service mark of Merck & Co., Inc., Whitehouse Station, NJ, USA and is registered in the United States Patent and Trademark Office.

=> s l1
 L2 1 L1

=> d all

L2 ANSWER 1 OF 1 MRCK COPYRIGHT (C) 2008 Merck and Co., Inc.,
 Whitehouse Station, New Jersey, USA. All rights reserved. on STN
 MERCK Number (MNO): 1404902

CAS Registry No. (RN): 152459-95-5
 MERCK Index Name (MIN): Imatinib
 CA Index Name (CN): 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide
 Synonym(s) (CN): N-[5-[4-(4-methylpiperazinomethyl)benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidineamine
 File Segment. (FS): Active Monographs
 Molecular Form. (MF): C₂₉ H₃₁ N₇ O
 Wgt Composition (COMP): C 70.57%, H 6.33%, N 19.86%, O 3.24%.
 Molecular Weight (MW): 493.60
 References (RE): Tyrosine kinase inhibitor; highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Also shown to inhibit the transmembrane receptor KIT and platelet-derived growth factor (PDGF) receptors. Prepn: J. Zimmermann, EP 564409; idem, US 5521184 (1993, 1996 both to Ciba-Geigy); idem et al., Bioorg. Med. Chem. Lett. 7, 187 (1997). Structural mechanism of ABL specificity: T. Schindler et al., Science 289, 1938 (2000). Activity vs KIT and PDGF receptor kinases: E. Buchdunger et al., J. Pharmacol. Exp. Ther. 295, 139 (2000). Clinical trial in CML: H. Kantarjian et al., N. Engl. J. Med. 346, 645 (2002); in gastrointestinal stromal tumors related to KIT: G. D. Demetri et al., ibid. 347, 472 (2002). Review of clinical experience: D. G. Savage, K. H. Antman, ibid. 346, 683-693 (2002); and pharmacology: V. K. Pindolia et al., Pharmacotherapy 22, 1249-1265 (2002); and development of therapeutic target: B. J. Druker, Adv. Cancer Res. 91, 1-30 (2004).



Melting Point (MP):

Value
 MP
 deg C
 =====
 211 - 213

Other Properties (OCPP):

mp 211-213° . pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52.

== DERIVATIVE == (1): Methanesulfonate

CAS Registry No. (RN.DRV): **220127-57-1**

Drug Code(s) (CN.DRV): STI-571; CGP-57148B

Trade Name(s) (CN.DRV): Gleevec (Novartis Pharma AG; Novartis); Glivec (Novartis Pharma AG; Novartis)


Lin. Str. Form. (LSF.DRV): C₂₉ H₃₁ N₇ O . C H₃ S O₃ H

Wgt Composition (COMP.DRV): C 61.10%, H 5.98%, N 16.63%, O 10.85%, S 5.44%.


Molecular Weight (MW.DRV): 589.71

References (RE.DRV): Prepn of crystalline form: J. Zimmermann et al., WO 9903854 (1999 to Novartis).

CM 1



CM 2



Melting Point (MP.DRV):

Deriv. Number	Derivative Type	Value MP.DRV deg C
1	Methanesulfonate	217

Other Properties (OCPD.DRV):

Occurs in 2 crystalline modifications. α -form, begins to melt at 226°; β -form, mp 217°. Lipophilic at pH 7.4. Soly in water: >100 g/l (pH 4.2); 49 mg/l (pH 7.4).

Therapeutic Codes (THER):

Antineoplastic.

Referenced Patent (RPN):

EP564409; US5521184; WO9903854

=> file ca

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.79

12.54

FILE 'CA' ENTERED AT 01:45:53 ON 15 AUG 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2008 VOL 149 ISS 7

FILE LAST UPDATED: 7 Aug 2008 (20080807/ED)

CA now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1

L3 2285 L1

=> s (diabete?)/ab,bi

93483 (DIABETE?)/AB

136470 (DIABETE?)/BI

L4 136470 (DIABETE?)/AB,BI

=> s l3 and l4

L5 41 L3 AND L4

=> d 1-41

L5 ANSWER 1 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 149:128862 CA

TI Preparation of pyridinyl-substituted pyrimidine derivatives as inhibitors of cyclin-dependently kinase (CDK)

IN Beckwith, Rohan Eric John; Curtis, Daniel Tim; Harrington, Edmund; Hinrichs, Jurgen Hans-Hermann; Tallarico, John Anthony

PA Novartis AG, Switz.

SO PCT Int. Appl., 113pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008079933	A2	20080703	WO 2007-US88292	20071220
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US	2006-871471P	P	20061222		

L5 ANSWER 2 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 149:128861 CA

TI Preparation of (indol-4-yl)pyrimidin-2-ylamine derivatives as cyclin-dependent kinase inhibitors

IN Beckwith, Rohan Eric John

PA Novartis A.-G., Switz.

SO PCT Int. Appl., 82pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008079918	A1	20080703	WO 2007-US88267	20071220
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US	2006-871469P	P	20061222		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 149:70417 CA

TI Methods, treatments, and compositions for modulating hedgehog pathways using inositols, folates, and other drugs to prevent congenital malformations and cancer

IN Jennings-Spring, Barbara L.

PA USA

SO U.S. Pat. Appl. Publ., 57pp., Cont.-in-part of U.S. Ser. No. 591,398.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080138379	A1	20080612	US 2007-1869	20071213
	US 20080103116	A1	20080501	US 2006-591398	20061101
PRAI	US 2006-591398	A2	20061101		
OS	MARPAT 149:70417				

L5 ANSWER 4 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:579588 CA

TI Methods and compositions using chelator-antibody conjugates

IN Kurzrock, Razelle; Gong, Jing; Yang, David J.; Kohanim, Saady

PA The Board of Regents of the University of Texas System, USA

SO PCT Int. Appl., 71pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008064040	A2	20080529	WO 2007-US84694	20071114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2006-867008P	P	20061122		

L5 ANSWER 5 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:575318 CA

TI Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenous leukemia (CML)

AU Tsapas, Apostolos; Vlachaki, Efthymia; Sarigianni, Maria; Klonizakis, Filippos; Paletas, Konstantinos

CS Metabolic Diseases Unit, 2nd Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

SO Leukemia Research (2008), 32(4), 674-675

CODEN: LEREDD; ISSN: 0145-2126

PB Elsevier Ltd.

DT Journal; General Review

LA English

L5 ANSWER 6 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:509715 CA

TI Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet

AU Haegerkvist, Robert; Jansson, Leif; Welsh, Nils

CS Department of Medical Cell Biology, Uppsala University, Uppsala, S-75123, Swed.

SO Clinical Science (2008), 114(1/2), 65-71

CODEN: CSCIAE; ISSN: 0143-5221

PB Portland Press Ltd.

DT Journal

LA English

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:285065 CA

TI Quinoline compounds as novel high affinity kinase ligands and their preparation, pharmaceutical compositions and use in the treatment of CDK2-mediated diseases
IN Deng, Yongqi; Curran, Patrick J.; Shipps, Gerald W.; Zhao, Lianyun; Siddiqui, M. Arshad; Popovici-Muller, Janeta; Duca, Jose S.; Hruza, Alan W.; Fischmann, Thierry O.; Madison, Vincent S.; Zhang, Rumin; Mcnemar, Charles W.; Mayhood, Todd W.; Windsor, William T.; Lees, Emma M.; Parry, David A.
PA Schering Corporation, USA
SO U.S. Pat. Appl. Publ., 158pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20080045568	A1	20080221	US 2006-504869	20060816
PRAI	US 2006-504869		20060816		
OS	MARPAT 148:285065				

L5 ANSWER 8 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:229358 CA
TI Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor
AU Haap, M.; Gallwitz, B.; Thamer, C.; Muessig, K.; Haering, H.-U.; Kanz, L.; Hartmann, J. T.
CS Department of Endocrinology, Metabolism, Nephrology, Clinical Chemistry and Vascular Medicine, Eberhard-Karls-University of Tuebingen, Germany
SO Journal of Endocrinological Investigation (2007), 30(8), 688-692
CODEN: JEIND7; ISSN: 0391-4097
PB Editrice Kurtis
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 148:206666 CA
TI Mucin MUC1 interaction with Abl and the use of agents that prevent such interaction for treatment of cancer and other associated disorders
IN Kufe, Donald W.
PA Dana-Farber Cancer Institute, Inc., USA
SO PCT Int. Appl., 134pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008014490	A2	20080131	WO 2007-US74657	20070727
	WO 2008014490	A3	20080522		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	US 20080107661	A1	20080508	US 2007-829687	20070727
PRAI	US 2006-834018P	P	20060728		

L5 ANSWER 10 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 147:486223 CA
TI Substituted cis- and trans-stilbenes as therapeutic agents and their

preparation
 IN Vander Jagt, David L.; Deck, Lorraine M.
 PA USA
 SO U.S. Pat. Appl. Publ., 40pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070249647	A1	20071025	US 2007-789583	20070425
PRAI	US 2006-794765P	P	20060425		
OS	MARPAT 147:486223				

L5 ANSWER 11 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 147:401089 CA
 TI Site-specific enzymatic deposition of metal in situ and use for diagnostic biomarker chromogenic immunohistochemical detection in situ
 IN Hainfeld, James F.; Liu, Wenqiu
 PA USA
 SO U.S. Pat. Appl. Publ., 41pp., Cont.-in-part of U.S. Ser. No. 627,735.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070224625	A1	20070927	US 2007-714682	20070305
	US 20020142411	A1	20021003	US 2001-822131	20010330
	US 6670113	B2	20031230		
	US 7183072	B1	20070227	US 2003-658609	20030908
	US 20070122833	A1	20070531	US 2007-627735	20070126
PRAI	US 2001-822131	A2	20010330		
	US 2003-658609	A3	20030908		
	US 2007-627735	A2	20070126		

L5 ANSWER 12 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 147:357201 CA
 TI Methods for regulating neurotransmitter systems by inducing counteradaptations
 IN Michalow, Alexander
 PA USA
 SO PCT Int. Appl., 136pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007100775	A2	20070907	WO 2007-US4959	20070227
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2006-777190P	P	20060227		
	US 2006-858186P	P	20061109		
OS	MARPAT 147:357201				

L5 ANSWER 13 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 147:227169 CA
 TI Use of aminopyrimidine compounds in the treatment of immune disorders

IN Bluestone, Jeffrey A.; Weiss, Arthur
 PA The Regents of the University of California, USA
 SO PCT Int. Appl., 57pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007089716	A2	20070809	WO 2007-US2423	20070129
	WO 2007089716	A3	20080117		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2006-764492P	P	20060201		
OS	MARPAT 147:227169				

L5 ANSWER 14 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:521831 CA
 TI Preparation of six membered heteroaromatic, particularly pyrimidine and triazine, inhibitors targeting resistant kinase mutations for treating angiogenic and hematological associated disorders
 IN Cao, Jianguo; Hood, John; Lohse, Dan; Mak, Chi Ching; Mc Pherson, Andrew; Noronha, Glenn; Pathak, Ved; Renick, Joel; Soll, Richard M.; Zeng, Binqi; Chow, Chun; Palanki, Moorthy; Dneprovskaja, Elena
 PA Targen, Inc., USA
 SO PCT Int. Appl., 389pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007056075	A2	20070518	WO 2006-US42838	20061031
	WO 2007056075	A3	20070920		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20070149508	A1	20070628	US 2006-591076	20061031
	US 20070161645	A1	20070712	US 2006-591252	20061031
PRAI	US 2005-733115P	P	20051102		
OS	MARPAT 146:521831				

L5 ANSWER 15 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:521787 CA
 TI Thiazoles as inhibitors targeting resistant and kinase mutations and their preparation and use in the treatment of angiogenic-associated or hematological disorders
 IN Cao, Jianguo; Hood, John; Lohse, Dan; Mak, Chi Ching; Mc Pherson, Andrew; Noronha, Glenn; Pathak, Ved; Renick, Joel; Soll, Richard M.; Zeng, Binqi; Chow, Chun; Palanki, Moorthy; Dneprovskaja, Elena
 PA Targen, Inc., USA

SO PCT Int. Appl., 93pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007056023	A2	20070518	WO 2006-US42697	20061031
	WO 2007056023	A3	20071018		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20070149508	A1	20070628	US 2006-591076	20061031
	US 20070161645	A1	20070712	US 2006-591252	20061031
PRAI	US 2005-733115P	P	20051102		
OS	MARPAT 146:521787				

L5 ANSWER 16 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:288146 CA

TI Amelioration of **diabetes** by imatinib mesylate (Gleevec): role of β -cell NF- κ B activation and anti-apoptotic preconditioning

AU Haegerkvist, Robert; Sandler, Stellan; Mokhtari, Dariush; Welsh, Nils

CS Department of Medical Cell Biology, Uppsala University, Uppsala, Swed.

SO FASEB Journal (2007), 21(2), 618-628

CODEN: FAJOEC; ISSN: 0892-6638

PB Federation of American Societies for Experimental Biology

DT Journal

LA English

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:274238 CA

TI Novel high affinity quinoline-based kinase ligands and their preparation, pharmaceutical compositions and use in the treatment and prevention of diseases

IN Deng, Yongqi; Curran, Patrick J.; Shipps, Gerald W., Jr.; Zhao, Lianyun; Siddiqui, M. Arshad; Popovici-Muller, Janeta; Duca, Jose S.; Hruza, Alan W.; Fischmann, Thierry O.; Madison, Vincent S.; Zhang, Rumin; McNemar, Charles Wayne; Mayhood, Todd W.; Windsor, William T.; Lees, Emma M.; Parry, David A.

PA Schering Corporation, USA

SO PCT Int. Appl., 201pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007022241	A2	20070222	WO 2006-US31945	20060816
	WO 2007022241	A3	20070927		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,			

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 CA 2619706 A1 20070222 CA 2006-2619706 20060816
 EP 1931657 A2 20080618 EP 2006-801601 20060816
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
 MX 200802363 A 20080318 MX 2008-2363 20080218
 PRAI US 2005-709142P P 20050817
 WO 2006-US31945 W 20060816
 OS MARPAT 146:274238

L5 ANSWER 18 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:274209 CA
 TI Novel high affinity thiophene-based and furan-based kinase ligands and their preparation, pharmaceutical compositions and use in the treatment of CDK-2 mediated diseases
 IN Deng, Yongqi; Zhao, Lianyun; Shipps, Gerald W., Jr.; Curran, Patrick J.; Siddiqui, M. Arshad; Zhang, Rumin; McNemar, Charles W.; Mayhood, Todd W.; Windsor, William T.; Lees, Emma M.; Parry, David A.
 PA Schering Corporation, USA
 SO PCT Int. Appl., 127pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007022258	A1	20070222	WO 2006-US31973	20060816
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	CA 2619790	A1	20070222	CA 2006-2619790	20060816
	US 20070043045	A1	20070222	US 2006-505263	20060816
	EP 1928865	A1	20080611	EP 2006-801620	20060816
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	MX 200802364	A	20080318	MX 2008-2364	20080218
PRAI	US 2005-709143P	P	20050817		
	WO 2006-US31973	W	20060816		
OS	MARPAT 146:274209				

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:266400 CA
 TI Imatinib mesylate (Gleevec) protects against streptozotocin-induced **diabetes** and islet cell death in vitro
 AU Haegerkvist, Robert; Makeeva, Natalia; Elliman, Stephen; Welsh, Nils
 CS Department of Medical Cell Biology, Biomedicum, Uppsala University, Uppsala, S-75123, Swed.
 SO Cell Biology International (2006), 30(12), 1013-1017
 CODEN: CBIIEV; ISSN: 1065-6995
 PB Elsevier B.V.
 DT Journal
 LA English
 RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 20 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:251861 CA
 TI Preparation of bis-aryl amide compounds for treating Lck and c-kit kinase mediated diseases
 IN Dimauro, Erin F.; Bemis, Jean E.; Chaffee, Stuart; Chen, Ning; Hu, Essa; Kunz, Roxanne; Martin, Matthew W.; McGowen, David C.; Rumfelt, Shannon
 PA Amgen Inc., USA
 SO PCT Int. Appl., 229 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007022380	A2	20070222	WO 2006-US32183	20060815
	WO 2007022380	A3	20070621		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	US 20070072862	A1	20070329	US 2006-503551	20060811
	AU 2006279372	A1	20070222	AU 2006-279372	20060815
	CA 2618393	A1	20070222	CA 2006-2618393	20060815
	EP 1928844	A2	20080611	EP 2006-824821	20060815
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRAI	US 2005-708720P	P	20050815		
	US 2006-503551	A	20060811		
	WO 2006-US32183	W	20060815		
OS	MARPAT 146:251861				

L5 ANSWER 21 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:244343 CA
 TI Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
 IN Fogelman, Alan M.; Navab, Mohamad
 PA The Regents of the University of California, USA
 SO U.S. Pat. Appl. Publ., 313pp., Cont.-in-part of U.S. Ser. No. 423,830.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070032430	A1	20070208	US 2006-407390	20060418
	US 6664230	B1	20031216	US 2000-645454	20000824
	US 20030045460	A1	20030306	US 2001-896841	20010629
	US 6933279	B2	20050823		
	CN 1375299	A	20021023	CN 2001-103876	20010823
	CN 1739787	A	20060301	CN 2005-10103876	20010823
	CN 1911439	A	20070214	CN 2006-10100670	20010823
	CN 1931358	A	20070321	CN 2006-10100667	20010823
	CN 1931359	A	20070321	CN 2006-10100669	20010823
	CN 1943781	A	20070411	CN 2006-10100668	20010823
	EP 1864675	A1	20071212	EP 2007-7775	20010823
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR				
	US 20030171277	A1	20030911	US 2002-187215	20020628
	US 7144862	B2	20061205		
	US 20030229015	A1	20031211	US 2002-273386	20021016
	US 7166578	B2	20070123		
	US 20040266671	A1	20041230	US 2003-423830	20030425

	US 7199102	B2	20070403		
	JP 2006056899	A	20060302	JP 2005-304531	20051019
	JP 2006312650	A	20061116	JP 2006-220831	20060814
	JP 2007277250	A	20071025	JP 2007-118451	20070427
	US 20080095821	A1	20080424	US 2007-830497	20070730
	JP 2008150358	A	20080703	JP 2007-250264	20070926
	AU 2007237157	A1	20071213	AU 2007-237157	20071126
PRAI	US 2000-645454	A2	20000824		
	US 2001-896841	A2	20010629		
	US 2002-187215	A2	20020628		
	US 2002-273386	A2	20021016		
	US 2003-423830	A2	20030425		
	US 2005-676431P	P	20050429		
	US 2005-697495P	P	20050707		
	CN 2001-103876	A3	20010823		
	CN 2001-817280	A3	20010823		
	CN 2005-10103876	A3	20010823		
	EP 2001-966198	A3	20010823		
	JP 2002-520844	A3	20010823		
	WO 2001-US26497	A2	20010823		
	JP 2005-304531	A3	20051019		
	AU 2006-200035	A3	20060106		
	US 2006-407390	A1	20060418		
	JP 2006-220831	A3	20060814		
OS	MARPAT 146:244343				

L5 ANSWER 22 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:38497 CA

TI Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections

AU Mumprecht, Sabine; Matter, Matthias; Pavelic, Viktor; Ochsenbein, Adrian F.

CS Tumor Immunology, Department of Clinical Research, University of Berne, Bern, Switz.

SO Blood (2006), 108(10), 3406-3413
CODEN: BLOOAW; ISSN: 0006-4971

PB American Society of Hematology

DT Journal

LA English

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 23 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 146:740 CA

TI Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

IN Fogelman, Alan M.; Navab, Mohamad

PA The Regents of the University of California, USA

SO PCT Int. Appl., 143pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2006118805	A2	20061109	WO 2006-US14839	20060418
	WO 2006118805	A9	20070118		
	WO 2006118805	A3	20070607		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

CN 1375299	A	20021023	CN 2001-103876	20010823
AU 2006242651	A1	20061109	AU 2006-242651	20060418
CA 2607483	A1	20061109	CA 2006-2607483	20060418
EP 1890715	A2	20080227	EP 2006-750791	20060418
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
MX 200713430	A	20080319	MX 2007-13430	20071026
IN 2007KN04199	A	20080215	IN 2007-KN4199	20071101
NO 2007006022	A	20080128	NO 2007-6022	20071122
AU 2007237157	A1	20071213	AU 2007-237157	20071126
KR 2008007491	A	20080121	KR 2007-727948	20071129
CN 101227918	A	20080723	CN 2006-80023011	20071226
PRAI US 2005-676431P	P	20050429		
US 2005-697495P	P	20050707		
AU 2006-200035	A3	20060106		
WO 2006-US14839	W	20060418		

L5 ANSWER 24 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 145:500120 CA
 TI Use of tyrosine kinase inhibitors in the treatment of metabolic disorders
 IN Porter, Jeffrey; Hughes, Thomas Edward
 PA Novartis AG, Switz.; Novartis Pharma GmbH
 SO PCT Int. Appl., 25pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006124544	A2	20061123	WO 2006-US18342	20060511
	WO 2006124544	A3	20070907		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRAI US 2005-680714P	P	20050513			
OS	MARPAT 145:500120				

L5 ANSWER 25 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 145:489215 CA
 TI Azapauillones as immunomodulators, their preparation, pharmaceutical compositions, and use for preventing and treating pancreatic autoimmune disorders
 IN Mussmann, Rainer; Kunick, Conrad; Stukenbrock, Hendrik; Geese, Marcus; Kegel, Simone; Burk, Ulrike
 PA Develogen Aktiengesellschaft, Germany; Technische Universitaet Carolo-Wilhelmina zu Braunschweig
 SO PCT Int. Appl., 83pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006117221	A1	20061109	WO 2006-EP4186	20060504
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 EP 1879591 A1 20080123 EP 2006-724715 20060504
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 PRAI EP 2005-9846 A 20050504
 EP 2005-15986 A 20050722
 EP 2005-23168 A 20051024
 EP 2006-1327 A 20060123
 WO 2006-EP4186 W 20060504
 OS MARPAT 145:489215
 RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 26 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 145:356813 CA
 TI Preparation of N-hydroxyamides omega-substituted with tricyclic groups as
 histone deacetylase inhibitors, their preparation and use in
 pharmaceutical formulations
 IN Guidi, Antonio; Dimoulas, Tula; Giannotti, Danilo; Harmat, Nicholas
 PA Menarini International Operations Luxembourg S.A., Luxembourg
 SO PCT Int. Appl., 39pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006097449	A1	20060921	WO 2006-EP60661	20060313
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2006222883 A1 20060921 AU 2006-222883 20060313 CA 2600521 A1 20060921 CA 2006-2600521 20060313 EP 1863776 A1 20071212 EP 2006-708743 20060313 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU MX 200711071 A 20071008 MX 2007-11071 20070910 CN 101142197 A 20080312 CN 2006-80008249 20070914 KR 2008003336 A 20080107 KR 2007-723278 20071011 NO 2007005229 A 20071108 NO 2007-5229 20071012 IN 2007CN04577 A 20080111 IN 2007-CN4577 20071015 PRAI IT 2005-FI42 A 20050315 WO 2006-EP60661 W 20060313 OS MARPAT 145:356813 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L5 ANSWER 27 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 145:356660 CA
 TI Hydroxamates as histone deacetylase inhibitors and their preparation,
 pharmaceutical formulations containing them, and use for treatment of
 diseases
 IN Rossi, Cristina; Porcelloni, Marina; D'Andrea, Piero; Fattori, Daniela;
 Marastoni, Elena
 PA Menarini International Operations Luxembourg S.A., Luxembourg
 SO PCT Int. Appl., 109pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006097460	A1	20060921	WO 2006-EP60687	20060314
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006224624	A1	20060921	AU 2006-224624	20060314
	CA 2600528	A1	20060921	CA 2006-2600528	20060314
	EP 1868997	A1	20071226	EP 2006-708749	20060314
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	CN 101155780	A	20080402	CN 2006-80006679	20070831
	MX 200711072	A	20071008	MX 2007-11072	20070910
	KR 2007112240	A	20071122	KR 2007-722763	20071005
	NO 2007005281	A	20071015	NO 2007-5281	20071015
	IN 2007CN04578	A	20080111	IN 2007-CN4578	20071015
PRAI	IT 2005-FI41	A	20050315		
	IT 2005-FI239	A	20051121		
	WO 2006-EP60687	W	20060314		

OS MARPAT 145:356660

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 28 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 145:76009 CA
TI A Priori Inference of Cross Reactivity for Drug-Targeted Kinases
AU Fernandez, Ariel; Maddipati, Sridhar
CS Department of Bioengineering, Rice University, Houston, TX, 77005, USA
SO Journal of Medicinal Chemistry (2006), 49(11), 3092-3100
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 144:425724 CA
TI Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
IN Zeligs, Michael A.
PA Bioresponse LLC, USA
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006047716	A2	20060504	WO 2005-US38862	20051026
	WO 2006047716	A3	20070531		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,				

SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
 YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 US 20060111423 A1 20060525 US 2005-260543 20051026
 PRAI US 2004-622333P P 20041026
 OS MARPAT 144:425724

L5 ANSWER 30 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 144:382039 CA
 TI Combination of a DPP-IV inhibitor and a PDGF kinase inhibitor
 IN Burkey, Bryan; Hughes, Thomas Edward
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006041976	A1	20060420	WO 2005-US35917	20051006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005294320	A1	20060420	AU 2005-294320	20051006
CA 2580266	A1	20060420	CA 2005-2580266	20051006
EP 1802308	A1	20070704	EP 2005-801149	20051006
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101035536	A	20070912	CN 2005-80033958	20051006
JP 2008515905	T	20080515	JP 2007-535797	20051006
IN 2007DN02034	A	20070817	IN 2007-DN2034	20070315
MX 200704021	A	20070524	MX 2007-4021	20070403
KR 2007099527	A	20071009	KR 2007-707859	20070406
US 20080070922	A1	20080320	US 2007-576860	20070406
PRAI US 2004-617201P	P	20041008		
WO 2005-US35917	W	20051006		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 31 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 144:101073 CA
 TI therapeutic uses of kinase inhibitors, and compositions thereof
 IN Caligiuri, Maureen G.; Kley, Nikolai A.; Murthi, Krishna K.
 PA GPC Biotech, Inc., USA
 SO PCT Int. Appl., 201 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006002119	A2	20060105	WO 2005-US21843	20050617
WO 2006002119	A3	20070222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,				

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
 SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
 ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,
 KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM
 CA 2584493 A1 20060105 CA 2005-2584493 20050617
 EP 1763345 A2 20070321 EP 2005-762859 20050617
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
 HR, LV, MK, YU
 US 20080146555 A1 20080619 US 2007-629638 20071220
 PRAI US 2004-580868P P 20040618
 WO 2005-US21843 W 20050617
 OS MARPAT 144:101073

L5 ANSWER 32 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 143:319149 CA
 TI Use of renin inhibitors, alone or in combination with other agents, for
 treatment of cardiovascular and other diseases
 IN Feldman, David Louis; Zelenkofske, Steven; Dinboeck, Michaela; Prescott,
 Margaret Forney
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005089731	A2	20050929	WO 2005-EP2809	20050316
	WO 2005089731	A3	20060511		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005224014	A1	20050929	AU 2005-224014	20050316
	CA 2558020	A1	20050929	CA 2005-2558020	20050316
	EP 1729749	A2	20061213	EP 2005-716127	20050316
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	CN 1933823	A	20070321	CN 2005-80008590	20050316
	BR 2005008880	A	20070904	BR 2005-8880	20050316
	JP 2007529459	T	20071025	JP 2007-503285	20050316
	MX 2006PA10416	A	20061110	MX 2006-PA10416	20060912
	KR 2007006774	A	20070111	KR 2006-718948	20060915
	NO 2006004672	A	20061214	NO 2006-4672	20061016
	US 20080161321	A1	20080703	US 2006-592973	20061107
PRAI	US 2004-553877P	P	20040317		
	US 2004-557358P	P	20040329		
	WO 2005-EP2809	W	20050316		

L5 ANSWER 33 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 143:179627 CA
 TI Combination of renin inhibitor and PDGF receptor tyrosine kinase inhibitor
 IN Feldman, David Louis
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DT Patent

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005070406	A1	20050804	WO 2005-EP597	20050121
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005205914	A1	20050804	AU 2005-205914	20050121
	CA 2552759	A1	20050804	CA 2005-2552759	20050121
	EP 1708691	A1	20061011	EP 2005-701109	20050121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1917865	A	20070221	CN 2005-80002969	20050121
	BR 2005007030	A	20070605	BR 2005-7030	20050121
	JP 2007518768	T	20070712	JP 2006-550053	20050121
	MX 2006PA08295	A	20060929	MX 2006-PA8295	20060721
	IN 2006CN02679	A	20070608	IN 2006-CN2679	20060721
PRAI	US 2004-538222P	P	20040122		
	WO 2005-EP597	W	20050121		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 34 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 142:409698 CA
TI Vaccines for cancer, autoimmune disease and infections
IN Molldrem, Jeffrey
PA Board of Regents, the University of Texas System, USA
SO PCT Int. Appl., 235 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005035714	A2	20050421	WO 2004-US27792	20040826
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1670899	A2	20060621	EP 2004-809624	20040826
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI	US 2003-498238P	P	20030826		
	WO 2004-US27792	W	20040826		

L5 ANSWER 35 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 142:219083 CA
TI Preparation of phosphorus-containing rapamycin derivatives for use in pharmaceutical compositions as immunosuppressive and anticancer agents
IN Metcalf, Chester A., III; Rozamus, Leonard W.; Wang, Yihan; Bernstein, David L.
PA Ariad Gene Therapeutics, Inc., USA
SO U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 635,054.
CODEN: USXXCO

DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050032825	A1	20050210	US 2004-862149	20040604
	US 7091213	B2	20060815		
	US 20030220297	A1	20031127	US 2003-357152	20030203
	US 20040073024	A1	20040415	US 2003-635054	20030806
	US 20060264405	A1	20061123	US 2006-429582	20060505
	US 20060264456	A1	20061123	US 2006-494418	20060727
	US 7186826	B2	20070306		
	US 20070190106	A1	20070816	US 2007-650017	20070105
PRAI	US 2002-353252P	P	20020201		
	US 2002-426928P	P	20021115		
	US 2002-428383P	P	20021122		
	US 2002-433930P	P	20021217		
	US 2003-357152	A2	20030203		
	US 2003-635054	A2	20030806		
	US 2003-486367P	P	20030711		
	US 2004-862149	A2	20040604		
	US 2004-889163	B2	20040712		
	US 2005-711859P	P	20050826		
	US 2006-494418	A1	20060727		

OS CASREACT 142:219083; MARPAT 142:219083

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 36 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 142:197889 CA

TI Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases

IN Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott

PA Bayer Pharmaceuticals Corporation, USA

SO PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005009961	A2	20050203	WO 2004-US23500	20040722
	WO 2005009961	A3	20050331		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004259760	A1	20050203	AU 2004-259760	20040722
	CA 2532865	A1	20050203	CA 2004-2532865	20040722
	US 20050038080	A1	20050217	US 2004-895985	20040722
	EP 1663978	A2	20060607	EP 2004-786091	20040722
	EP 1663978	B1	20071128		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004012219	A	20060822	BR 2004-12219	20040722
	CN 1856469	A	20061101	CN 2004-80021091	20040722
	JP 2006528196	T	20061214	JP 2006-521221	20040722
	ES 2297490	T3	20080501	ES 2004-786091	20040722
	MX 2006PA00860	A	20060720	MX 2006-PA860	20060123
	IN 2006DN00402	A	20070824	IN 2006-DN402	20060123
	NO 2006000870	A	20060407	NO 2006-870	20060222
PRAI	US 2003-489102P	P	20030723		
	US 2004-540326P	P	20040202		
	WO 2004-US23500	W	20040722		

OS CASREACT 142:197889

L5 ANSWER 37 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 142:32986 CA

TI Use of a c-abl-, PDGFR-, or c-kit-tyrosine kinase inhibitor for the treatment of **diabetes**

IN Hagerkvist, Robert Per; Welsh, Nils Richard

PA Swed.

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004105763	A2	20041209	WO 2004-EP5679	20040526
	WO 2004105763	A3	20050602		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2004243491	A1	20041209	AU 2004-243491	20040526
	CA 2526594	A1	20041209	CA 2004-2526594	20040526
	EP 1631291	A2	20060308	EP 2004-739375	20040526
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR			
	BR 2004010704	A	20060613	BR 2004-10704	20040526
	CN 1794995	A	20060628	CN 2004-80014278	20040526
	JP 2006528225	T	20061214	JP 2006-529925	20040526
	MX 2005PA12739	A	20060517	MX 2005-PA12739	20051125
	NO 2005006188	A	20051223	NO 2005-6188	20051223
	US 20070072932	A1	20070329	US 2006-556984	20060622
PRAI	GB 2003-12086	A	20030527		
	GB 2004-2682	A	20040206		
	WO 2004-EP5679	W	20040526		

L5 ANSWER 38 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 140:399721 CA

TI Imatinib Attenuates **Diabetes**-Associated Atherosclerosis

AU Lassila, Marko; Allen, Terri J.; Cao, Zemin; Thallas, Vicki;

Jandeleit-Dahm, Karin A.; Candido, Riccardo; Cooper, Mark E.

CS Vascular Division, Danielle Alberti Memorial Centre for Diabetes

Complications, Baker Heart Research Institute, Melbourne, Australia

SO Arteriosclerosis, Thrombosis, and Vascular Biology (2004), 24(5), 935-942

CODEN: ATVBFA; ISSN: 1079-5642

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 39 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 140:789 CA

TI Modulators of c-Abl activation for control of glycosaminoglycan chain length in a cell, and therapeutic use

IN Little, Peter James

PA Baker Medical Research Institute, Australia

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003097110	A1	20031127	WO 2003-AU608	20030520
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003229364	A1	20031202	AU 2003-229364	20030520
	US 20060116403	A1	20060601	US 2005-515393	20051219
PRAI	AU 2002-2430	A	20020520		
	WO 2003-AU608	W	20030520		
RE.CNT	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L5 ANSWER 40 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 139:317425 CA
 TI Smac-peptides as therapeutics against cancer and autoimmune diseases by sensitizing for TRAIL- or anticancer drug-induced apoptosis
 IN Debatin, Klaus Michael; Fulda, Simone
 PA Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts, Germany
 SO Eur. Pat. Appl., 19 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1354952	A1	20031022	EP 2002-8199	20020417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1354953	A1	20031022	EP 2002-15499	20020712
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	WO 2003086470	A2	20031023	WO 2003-EP4039	20030417
	WO 2003086470	A3	20040506		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003236211	A1	20031027	AU 2003-236211	20030417
	EP 1495124	A2	20050112	EP 2003-722503	20030417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005536457	T	20051202	JP 2003-583486	20030417
	US 20050222387	A1	20051006	US 2005-511037	20050119
PRAI	EP 2002-8199	A	20020417		
	EP 2002-15499	A	20020712		
	WO 2003-EP4039	W	20030417		
RE.CNT	12	THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L5 ANSWER 41 OF 41 CA COPYRIGHT 2008 ACS on STN

Full Text

AN 135:221308 CA
 TI Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
 IN Atkins, Robert Charles; Chadban, Steven James; Cooper, Mark Emmanuel; Gilbert, Richard Ernest; Hill, Prudence Ann; Kelly, Darren James;

Nikolic-Paterson, David John
 PA Novartis A.-G., Switz.; The University of Melbourne; Southern Health
 SO PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064200	A2	20010907	WO 2001-EP2340	20010301
	WO 2001064200	A3	20020117		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2401812	A1	20010907	CA 2001-2401812	20010301
	EP 1259242	A2	20021127	EP 2001-921298	20010301
	EP 1259242	B1	20070815		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003525240	T	20030826	JP 2001-563097	20010301
	AU 2001248324	B2	20050915	AU 2001-248324	20010301
	AT 369860	T	20070915	AT 2001-921298	20010301
	ES 2291306	T3	20080301	ES 2001-921298	20010301
	US 20030186977	A1	20031002	US 2003-220214	20030415
	US 7087608	B2	20060808		
	HK 1052864	A1	20080314	HK 2003-103784	20030527
	AU 2005244525	A1	20060112	AU 2005-244525	20051214
PRAI	EP 2000-810181	A	20000303		
	AU 2001-248324	A3	20010301		
	WO 2001-EP2340	W	20010301		
OS	MARPAT 135:221308				

=> file uspatall
 COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
52.96	65.50

FULL ESTIMATED COST

FILE 'USPATFULL' ENTERED AT 01:47:44 ON 15 AUG 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 01:47:44 ON 15 AUG 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 01:47:44 ON 15 AUG 2008
 CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1

L6 472 L1

=> s (diabete?)

L7 78627 (DIABETE?)

=> s (diabete?)/clm

L8 14871 (DIABETE?)/CLM

=> s l6 and l7

L9 152 L6 AND L7

=> s l6 and l9

L10 152 L6 AND L9

=> d 1-152

L10 ANSWER 1 OF 152 USPATFULL on STN

Full Text

AN 2008:184118 USPATFULL
 TI Pharmaceutical Compounds
 IN Curry, Jayne Elizabeth, Cambridge, UNITED KINGDOM
 Lyons, John Francis, Cambridge, UNITED KINGDOM
 Squires, Matthew Simon, Cambridge, UNITED KINGDOM
 Thompson, Neil Thomas, Cambridge, UNITED KINGDOM
 Thompson, Kyla Merriom, Cambridge, UNITED KINGDOM
 Wyatt, Paul Graham, Perth, UNITED KINGDOM
 PA ASTEX THERAPEUTICS LIMITED, Cambridge, UK (non-U.S. corporation)
 PI US 20080161251 A1 20080703
 AI US 2006-814456 A1 20060120 (11)
 WO 2006-GB204 20060120
 20080124 PCT 371 date
 PRAI US 2005-645987P 20050121 (60)
 US 2005-645986P 20050121 (60)
 US 2005-646113P 20050121 (60)
 US 2005-645976P 20050121 (60)
 US 2005-645975P 20050121 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8689
 INCL INCLM: 514/034.000
 INCLS: 514/407.000; 514/381.000; 514/341.000; 514/383.000; 514/326.000;
 514/254.050; 514/397.000; 514/236.500; 514/255.050; 514/314.000;
 514/275.000; 514/305.000; 514/283.000; 514/449.000; 514/274.000;
 514/049.000; 514/265.100; 514/249.000; 514/234.500; 514/266.400;
 514/252.180; 514/350.000
 NCL NCLM: 514/034.000
 NCLS: 514/407.000; 514/381.000; 514/341.000; 514/383.000; 514/326.000;
 514/254.050; 514/397.000; 514/236.500; 514/255.050; 514/314.000;
 514/275.000; 514/305.000; 514/283.000; 514/449.000; 514/274.000;
 514/049.000; 514/265.100; 514/249.000; 514/234.500; 514/266.400;
 514/252.180; 514/350.000
 IC IPCI A61K0031-4155 [I,A]; A61K0031-415 [I,A]; A61K0031-4439 [I,A];
 A61K0031-4427 [I,C*]; A61K0031-4196 [I,A]; A61K0031-454 [I,A];
 A61K0031-4523 [I,C*]; A61K0031-496 [I,A]; A61K0031-4178 [I,A];
 A61K0031-4164 [I,C*]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*];
 A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-4709 [I,A];
 A61K0031-506 [I,A]; A61K0031-439 [I,A]; A61P0035-00 [I,A];
 A61K0031-4375 [I,A]; A61K0031-4353 [I,C*]; A61K0031-337 [I,A];
 A61K0031-7068 [I,A]; A61K0031-7042 [I,C*]; A61K0031-519 [I,A];
 A61K0031-517 [I,A]; A61K0031-44 [I,A]; A61K0031-704 [I,A];
 A61K0031-7028 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 152 USPATFULL on STN

Full Text

AN 2008:167897 USPATFULL
 TI Uses of Kinase Inhibitors and Compositions Thereof
 IN Caligiuri, Maureen G., Reading, MA, UNITED STATES
 Kley, Nikolai A., Wellesley, MA, UNITED STATES
 Murthi, Krishna K., Andover, MA, UNITED STATES
 PA GPC Biotech, Inc, Waltham, MA, UNITED STATES (U.S. corporation)
 PI US 20080146555 A1 20080619
 AI US 2005-629638 A1 20050617 (11)
 WO 2005-US21843 20050617
 20071220 PCT 371 date
 PRAI US 2004-580868P 20040618 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6096
 INCL INCLM: 514/232.500
 INCLS: 514/232.800; 514/254.060; 514/252.110; 435/375.000
 NCL NCLM: 514/232.500
 NCLS: 435/375.000; 514/232.800; 514/252.110; 514/254.060
 IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; C12N0005-00 [I,A];
 A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61P0035-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 152 USPATFULL on STN

Full Text

AN 2008:166740 USPATFULL

TI Coating of fast absorption or dissolution
 IN Trollas, Mikael O., San Jose, CA, UNITED STATES
 Ngo, Michael Huy, San Jose, CA, UNITED STATES
 Maslanka, Bozena Zofia, Aptos, CA, UNITED STATES
 Hossainy, Syed Faiyaz Ahmed, Fremont, CA, UNITED STATES
 Kleiner, Lothar W., Los Altos, CA, UNITED STATES
 PI US 20080145393 A1 20080619
 AI US 2006-638780 A1 20061213 (11)
 DT Utility
 FS APPLICATION
 LN.CNT 762
 INCL INCLM: 424/423.000
 INCLS: 523/113.000
 NCL NCLM: 424/423.000
 NCLS: 523/113.000
 IC IPCI A61F0002-82 [I,A]; A61P0009-10 [I,A]; A61P0009-00 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 152 USPATFULL on STN

Full Text

AN 2008:160164 USPATFULL
 TI IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS
 IN Belanger, David B., Cambridge, MA, UNITED STATES
 Siddiqui, M. Arshad, Newton, MA, UNITED STATES
 Guzi, Timothy J., Sudbury, MA, UNITED STATES
 Curran, Patrick J., Winthrop, MA, UNITED STATES
 Tadikonda, Praveen K., Norwood, MA, UNITED STATES
 Hamann, Blake, Linthicum, MD, UNITED STATES
 Reddy, Panduranga Adulla P., Walpole, MA, UNITED STATES
 Zhao, Lianyun, Burlington, MA, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 PI US 20080139571 A1 20080612
 AI US 2007-936380 A1 20071107 (11)
 PRAI US 2006-858244P 20061108 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3501
 INCL INCLM: 514/249.000
 INCLS: 544/350.000
 NCL NCLM: 514/249.000
 NCLS: 544/350.000
 IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*];
 A61P0035-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 152 USPATFULL on STN

Full Text

AN 2008:158973 USPATFULL
 TI Methods, treatments, and compositions for modulating Hedgehog pathways
 IN Jennings-Spring, Barbara L., Jupiter, FL, UNITED STATES
 PI US 20080138379 A1 20080612
 AI US 2007-1869 A1 20071213 (12)
 RLI Continuation-in-part of Ser. No. US 2006-591398, filed on 1 Nov 2006,
 PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 6011
 INCL INCLM: 424/423.000
 INCLS: 514/129.000; 514/738.000; 424/484.000; 435/375.000; 424/400.000
 NCL NCLM: 424/423.000
 NCLS: 424/400.000; 424/484.000; 435/375.000; 514/129.000; 514/738.000
 IC IPCI A61K0009-00 [I,A]; A61K0031-66 [I,A]; C12N0005-06 [I,A];
 A61P0035-00 [I,A]; A61K0031-047 [I,A]; A61K0031-045 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 152 USPATFULL on STN

Full Text

AN 2008:143138 USPATFULL
 TI Morphology profiles for control of agent release rates from polymer
 matrices
 IN Hossainy, Syed F. A., Fremont, CA, UNITED STATES
 Tang, Fuh-Wei, Temecula, CA, UNITED STATES

Kleiner, Lothar, Los Altos, CA, UNITED STATES
 Glauser, Thierry, Redwood City, CA, UNITED STATES
 Tang, Yiwen, San Jose, CA, UNITED STATES
 Roorda, Wouter, Palo Alto, CA, UNITED STATES
 Pacetti, Stephen, San Jose, CA, UNITED STATES
 Zhang, Gina, Sunnyvale, CA, UNITED STATES
 Chen, Yung-Ming, Cupertino, CA, UNITED STATES
 McNiven, Andrew F., Clonmel, IRELAND
 McNiven, Sean A., Del Mar, CA, UNITED STATES
 Yoe, Brandon J., Temecula, CA, UNITED STATES

PI US 20080124372 A1 20080529
 AI US 2006-448956 A1 20060606 (11)
 DT Utility
 FS APPLICATION
 LN.CNT 1982
 INCL INCLM: 424/423.000
 INCLS: 623/014.200; 623/023.700; 427/022.400; 424/484.000; 514/772.400;
 514/291.000; 514/449.000; 514/182.000
 NCL NCLM: 424/423.000
 NCLS: 424/484.000; 427/002.240; 514/182.000; 514/291.000; 514/449.000;
 514/772.400; 623/001.420; 623/023.700
 IC IPCI A61F0002-06 [I,A]; B05D0003-00 [I,A]; A61K0047-48 [I,A];
 A61K0031-436 [I,A]; A61K0031-4353 [I,C*]; A61K0031-337 [I,A];
 A61K0031-46 [I,A]; A61P0009-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 152 USPATFULL on STN

Full Text

AN 2008:131016 USPATFULL
 TI 3-Aryl-6-aryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles and related
 compounds as activators of caspases and inducers of apoptosis and the
 use thereof
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Drewe, John A., Carlsbad, CA, UNITED STATES
 Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
 Zhang, Han-Zhong, San Diego, CA, UNITED STATES
 PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 20080113984 A1 20080515
 AI US 2007-984296 A1 20071115 (11)
 PRAI US 2006-858936P 20061115 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1835
 INCL INCLM: 514/233.200
 INCLS: 514/307.000; 514/314.000; 514/338.000; 514/362.000; 544/134.000;
 548/126.000
 NCL NCLM: 514/233.200
 NCLS: 514/307.000; 514/314.000; 514/338.000; 514/362.000; 544/134.000;
 548/126.000
 IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-4245 [I,A];
 A61K0031-4709 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 152 USPATFULL on STN

Full Text

AN 2008:130978 USPATFULL
 TI N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as
 activators of caspases and inducers of apoptosis and the use thereof
 IN Zhang, Han-Zhong, San Diego, CA, UNITED STATES
 Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Kemnitzer, William Edward, San Diego, CA, UNITED STATES
 PA Cyntovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 20080113946 A1 20080515
 AI US 2007-984179 A1 20071114 (11)
 RLI Continuation-in-part of Ser. No. WO 2007-US18183, filed on 16 Aug 2007,
 PENDING
 PRAI US 2006-837921P 20060816 (60)
 US 2006-858695P 20061114 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2211
 INCL INCLM: 514/151.000

INCLS: 514/260.100; 514/265.100; 514/258.100
NCL NCLM: 514/151.000
NCLS: 514/258.100; 514/260.100; 514/265.100
IC IPCI A61K0031-655 [I,A]; A61K0031-519 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 9 OF 152 USPATFULL on STN

Full Text

AN 2008:123863 USPATFULL
TI MUC1 and ABL
IN Kufe, Donald W., Wellesley, MA, UNITED STATES
PA Dana-Farber Cancer Institute, Inc., Boston, MA, UNITED STATES, 02115
(U.S. corporation)
PI US 20080107661 A1 20080508
AI US 2007-829687 A1 20070727 (11)
PRAI US 2006-834018P 20060728 (60)
DT Utility
FS APPLICATION
LN.CNT 4507
INCL INCLM: 424/172.100
INCLS: 435/015.000; 703/011.000; 435/375.000; 514/002.000; 514/567.000
NCL NCLM: 424/172.100
NCLS: 435/015.000; 435/375.000; 514/002.000; 514/567.000; 703/011.000
IC IPCI A61K0038-00 [I,A]; C12Q0001-48 [I,A]; G06G0007-48 [I,A];
G06G0007-00 [I,C*]; A61K0031-195 [I,A]; A61K0031-185 [I,C*];
A61P0043-00 [I,A]; C12N0005-06 [I,A]; A61K0039-395 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 10 OF 152 USPATFULL on STN

Full Text

AN 2008:117781 USPATFULL
TI Oncokine fusion polypeptides associated with hyperproliferative and
related disorders, nucleic acids encoding the same and methods for
detecting and identifying the same
IN Briesewitz, Roger, Mountain View, CA, UNITED STATES
Griffin, John H., Atherton, CA, UNITED STATES
PI US 20080102472 A1 20080501
AI US 2007-1328 A1 20071211 (12)
RLI Continuation of Ser. No. US 2007-706519, filed on 15 Feb 2007, PENDING
Division of Ser. No. US 2003-637356, filed on 8 Aug 2003, GRANTED, Pat.
No. US 7195876
PRAI US 2002-402330P 20020809 (60)
US 2003-440491P 20030116 (60)
DT Utility
FS APPLICATION
LN.CNT 3405
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC IPCI C12Q0001-68 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 11 OF 152 USPATFULL on STN

Full Text

AN 2008:111298 USPATFULL
TI Substituted N-Aryl-9-Oxo-9H-Fluorene-1-Carboxamides and Analogs as
Activators of Caspases and Inducers of Apoptosis
IN Kemnitzer, William E., San Diego, CA, UNITED STATES
Cai, Sui Xiong, San Diego, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
PA CYTOVIA INC., SAN DIEGO CA, CANADA, 92121 (U.S. corporation)
PI US 20080096848 A1 20080424
AI US 2005-664060 A1 20050929 (11)
WO 2005-US34890 20050929
20070329 PCT 371 date
PRAI US 2004-613817P 20040929 (60)
DT Utility
FS APPLICATION
LN.CNT 2271
INCL INCLM: 514/150.000
INCLS: 534/838.000; 514/237.800; 544/162.000; 548/564.000; 514/427.000;
514/315.000; 546/246.000; 546/329.000; 514/357.000; 514/399.000;

548/335.500; 548/254.000; 514/381.000; 514/406.000; 548/375.100;
564/123.000; 514/613.000
NCL NCLM: 514/150.000
NCLS: 514/237.800; 514/315.000; 514/357.000; 514/381.000; 514/399.000;
514/406.000; 514/427.000; 514/613.000; 534/838.000; 544/162.000;
546/246.000; 546/329.000; 548/254.000; 548/335.500; 548/375.100;
548/564.000; 564/123.000
IC IPCI A61K0031-16 [I,A]; A61P0035-00 [I,A]; A61K0031-655 [I,A];
C07C0245-22 [I,A]; C07C0245-00 [I,C*]; A61K0031-5375 [I,A];
C07D0265-30 [I,A]; C07D0265-00 [I,C*]; C07D0207-323 [I,A];
C07D0207-00 [I,C*]; A61K0031-40 [I,A]; A61K0031-445 [I,A];
C07D0211-04 [I,A]; C07D0211-00 [I,C*]; A61K0031-44 [I,A];
A61K0031-415 [I,A]; C07D0233-61 [I,A]; C07D0257-04 [I,A];
C07D0257-00 [I,C*]; A61K0031-41 [I,A]; A61K0031-4164 [I,A];
C07D0233-00 [I,A]; C07C0233-01 [I,A]; C07C0233-00 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 12 OF 152 USPATFULL on STN

Full Text

AN 2008:80791 USPATFULL
TI Combination of Organic Compounds
IN Burkey, Bryan, Winchester, MA, UNITED STATES
Hughes, Thomas, Concord, MA, UNITED STATES
PI US 20080070922 A1 20080320
AI US 2005-576860 A1 20051006 (11)
WO 2005-US35917 20051006
20070406 PCT 371 date
PRAI US 2004-617201P 20041008 (60)
DT Utility
FS APPLICATION
LN.CNT 1392
INCL INCLM: 514/252.180
INCLS: 514/423.000
NCL NCLM: 514/252.180
NCLS: 514/423.000
IC IPCI A61K0031-496 [I,A]; A61K0031-40 [I,A]; A61P0015-00 [I,A];
A61P0017-00 [I,A]; A61P0027-02 [I,A]; A61P0027-00 [I,C*];
A61P0003-04 [I,A]; A61P0003-08 [I,A]; A61P0003-10 [I,A];
A61P0003-00 [I,C*]; A61P0005-00 [I,A]; A61P0009-00 [I,A]
IPCR A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-40 [I,C];
A61K0031-40 [I,A]; A61P0003-00 [I,C]; A61P0003-04 [I,A];
A61P0003-08 [I,A]; A61P0003-10 [I,A]; A61P0005-00 [I,C];
A61P0005-00 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A];
A61P0015-00 [I,C]; A61P0015-00 [I,A]; A61P0017-00 [I,C];
A61P0017-00 [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 13 OF 152 USPATFULL on STN

Full Text

AN 2008:58565 USPATFULL
TI Protein Kinase Targeted Therapeutics
IN Watterson, D. Martin, Chicago, IL, UNITED STATES
Van Eldik, Linda J., Chicago, IL, UNITED STATES
PA Northwestern University, Evanston, IL, UNITED STATES, 60208 (U.S.
corporation)
PI US 20080051410 A1 20080228
AI US 2007-833152 A1 20070802 (11)
PRAI US 2006-834962P 20060802 (60)
DT Utility
FS APPLICATION
LN.CNT 1149
INCL INCLM: 514/252.020
NCL NCLM: 514/252.020
IC IPCI A61K0031-50 [I,A]; A61P0043-00 [I,A]
IPCR A61K0031-50 [I,C]; A61K0031-50 [I,A]; A61P0043-00 [I,C];
A61P0043-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 14 OF 152 USPATFULL on STN

Full Text

AN 2008:57543 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors

IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Mallams, Alan, Hackettstown, NJ, UNITED STATES
 Alvarez, Carmen S., Livingston, NJ, UNITED STATES
 Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
 Rivera, Jocelyn, Monmouth Junction, NJ, UNITED STATES
 Chan, Tin-Yau, Edison, NJ, UNITED STATES
 Madison, Vincent S., Mountain Lakes, NJ, UNITED STATES
 Fischmann, Thierry O., Scotch Plains, NJ, UNITED STATES
 Dillard, Lawrence W., Skillman, NJ, UNITED STATES
 Tran, Vinh D., Fountain Valley, CA, UNITED STATES
 He, Zhenmin, Shanghai, CHINA
 James, Ray Anthony, Bensalem, PA, UNITED STATES
 Park, Haengsoon, Plainsboro, NJ, UNITED STATES
 Paradkar, Vidyadhar M., Somerville, NJ, UNITED STATES
 Hobbs, Douglas Walsh, Yardley, PA, UNITED STATES
 Kirschmeier, Paul, Basking Ridge, NJ, UNITED STATES
 Bannerji, Rajat, Morristown, NJ, UNITED STATES
 PA Shering Corporation and Pharmacopeia, Inc. (U.S. corporation)
 PI US 20080050384 A1 20080228
 AI US 2007-788847 A1 20070420 (11)
 RLI Continuation-in-part of Ser. No. US 2006-396079, filed on 31 Mar 2006,
 ABANDONED Division of Ser. No. US 2004-776988, filed on 11 Feb 2004,
 GRANTED, Pat. No. US 7119200 Continuation-in-part of Ser. No. US
 2003-654546, filed on 3 Sep 2003, GRANTED, Pat. No. US 7161003
 PRAI US 2002-421959P 20021029 (60)
 US 2002-408027P 20020904 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 7259
 INCL INCLM: 424/141.100
 INCLS: 424/130.100; 424/623.000; 424/649.000; 424/094.600; 514/151.000;
 514/177.000; 514/178.000; 514/180.000; 514/182.000; 514/183.000;
 514/234.500; 514/252.120; 514/255.050; 514/255.060; 514/259.300;
 514/048.000; 514/049.000; 514/090.000
 NCL NCLM: 424/141.100
 NCLS: 424/094.600; 424/130.100; 424/623.000; 424/649.000; 514/048.000;
 514/049.000; 514/090.000; 514/151.000; 514/177.000; 514/178.000;
 514/180.000; 514/182.000; 514/183.000; 514/234.500; 514/252.120;
 514/255.050; 514/255.060; 514/259.300
 IC IPCI A61K0031-519 [I,A]; A61K0031-33 [I,A]; A61K0031-4965 [I,A];
 A61K0031-56 [I,A]; A61K0031-675 [I,A]; A61K0033-24 [I,A];
 A61K0038-46 [I,A]; A61K0038-43 [I,C*]; A61P0019-02 [I,A];
 A61P0019-00 [I,C*]; A61P0035-00 [I,A]; A61P0043-00 [I,A];
 A61P0029-00 [I,A]; A61K0039-395 [I,A]; A61K0033-36 [I,A];
 A61K0031-7004 [I,A]; A61K0031-655 [I,A]; A61K0031-535 [I,A];
 A61K0031-497 [I,A]
 IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61K0031-33 [I,C];
 A61K0031-33 [I,A]; A61K0031-4965 [I,C]; A61K0031-4965 [I,A];
 A61K0031-497 [I,A]; A61K0031-535 [I,C]; A61K0031-535 [I,A];
 A61K0031-56 [I,C]; A61K0031-56 [I,A]; A61K0031-655 [I,C];
 A61K0031-655 [I,A]; A61K0031-675 [I,C]; A61K0031-675 [I,A];
 A61K0031-7004 [I,C]; A61K0031-7004 [I,A]; A61K0033-24 [I,C];
 A61K0033-24 [I,A]; A61K0033-36 [I,C]; A61K0033-36 [I,A];
 A61K0038-43 [I,C]; A61K0038-46 [I,A]; A61K0039-395 [I,C];
 A61K0039-395 [I,A]; A61P0019-00 [I,C]; A61P0019-02 [I,A];
 A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0035-00 [I,C];
 A61P0035-00 [I,A]; A61P0043-00 [I,C]; A61P0043-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 15 OF 152 USPATFULL on STN

Full Text

AN 2008:51812 USPATFULL
 TI Novel high affinity quinoline-based kinase ligands
 IN Deng, Yongqi, Newton, MA, UNITED STATES
 Curran, Patrick J., Winthrop, MA, UNITED STATES
 Shipps, Gerald W., Stoneham, MA, UNITED STATES
 Zhao, Lianyun, Burlington, MA, UNITED STATES
 Siddiqui, M. Arshad, Newton, MA, UNITED STATES

Popovici-Muller, Janeta, Waltham, MA, UNITED STATES
 Duca, Jose S., Cranford, NJ, UNITED STATES
 Hruza, Alan W., Hackettstown, NJ, UNITED STATES
 Fischmann, Thierry O., Scotch Plains, NJ, UNITED STATES
 Madison, Vincent S., Mountain Lakes, NJ, UNITED STATES
 Zhang, Rumin, Edison, NJ, UNITED STATES
 McNemar, Charles W., High Bridge, NJ, UNITED STATES
 Mayhood, Todd W., Randolph, NJ, UNITED STATES
 Windsor, William T., East Brunswick, NJ, UNITED STATES
 Lees, Emma M., Oakland, CA, UNITED STATES
 Parry, David A., Mountain View, CA, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 PI US 20080045568 A1 20080221
 AI US 2006-504869 A1 20060816 (11)
 DT Utility
 FS APPLICATION
 LN.CNT 4013
 INCL INCLM: 514/312.000
 INCLS: 546/156.000; 546/159.000; 546/169.000; 514/313.000; 514/314.000
 NCL NCLM: 514/312.000
 NCLS: 514/313.000; 514/314.000; 546/156.000; 546/159.000; 546/169.000
 IC IPCI A61K0031-4709 [I,A]; A61K0031-4706 [I,A]; C07D0215-38 [I,A];
 C07D0215-00 [I,C*]
 IPCR A61K0031-4709 [I,C]; A61K0031-4709 [I,A]; A61K0031-4706 [I,C];
 A61K0031-4706 [I,A]; C07D0215-00 [I,C]; C07D0215-38 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 16 OF 152 USPATFULL on STN

Full Text

AN 2008:51758 USPATFULL
 TI 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs
 as activators of caspases and inducers of apoptosis and the use thereof
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Drewe, John A., Carlsbad, CA, UNITED STATES
 Zhang, Han-Zhong, San Diego, CA, UNITED STATES
 Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
 Claassen, Gisela, San Diego, CA, UNITED STATES
 Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
 Kemnitzer, William Edward, San Diego, CA, UNITED STATES
 PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 20080045514 A1 20080221
 AI US 2007-879517 A1 20070718 (11)
 PRAI US 2006-831458P 20060718 (60)
 US 2007-879538P 20070110 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4289
 INCL INCLM: 514/222.800
 INCLS: 514/243.000; 544/010.000; 544/184.000
 NCL NCLM: 514/222.800
 NCLS: 514/243.000; 544/010.000; 544/184.000
 IC IPCI A61K0031-542 [I,A]; A61K0031-53 [I,A]; A61P0035-00 [I,A];
 C07D0487-04 [I,A]; C07D0487-00 [I,C*]; C07D0513-04 [I,A];
 C07D0513-00 [I,C*]
 IPCR A61K0031-542 [I,C]; A61K0031-542 [I,A]; A61K0031-53 [I,C];
 A61K0031-53 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A];
 C07D0487-00 [I,C]; C07D0487-04 [I,A]; C07D0513-00 [I,C];
 C07D0513-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 17 OF 152 USPATFULL on STN

Full Text

AN 2008:44856 USPATFULL
 TI COMPOUNDS AND THERAPEUTICAL USE THEREOF
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
 Pervin, Azra, Escondido, CA, UNITED STATES
 Drewe, John A., Carlsbad, CA, UNITED STATES
 Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
 Jiang, Songchun, San Diego, CA, UNITED STATES
 Zhang, Hong, San Diego, CA, UNITED STATES
 Pleiman, Chris, Holladay, UT, UNITED STATES

Baichwal, Vijay, Salt Lake City, UT, UNITED STATES
 Manfredi, John, Salt Lake City, UT, UNITED STATES
 Bhoite, Leena, Salt Lake City, UT, UNITED STATES
 PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S. corporation)
 Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 20080039479 A1 20080214
 AI US 2007-781660 A1 20070723 (11)
 RLI Division of Ser. No. US 2004-885903, filed on 6 Jul 2004, PENDING
 PRAI US 2003-484325P 20030703 (60)
 US 2003-493006P 20030807 (60)
 US 2004-557556P 20040329 (60)
 US 2004-571288P 20040514 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8879
 INCL INCLM: 514/266.100
 INCLS: 544/283.000
 NCL NCLM: 514/266.100
 NCLS: 544/283.000
 IC IPCI A61K0031-517 [I,A]; A61P0035-00 [I,A]; C07D0239-72 [I,A];
 C07D0239-00 [I,C*]
 IPCR A61K0031-517 [I,C]; A61K0031-517 [I,A]; A61K0031-519 [I,C*];
 A61K0031-519 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A];
 C07D0239-00 [I,C]; C07D0239-72 [I,A]; C07D0239-94 [I,A];
 C07D0239-95 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A];
 C07D0403-00 [I,C*]; C07D0403-04 [I,A]; C07D0403-12 [I,A];
 C07D0405-00 [I,C*]; C07D0405-12 [I,A]; C07D0487-00 [I,C*];
 C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 18 OF 152 USPATFULL on STN

Full Text

AN 2008:44817 USPATFULL
 TI Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors
 IN Bold, Guido, Gipf-Oberfrick, SWITZERLAND
 Caravatti, Giorgio, Bottmingen, SWITZERLAND
 Floersheimer, Andreas, Dornach, SWITZERLAND
 Furet, Pascal, Thann, FRANCE
 Manley, Paul W., Arlesheim, SWITZERLAND
 Pissot Soldermann, Carole, Rosenau, FRANCE
 Vaupel, Andrea, Riehen, SWITZERLAND
 PI US 20080039440 A1 20080214
 AI US 2005-575601 A1 20050927 (11)
 WO 2005-EP10408 20050927
 20070320 PCT 371 date
 PRAI GB 2004-21525 20040928
 DT Utility
 FS APPLICATION
 LN.CNT 4596
 INCL INCLM: 514/213.010
 INCLS: 514/235.200; 514/252.180; 514/269.000; 540/593.000; 544/123.000;
 544/319.000
 NCL NCLM: 514/213.010
 NCLS: 514/235.200; 514/252.180; 514/269.000; 540/593.000; 544/123.000;
 544/319.000
 IC IPCI A61K0031-506 [I,A]; A61K0031-496 [I,A]; A61K0031-55 [I,A];
 A61P0035-00 [I,A]; C07D0401-12 [I,A]; C07D0401-00 [I,C*];
 C07D0403-12 [I,A]; C07D0403-00 [I,C*]; C07D0413-14 [I,A];
 C07D0413-00 [I,C*]
 IPCR A61K0031-506 [I,C]; A61K0031-506 [I,A]; A61K0031-496 [I,C];
 A61K0031-496 [I,A]; A61K0031-55 [I,C]; A61K0031-55 [I,A];
 A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07D0401-00 [I,C];
 C07D0401-12 [I,A]; C07D0401-14 [I,A]; C07D0403-00 [I,C];
 C07D0403-12 [I,A]; C07D0403-14 [I,A]; C07D0409-00 [I,C*];
 C07D0409-14 [I,A]; C07D0413-00 [I,C]; C07D0413-14 [I,A];
 C07D0417-00 [I,C*]; C07D0417-12 [I,A]; C07D0417-14 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 19 OF 152 USPATFULL on STN

Full Text

AN 2008:43696 USPATFULL

TI Conveniently implantable sustained release drug compositions
 IN Wong, Vernon G., Menlo Park, CA, UNITED STATES
 Wood, Louis L., Potomac, MD, UNITED STATES
 PI US 20080038316 A1 20080214
 AI US 2007-826833 A1 20070718 (11)
 RLI Continuation-in-part of Ser. No. US 2005-236426, filed on 27 Sep 2005,
 PENDING
 PRAI US 2005-709665P 20050819 (60)
 US 2004-614484P 20041001 (60)
 US 2006-831991P 20060719 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3606
 INCL INCLM: 424/426.000
 INCLS: 514/169.000
 NCL NCLM: 424/426.000
 NCLS: 514/169.000
 IC IPCI A61F0002-00 [I,A]; A61K0031-56 [I,A]
 IPCR A61F0002-00 [I,C]; A61F0002-00 [I,A]; A61K0031-56 [I,C];
 A61K0031-56 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 20 OF 152 USPATFULL on STN

Full Text

AN 2008:37550 USPATFULL
 TI Method of treating inflammatory diseases using tyrosine kinase
 inhibitors
 IN Robinson, William H., Palo Alto, CA, UNITED STATES
 Paniagua, Ricardo T., Redwood City, CA, UNITED STATES
 PI US 20080032989 A1 20080207
 AI US 2007-809515 A1 20070531 (11)
 PRAI US 2006-810030P 20060531 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2368
 INCL INCLM: 514/252.180
 INCLS: 514/264.110; 514/275.000; 514/414.000; 514/789.000
 NCL NCLM: 514/252.180
 NCLS: 514/264.110; 514/275.000; 514/414.000; 514/789.000
 IC IPCI A61K0031-496 [I,A]; A61K0031-403 [I,A]; A61K0031-506 [I,A];
 A61K0031-519 [I,A]; A61P0017-06 [I,A]; A61P0017-00 [I,C*];
 A61P0019-02 [I,A]; A61P0019-00 [I,C*]
 IPCR A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-403 [I,C];
 A61K0031-403 [I,A]; A61K0031-506 [I,C]; A61K0031-506 [I,A];
 A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61P0017-00 [I,C];
 A61P0017-06 [I,A]; A61P0019-00 [I,C]; A61P0019-02 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 21 OF 152 USPATFULL on STN

Full Text

AN 2008:37535 USPATFULL
 TI COMPOUNDS AND THERAPEUTICAL USE THEREOF
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
 Pervin, Azra, Escondido, CA, UNITED STATES
 Drewe, John A., Carlsbad, CA, UNITED STATES
 Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
 Jiang, Songchun, San Diego, CA, UNITED STATES
 Zhang, Hong, San Diego, CA, UNITED STATES
 Pleiman, Chris, Holladay, UT, UNITED STATES
 Baichwal, Vijay, Salt Lake City, UT, UNITED STATES
 Manfredi, John, Salt Lake City, UT, UNITED STATES
 Bhoite, Leena, Salt Lake City, UT, UNITED STATES
 PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES, 84108
 (U.S. corporation)
 Cytovia, Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
 PI US 20080032974 A1 20080207
 AI US 2007-779086 A1 20070717 (11)
 RLI Division of Ser. No. US 2004-885903, filed on 6 Jul 2004, PENDING
 PRAI US 2003-484325P 20030703 (60)
 US 2003-493006P 20030807 (60)
 US 2004-557556P 20040329 (60)

US 2004-571288P 20040514 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8893
 INCL INCLM: 514/234.500
 INCLS: 514/263.400; 514/266.210; 514/266.400; 544/119.000; 544/277.000;
 544/284.000; 544/293.000
 NCL NCLM: 514/234.500
 NCLS: 514/263.400; 514/266.210; 514/266.400; 544/119.000; 544/277.000;
 544/284.000; 544/293.000
 IC IPCI A61K0031-517 [I,A]; A61K0031-52 [I,A]; A61K0031-519 [I,C*];
 A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61P0031-10 [I,A];
 A61P0031-00 [I,C*]; A61P0035-00 [I,A]; C07D0239-94 [I,A];
 C07D0239-00 [I,C*]; C07D0401-12 [I,A]; C07D0401-00 [I,C*];
 C07D0413-12 [I,A]; C07D0413-00 [I,C*]; C07D0473-16 [I,A];
 C07D0473-00 [I,C*]
 IPCR A61K0031-517 [I,C]; A61K0031-517 [I,A]; A61K0031-519 [I,C];
 A61K0031-519 [I,A]; A61K0031-52 [I,A]; A61K0031-5375 [I,C];
 A61K0031-5377 [I,A]; A61P0031-00 [I,C]; A61P0031-10 [I,A];
 A61P0035-00 [I,C]; A61P0035-00 [I,A]; C07D0239-00 [I,C];
 C07D0239-94 [I,A]; C07D0239-95 [I,A]; C07D0401-00 [I,C];
 C07D0401-12 [I,A]; C07D0403-00 [I,C*]; C07D0403-04 [I,A];
 C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A];
 C07D0413-00 [I,C]; C07D0413-12 [I,A]; C07D0473-00 [I,C];
 C07D0473-16 [I,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 22 OF 152 USPATFULL on STN

Full Text

AN 2008:30767 USPATFULL
 TI IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS
 IN Zhao, Lianyun, Burlington, MA, UNITED STATES
 Reddy, Panduranga Adulla P., Walpole, MA, UNITED STATES
 Shih, Neng-Yang, Warren, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Siddiqui, M. Arshad, Newton, MA, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 PI US 20080027063 A1 20080131
 AI US 2007-758243 A1 20070605 (11)
 PRAI US 2006-811351P 20060606 (60)

DT Utility
 FS APPLICATION
 LN.CNT 3904

INCL INCLM: 514/249.000
 INCLS: 544/350.000
 NCL NCLM: 514/249.000
 NCLS: 544/350.000
 IC IPCI A61K0031-4985 [I,A]; A61P0035-00 [I,A]; C07D0487-04 [I,A];
 C07D0487-00 [I,C*]
 IPCR A61K0031-4985 [I,C]; A61K0031-4985 [I,A]; A61P0035-00 [I,C];
 A61P0035-00 [I,A]; C07D0487-00 [I,C]; C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 23 OF 152 USPATFULL on STN

Full Text

AN 2008:23804 USPATFULL
 TI PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF
 APOPTOSIS AND THE USE THEREOF
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Anderson, Mark B., Salt Lake City, UT, UNITED STATES
 Willardsen, Adam, Sandy, UT, UNITED STATES
 Jiang, Songchun, San Diego, CA, UNITED STATES
 Halter, Robert J., Salt Lake City, UT, UNITED STATES
 Slade, Rachel, Salt Lake City, UT, UNITED STATES
 Klimova, Yevgeniya, Sandy, UT, UNITED STATES
 PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES, 84108 (U.S.
 corporation)
 Cytovia, Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
 PI US 20080020985 A1 20080124
 AI US 2007-773293 A1 20070703 (11)
 RLI Continuation of Ser. No. WO 2006-US176, filed on 3 Jan 2006, PENDING

PRAI US 2005-641356P 20050103 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2665
 INCL INCLM: 514/016.000
 INCLS: 514/110.000; 514/245.000; 514/248.000; 514/034.000; 514/047.000;
 544/211.000; 544/237.000
 NCL NCLM: 514/016.000
 NCLS: 514/034.000; 514/047.000; 514/110.000; 514/245.000; 514/248.000;
 544/211.000; 544/237.000
 IC IPCI A61K0031-53 [I,A]; A61K0031-502 [I,A]; A61K0031-66 [I,A];
 A61K0031-704 [I,A]; A61K0031-7028 [I,C*]; A61K0031-7076 [I,A];
 A61K0031-7042 [I,C*]; A61K0038-08 [I,A]; A61P0029-00 [I,A];
 A61P0031-12 [I,A]; A61P0031-00 [I,C*]; A61P0035-00 [I,A];
 A61P0037-00 [I,A]; C07D0237-34 [I,A]; C07D0237-00 [I,C*];
 C07D0253-08 [I,A]; C07D0253-00 [I,C*]
 IPCR A61K0031-53 [I,C]; A61K0031-53 [I,A]; A61K0031-502 [I,C];
 A61K0031-502 [I,A]; A61K0031-66 [I,C]; A61K0031-66 [I,A];
 A61K0031-7028 [I,C]; A61K0031-704 [I,A]; A61K0031-7042 [I,C];
 A61K0031-7076 [I,A]; A61K0038-08 [I,C]; A61K0038-08 [I,A];
 A61P0029-00 [I,C]; A61P0029-00 [I,A]; A61P0031-00 [I,C];
 A61P0031-12 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A];
 A61P0037-00 [I,C]; A61P0037-00 [I,A]; C07D0237-00 [I,C];
 C07D0237-34 [I,A]; C07D0253-00 [I,C]; C07D0253-08 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 24 OF 152 USPATFULL on STN

Full Text

AN 2008:5119 USPATFULL
 TI COMPOUNDS AND THERAPEUTICAL USE THEREOF
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Anderson, Mark B., Salt Lake City, UT, UNITED STATES
 Willardsen, Adam, Sandy, UT, UNITED STATES
 Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
 Zhang, Hong, San Diego, CA, UNITED STATES
 Suzuki, Kazuyuki, Murray, UT, UNITED STATES
 PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S.
 corporation)
 Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 20080004297 A1 20080103
 AI US 2007-773303 A1 20070703 (11)
 RLI Continuation-in-part of Ser. No. US 2004-885903, filed on 6 Jul 2004,
 PENDING Continuation-in-part of Ser. No. WO 2006-US56, filed on 3 Jan
 2006, PENDING
 PRAI US 2003-484325P 20030703 (60)
 US 2003-493006P 20030807 (60)
 US 2004-557556P 20040329 (60)
 US 2004-571288P 20040514 (60)
 US 2005-641260P 20050103 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3734
 INCL INCLM: 514/266.210
 INCLS: 514/266.230; 514/266.400; 544/284.000; 544/291.000; 544/293.000
 NCL NCLM: 514/266.210
 NCLS: 514/266.230; 514/266.400; 544/284.000; 544/291.000; 544/293.000
 IC IPCI A61K0031-517 [I,A]; A61P0031-10 [I,A]; A61P0031-12 [I,A];
 A61P0031-00 [I,C*]; A61P0035-00 [I,A]; A61P0037-00 [I,A];
 C07D0239-84 [I,A]; C07D0239-94 [I,A]; C07D0239-00 [I,C*];
 C07D0401-12 [I,A]; C07D0401-00 [I,C*]; C07D0403-12 [I,A];
 C07D0403-00 [I,C*]
 IPCR A61K0031-517 [I,C]; A61K0031-517 [I,A]; A61P0031-00 [I,C];
 A61P0031-10 [I,A]; A61P0031-12 [I,A]; A61P0035-00 [I,C];
 A61P0035-00 [I,A]; A61P0037-00 [I,C]; A61P0037-00 [I,A];
 C07D0239-00 [I,C]; C07D0239-84 [I,A]; C07D0239-94 [I,A];
 C07D0401-00 [I,C]; C07D0401-12 [I,A]; C07D0403-00 [I,C];
 C07D0403-12 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 25 OF 152 USPATFULL on STN

Full Text

AN 2007:336870 USPATFULL

TI Zebrafish model for assessing gastrointestinal motility
 IN Rich, Adam, Brockport, NY, UNITED STATES
 PI US 20070294778 A1 20071220
 AI US 2007-724741 A1 20070316 (11)
 PRAI US 2006-782993P 20060316 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1136
 INCL INCLM: 800/003.000
 NCL NCLM: 800/003.000
 IC IPCI A01K0067-027 [I,A]
 IPCR A01K0067-027 [I,C]; A01K0067-027 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 26 OF 152 USPATFULL on STN

Full Text

AN 2007:334601 USPATFULL
 TI Nanoshells for drug delivery
 IN Ludwig, Florian N., Mountain View, CA, UNITED STATES
 Pacetti, Stephen D., San Jose, CA, UNITED STATES
 Hossainy, Syed F.A., Fremont, CA, UNITED STATES
 Davalian, Dariush, San Jose, CA, UNITED STATES
 PI US 20070292495 A1 20071220
 AI US 2006-454813 A1 20060615 (11)
 DT Utility
 FS APPLICATION
 LN.CNT 717
 INCL INCLM: 424/450.000
 INCLS: 424/490.000; 977/906.000; 977/907.000
 NCL NCLM: 424/450.000
 NCLS: 424/490.000; 977/906.000; 977/907.000
 IC IPCI A61K0009-127 [I,A]; A61K0009-50 [I,A]
 IPCR A61K0009-127 [I,C]; A61K0009-127 [I,A]; A61K0009-50 [I,C];
 A61K0009-50 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 27 OF 152 USPATFULL on STN

Full Text

AN 2007:322619 USPATFULL
 TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Labroli, Marc, Mount Laurel, NJ, UNITED STATES
 Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 PI US 20070281951 A1 20071206
 AI US 2007-788856 A1 20070420 (11)
 RLI Continuation-in-part of Ser. No. US 2007-710644, filed on 23 Feb 2007,
 PENDING Division of Ser. No. US 2005-245401, filed on 6 Oct 2005,
 GRANTED, Pat. No. US 7196078 Continuation-in-part of Ser. No. US
 2004-776988, filed on 11 Feb 2004, GRANTED, Pat. No. US 7119200
 Continuation-in-part of Ser. No. US 2003-654546, filed on 3 Sep 2003,
 GRANTED, Pat. No. US 7161003
 PRAI US 2002-408027P 20020904 (60)
 US 2002-421959P 20021029 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8541
 INCL INCLM: 514/259.310
 NCL NCLM: 514/259.310
 IC IPCI A61K0031-495 [I,A]
 IPCR A61K0031-495 [I,C]; A61K0031-495 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 28 OF 152 USPATFULL on STN

Full Text

AN 2007:315778 USPATFULL
 TI NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES

Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Dillard, Lawrence W., Skillman, NJ, UNITED STATES
 Tran, Vinh D., Fountain Valley, CA, UNITED STATES
 He, Zhenmin, Shanghai, CHINA
 James, Ray Anthony, Bristol, PA, UNITED STATES
 Park, Haengsoon, Plainsboro, NJ, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 Pharmacoceia, Inc. (U.S. corporation)
 PI US 20070275983 A1 20071129
 AI US 2007-779050 A1 20070717 (11)
 RLI Division of Ser. No. US 2006-395824, filed on 31 Mar 2006, PENDING
 Division of Ser. No. US 2003-653868, filed on 3 Sep 2003, GRANTED, Pat.
 No. US 7074924
 PRAI US 2002-407999P 20020904 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1885
 INCL INCLM: 514/259.310
 INCLS: 514/252.160; 514/034.000; 514/049.000; 514/251.000; 514/008.000;
 514/109.000; 514/449.000; 514/263.320; 514/283.000; 514/651.000;
 514/269.000; 424/155.100; 424/649.000
 NCL NCLM: 514/259.310
 NCLS: 424/155.100; 424/649.000; 514/008.000; 514/034.000; 514/049.000;
 514/109.000; 514/251.000; 514/252.160; 514/263.320; 514/269.000;
 514/283.000; 514/449.000; 514/651.000
 IC IPCI A61K0031-519 [I,A]; A61K0038-14 [I,A]; A61K0031-704 [I,A];
 A61K0031-7028 [I,C*]; A61K0031-7072 [I,A]; A61K0031-7042 [I,C*];
 A61K0031-52 [I,A]
 IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61K0031-52 [I,A];
 A61K0031-7028 [I,C]; A61K0031-704 [I,A]; A61K0031-7042 [I,C];
 A61K0031-7072 [I,A]; A61K0038-14 [I,C]; A61K0038-14 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 29 OF 152 USPATFULL on STN

Full Text

AN 2007:315758 USPATFULL
 TI PYRAZOLO[1,5-a]PYRIMIDINES
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Nomeir, Amin A., Milford, NJ, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 PI US 20070275963 A1 20071129
 AI US 2007-751282 A1 20070521 (11)
 PRAI US 2006-802577P 20060522 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1832
 INCL INCLM: 514/234.200
 INCLS: 514/252.160; 514/259.300; 544/281.000; 544/120.000
 NCL NCLM: 514/234.200
 NCLS: 514/252.160; 514/259.300; 544/120.000; 544/281.000
 IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-519 [I,A]
 IPCR A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-519 [I,C];
 A61K0031-519 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 30 OF 152 USPATFULL on STN

Full Text

AN 2007:297021 USPATFULL
 TI Aminopyrimidines useful as kinase inhibitors
 IN Binch, Hayley, San Diego, CA, UNITED STATES
 Mortimore, Michael, Oxfordshire, UNITED KINGDOM
 Davis, Chris, Wiltshire, UNITED KINGDOM
 Boyall, Dean, Oxon, UNITED KINGDOM
 Everitt, Simon, Bucks, UNITED KINGDOM
 Robinson, Daniel, Oxfordshire, UNITED KINGDOM
 Ramaya, Sharn, Berkshire, UNITED KINGDOM
 Fraysse, Damien, Oxfordshire, UNITED KINGDOM
 Studley, John, Oxfordshire, UNITED KINGDOM
 Miller, Andrew, Oxfordshire, UNITED KINGDOM
 O'Donnell, Michael, Oxfordshire, UNITED KINGDOM

Rutherford, Alistair, Oxfordshire, UNITED KINGDOM
Pinder, Joanne, Oxfordshire, UNITED KINGDOM
PA Vertex Pharmaceuticals Incorporated, Cambridge, MA, UNITED STATES (U.S. corporation)
PI US 20070259869 A1 20071108
AI US 2006-592114 A1 20061103 (11)
PRAI US 2005-732951P 20051103 (60)
US 2005-733557P 20051104 (60)
DT Utility
FS APPLICATION
LN.CNT 4814
INCL INCLM: 514/234.800
INCLS: 435/375.000; 514/235.800; 514/252.180; 514/252.190; 514/266.400; 514/274.000; 514/275.000; 544/122.000; 544/297.000; 544/317.000
NCL NCLM: 514/234.800
NCLS: 435/375.000; 514/235.800; 514/252.180; 514/252.190; 514/266.400; 514/274.000; 514/275.000; 544/122.000; 544/297.000; 544/317.000
IC IPCI A61K0031-506 [I,A]; A61K0031-496 [I,A]; A61K0031-517 [I,A]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A]; C07D0239-47 [I,A]; C07D0239-48 [I,A]; C07D0239-50 [I,A]; C07D0239-00 [I,C*]; C07D0413-14 [I,A]; C07D0413-00 [I,C*]; C12N0005-02 [I,A]
IPCR A61K0031-506 [I,C]; A61K0031-506 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-517 [I,C]; A61K0031-517 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; A61P0035-02 [I,A]; C07D0239-00 [I,C]; C07D0239-47 [I,A]; C07D0239-48 [I,A]; C07D0239-50 [I,A]; C07D0413-00 [I,C]; C07D0413-14 [I,A]; C12N0005-02 [I,C]; C12N0005-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 31 OF 152 USPATFULL on STN

Full Text

AN 2007:290262 USPATFULL
TI Substituted N-Aryl-1H-Pyrazolo[3,4-B]Quinolin-4-Amines and Analogs as Activators of Caspases and Inducers of Apoptosis
IN Zhang, Han-Zhong, San Diego, CA, UNITED STATES
Cai, Sui Xiong, San Diego, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
PA Cytovia, Inc., San Diego, CA, UNITED STATES, 92121 (U.S. corporation)
PI US 20070253957 A1 20071101
AI US 2005-664059 A1 20051006 (11)
WO 2005-US35793 20051006
20070329 PCT 371 date
PRAI US 2004-616539P 20041007 (60)
DT Utility
FS APPLICATION
LN.CNT 2100
INCL INCLM: 424/141.100
INCLS: 514/234.800; 514/252.170; 514/252.180; 514/253.110; 514/290.000; 514/292.000; 514/293.000; 546/079.000; 546/082.000; 546/085.000
NCL NCLM: 424/141.100
NCLS: 514/234.800; 514/252.170; 514/252.180; 514/253.110; 514/290.000; 514/292.000; 514/293.000; 546/079.000; 546/082.000; 546/085.000
IC IPCI A61K0031-4745 [I,A]; A61K0031-4738 [I,C*]; A61K0031-435 [I,A]; A61K0031-496 [I,A]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0039-395 [I,A]; A61P0017-00 [I,A]; A61P0019-02 [I,A]; A61P0019-00 [I,C*]; A61P0031-12 [I,A]; A61P0031-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A]; C07D0221-06 [I,A]; C07D0221-00 [I,C*]; C07D0471-04 [I,A]; C07D0471-00 [I,C*]
IPCR A61K0031-4738 [I,C]; A61K0031-4745 [I,A]; A61K0031-435 [I,C]; A61K0031-435 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0039-395 [I,C]; A61K0039-395 [I,A]; A61P0017-00 [I,C]; A61P0017-00 [I,A]; A61P0019-00 [I,C]; A61P0019-02 [I,A]; A61P0031-00 [I,C]; A61P0031-12 [I,A]; A61P0035-00 [I,C]; A61P0035-00 [I,A]; A61P0035-02 [I,A]; C07D0221-00 [I,C]; C07D0221-06 [I,A]; C07D0471-00 [I,C]; C07D0471-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 32 OF 152 USPATFULL on STN

Full Text

AN 2007:285091 USPATFULL
 TI Substituted CIS- and trans-stilbenes as therapeutic agents
 IN Vander Jagt, David L., Albuquerque, NM, UNITED STATES
 Deck, Lorraine M., Albuquerque, NM, UNITED STATES
 PI US 20070249647 A1 20071025
 AI US 2007-789583 A1 20070425 (11)
 PRAI US 2006-794765P 20060425 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2051
 INCL INCLM: 514/277.000
 INCLS: 514/438.000; 514/733.000; 514/720.000; 514/034.000; 514/492.000;
 514/109.000; 514/027.000; 514/049.000; 514/262.100; 514 8;
 514/406.000; 424/623.000; 514/283.000; 424/094.630; 514/559.000;
 424/085.700; 514/251.000; 514/651.000; 546/339.000; 549/078.000
 NCL NCLM: 514/277.000
 NCLS: 424/085.700; 424/094.630; 424/623.000; 514/008.000; 514/027.000;
 514/034.000; 514/049.000; 514/109.000; 514/251.000; 514/262.100;
 514/283.000; 514/406.000; 514/438.000; 514/492.000; 514/559.000;
 514/651.000; 514/720.000; 514/733.000; 546/339.000; 549/078.000
 IC IPCI A61K0031-44 [I,A]; A61K0031-381 [I,A]; C07D0333-16 [I,A];
 C07D0333-00 [I,C*]; A61K0038-48 [I,A]; A61K0038-43 [I,C*];
 A61K0038-21 [I,A]; A61K0031-66 [I,A]; A61K0031-525 [I,A];
 A61K0031-519 [I,C*]
 IPCR A61K0031-44 [I,C]; A61K0031-44 [I,A]; A61K0031-381 [I,C];
 A61K0031-381 [I,A]; A61K0031-519 [I,C]; A61K0031-525 [I,A];
 A61K0031-66 [I,C]; A61K0031-66 [I,A]; A61K0038-21 [I,C];
 A61K0038-21 [I,A]; A61K0038-43 [I,C]; A61K0038-48 [I,A];
 C07D0333-00 [I,C]; C07D0333-16 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 33 OF 152 USPATFULL on STN

Full Text

AN 2007:285045 USPATFULL
 TI COMPOUNDS AND THERAPEUTICAL USE THEREOF
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
 Pervin, Azra, Escondido, CA, UNITED STATES
 Drewe, John A., Carlsbad, CA, UNITED STATES
 Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
 Jiang, Songchun, San Diego, CA, UNITED STATES
 Zhang, Hong, San Diego, CA, UNITED STATES
 Pleiman, Chris, Holladay, UT, UNITED STATES
 Baichwal, Vijay, Salt Lake City, UT, UNITED STATES
 Manfredi, John, Salt Lake City, UT, UNITED STATES
 Bhoite, Leena, Salt Lake City, UT, UNITED STATES
 PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S.
 corporation)
 Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 20070249601 A1 20071025
 AI US 2007-693432 A1 20070329 (11)
 RLI Continuation of Ser. No. US 2004-885903, filed on 6 Jul 2004, PENDING
 PRAI US 2003-484325P 20030703 (60)
 US 2003-493006P 20030807 (60)
 US 2004-557556P 20040329 (60)
 US 2004-571288P 20040514 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 9007
 INCL INCLM: 514/234.800
 INCLS: 514/252.020; 514/255.050; 514/263.100; 514/266.100; 514/266.200;
 514/311.000; 544/116.000; 544/238.000; 544/258.000; 544/264.000;
 544/284.000; 544/293.000; 546/159.000
 NCL NCLM: 514/234.800
 NCLS: 514/252.020; 514/255.050; 514/263.100; 514/266.100; 514/266.200;
 514/311.000; 544/116.000; 544/238.000; 544/258.000; 544/264.000;
 544/284.000; 544/293.000; 546/159.000
 IC IPCI A61K0031-47 [I,A]; A61K0031-50 [I,A]; A61K0031-517 [I,A];
 A61K0031-52 [I,A]; A61K0031-519 [I,C*]; A61K0031-535 [I,A];
 A61P0031-00 [I,A]
 IPCR A61K0031-47 [I,C]; A61K0031-47 [I,A]; A61K0031-50 [I,C];
 A61K0031-50 [I,A]; A61K0031-517 [I,C]; A61K0031-517 [I,A];

A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61K0031-52 [I,A];
A61K0031-535 [I,C]; A61K0031-535 [I,A]; A61P0031-00 [I,C];
A61P0031-00 [I,A]; C07D0239-00 [I,C*]; C07D0239-94 [I,A];
C07D0239-95 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A];
C07D0403-00 [I,C*]; C07D0403-04 [I,A]; C07D0403-12 [I,A];
C07D0405-00 [I,C*]; C07D0405-12 [I,A]; C07D0487-00 [I,C*];
C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 34 OF 152 USPATFULL on STN

Full Text

AN 2007:278680 USPATFULL
TI COMPOUNDS AND THERAPEUTICAL USE THEREOF
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
Pervin, Azra, Escondido, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Jiang, Songchun, San Diego, CA, UNITED STATES
Zhang, Hong, San Diego, CA, UNITED STATES
Pleiman, Chris, Holladay, UT, UNITED STATES
Baichwal, Vijay, Salt Lake City, UT, UNITED STATES
Manfredi, John, Salt Lake City, UT, UNITED STATES
Bhoite, Leena, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S. corporation)
Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20070244114 A1 20071018
AI US 2007-685342 A1 20070313 (11)
RLI Continuation of Ser. No. US 2004-885903, filed on 6 Jul 2004, PENDING
DT Utility
FS APPLICATION
LN.CNT 8909
INCL INCLM: 514/233.800
INCLS: 514/264.110; 514/266.200; 514/266.210; 514/266.230; 514/266.240;
514/266.300; 514/266.400; 544/119.000; 544/264.000; 544/284.000;
544/293.000
NCL NCLM: 514/233.800
NCLS: 514/264.110; 514/266.200; 514/266.210; 514/266.230; 514/266.240;
514/266.300; 514/266.400; 544/119.000; 544/264.000; 544/284.000;
544/293.000
IC IPCI A61K0031-517 [I,A]; A61K0031-5355 [I,A]; C07D0239-94 [I,A];
C07D0239-00 [I,C*]; C07D0401-12 [I,A]; C07D0401-00 [I,C*];
C07D0413-12 [I,A]; C07D0413-00 [I,C*]; C07D0473-00 [I,A]
IPCR A61K0031-517 [I,C]; A61K0031-517 [I,A]; A61K0031-5355 [I,C];
A61K0031-5355 [I,A]; C07D0239-00 [I,C]; C07D0239-94 [I,A];
C07D0401-00 [I,C]; C07D0401-12 [I,A]; C07D0413-00 [I,C];
C07D0413-12 [I,A]; C07D0473-00 [I,C]; C07D0473-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 35 OF 152 USPATFULL on STN

Full Text

AN 2007:278679 USPATFULL
TI COMPOUNDS AND THERAPEUTICAL USE THEREOF
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
Pervin, Azra, Escondido, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Jiang, Songchun, San Diego, CA, UNITED STATES
Zhang, Hong, San Diego, CA, UNITED STATES
Pleiman, Chris, Holladay, UT, UNITED STATES
Baichwal, Vijay, Salt Lake City, UT, UNITED STATES
Manfredi, John, Salt Lake City, UT, UNITED STATES
Bhoite, Leena, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S. corporation)
Cytovia, Inc, San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20070244113 A1 20071018
AI US 2007-680843 A1 20070301 (11)
RLI Continuation of Ser. No. US 2004-885903, filed on 6 Jul 2004, PENDING
PRAI US 2003-484325P 20030703 (60)

US 2003-493006P 20030807 (60)
 US 2004-557556P 20040329 (60)
 US 2004-571288P 20040514 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8898
 INCL INCLM: 514/233.800
 INCLS: 514/264.110; 514/266.200; 514/266.210; 514/266.230; 514/266.240;
 514/266.300; 514/266.400; 544/119.000; 544/264.000; 544/284.000;
 544/293.000
 NCL NCLM: 514/233.800
 NCLS: 514/264.110; 514/266.200; 514/266.210; 514/266.230; 514/266.240;
 514/266.300; 514/266.400; 544/119.000; 544/264.000; 544/284.000;
 544/293.000
 IC IPCI A61K0031-517 [I,A]; A61K0031-5355 [I,A]; C07D0239-94 [I,A];
 C07D0239-00 [I,C*]; C07D0401-12 [I,A]; C07D0401-00 [I,C*];
 C07D0413-12 [I,A]; C07D0413-00 [I,C*]; C07D0473-00 [I,A]
 IPCR A61K0031-517 [I,C]; A61K0031-517 [I,A]; A61K0031-519 [I,C*];
 A61K0031-519 [I,A]; A61K0031-5355 [I,C]; A61K0031-5355 [I,A];
 C07D0239-00 [I,C]; C07D0239-94 [I,A]; C07D0239-95 [I,A];
 C07D0401-00 [I,C]; C07D0401-12 [I,A]; C07D0403-00 [I,C*];
 C07D0403-04 [I,A]; C07D0403-12 [I,A]; C07D0405-00 [I,C*];
 C07D0405-12 [I,A]; C07D0413-00 [I,C]; C07D0413-12 [I,A];
 C07D0473-00 [I,C]; C07D0473-00 [I,A]; C07D0487-00 [I,C*];
 C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 36 OF 152 USPATFULL on STN

Full Text

AN 2007:256682 USPATFULL
 TI Site-specific enzymatic deposition of metal in situ
 IN Hainfeld, James F., Shoreham, NY, UNITED STATES
 Liu, Wenqiu, Miller Place, NY, UNITED STATES
 PI US 20070224625 A1 20070927
 AI US 2007-714682 A1 20070305 (11)
 RLI Continuation-in-part of Ser. No. US 2007-627735, filed on 26 Jan 2007,
 PENDING Division of Ser. No. US 2003-658609, filed on 8 Sep 2003,
 GRANTED, Pat. No. US 7183072 Continuation-in-part of Ser. No. US
 2001-822131, filed on 30 Mar 2001, GRANTED, Pat. No. US 6670113
 DT Utility
 FS APPLICATION
 LN.CNT 2966
 INCL INCLM: 435/006.000
 INCLS: 435/183.000; 435/007.940
 NCL NCLM: 435/006.000
 NCLS: 435/007.940; 435/183.000
 IC IPCI G01N0033-53 [I,A]; C12N0009-00 [I,A]; C12Q0001-68 [I,A]
 IPCR G01N0033-53 [I,C]; G01N0033-53 [I,A]; C12N0009-00 [I,C];
 C12N0009-00 [I,A]; C12Q0001-68 [I,C]; C12Q0001-68 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 37 OF 152 USPATFULL on STN

Full Text

AN 2007:243793 USPATFULL
 TI N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of
 caspases and inducers of apoptosis and the use thereof
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Kemnitzer, William E., San Diego, CA, UNITED STATES
 Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
 PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 20070213305 A1 20070913
 AI US 2006-591488 A1 20061102 (11)
 PRAI US 2005-732131P 20051102 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1978
 INCL INCLM: 514/151.000
 INCLS: 514/260.100
 NCL NCLM: 514/151.000
 NCLS: 514/260.100
 IC IPCI A61K0031-655 [I,A]; A61K0031-519 [I,A]
 IPCR A61K0031-655 [I,C]; A61K0031-655 [I,A]; A61K0031-519 [I,C];

A61K0031-519 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 38 OF 152 USPATFULL on STN

Full Text

AN 2007:237669 USPATFULL
TI COMPOUNDS AND THERAPEUTICAL USE THEREOF
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
Pervin, Azra, Escondido, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Jiang, Songchun, San Diego, CA, UNITED STATES
Zhang, Hong, San Diego, CA, UNITED STATES
Pleiman, Chris, Holladay, UT, UNITED STATES
Baichwal, Vijay, Salt Lake City, UT, UNITED STATES
Manfredi, John, Salt Lake City, UT, UNITED STATES
Bhoite, Leena, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 20070208044 A1 20070906
AI US 2007-620498 A1 20070105 (11)
RLI Continuation of Ser. No. US 2004-885903, filed on 6 Jul 2004, PENDING
PRAI US 2003-484325P 20030703 (60)
US 2003-493006P 20030807 (60)
US 2004-557556P 20040329 (60)
US 2004-571288P 20040514 (60)
DT Utility
FS APPLICATION
LN.CNT 8859
INCL INCLM: 514/266.200
INCLS: 514/266.300; 514/266.400; 544/284.000; 544/286.000; 544/293.000
NCL NCLM: 514/266.200
NCLS: 514/266.300; 514/266.400; 544/284.000; 544/286.000; 544/293.000
IC IPCI A61K0031-517 [I,A]; C07D0403-02 [I,A]; C07D0403-00 [I,C*];
C07D0239-94 [I,A]; C07D0239-00 [I,C*]
IPCR A61K0031-517 [I,C]; A61K0031-517 [I,A]; A61K0031-519 [I,C*];
A61K0031-519 [I,A]; C07D0239-00 [I,C]; C07D0239-94 [I,A];
C07D0239-95 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A];
C07D0403-00 [I,C]; C07D0403-02 [I,A]; C07D0403-04 [I,A];
C07D0403-12 [I,A]; C07D0405-00 [I,C*]; C07D0405-12 [I,A];
C07D0487-00 [I,C*]; C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 39 OF 152 USPATFULL on STN

Full Text

AN 2007:225438 USPATFULL
TI Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
IN Nesbit, Mark, Vincennes, FRANCE
Spada, Alfred P., Lansdale, PA, UNITED STATES
He, Wei, Audubon, PA, UNITED STATES
Myers, Michael R., Fishers, IN, UNITED STATES
PI US 20070197538 A1 20070823
AI US 2006-519935 A1 20060913 (11)
RLI Continuation of Ser. No. WO 2004-EP12185, filed on 7 Oct 2004, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 5603
INCL INCLM: 514/249.000
INCLS: 514/311.000; 514/312.000
NCL NCLM: 514/249.000
NCLS: 514/311.000; 514/312.000
IC IPCI A61K0031-498 [I,A]; A61K0031-47 [I,A]
IPCR A61K0031-498 [I,C]; A61K0031-498 [I,A]; A61K0031-47 [I,C];
A61K0031-47 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 40 OF 152 USPATFULL on STN

Full Text

AN 2007:224194 USPATFULL
TI Uv filters in powder form

IN Pflucker, Frank, Darmstadt, GERMANY, FEDERAL REPUBLIC OF
 Beck, Jorn, Seeheim-Jugenheim, GERMANY, FEDERAL REPUBLIC OF
 Driller, Hansjürgen, Gross-Umstadt, GERMANY, FEDERAL REPUBLIC OF

PI US 20070196290 A1 20070823

AI US 2005-591531 A1 20050208 (10)
 WO 2005-EP1244 20050208
 20060901 PCT 371 date

PRAI DE 2004-10200401031320040303

DT Utility

FS APPLICATION

LN.CNT 2335

INCL INCLM: 424/059.000
 INCLS: 977/926.000

NCL NCLM: 424/059.000
 NCLS: 977/926.000

IC IPCI A61K0008-37 [I,A]; A61K0008-42 [I,A]; A61K0008-30 [I,C*]
 IPCR A61K0008-30 [I,C]; A61K0008-37 [I,A]; A61K0008-04 [I,C*];
 A61K0008-04 [I,A]; A61K0008-11 [I,C*]; A61K0008-11 [I,A];
 A61K0008-19 [I,C*]; A61K0008-25 [I,A]; A61K0008-42 [I,A];
 A61Q0017-04 [I,C*]; A61Q0017-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 41 OF 152 USPATFULL on STN

Full Text

AN 2007:211261 USPATFULL

TI Anti-angiogenic activity of 2-methoxyestradiol in combination with
 anti-cancer agents

IN Plum, Stacy M., Arlington, VA, UNITED STATES
 Strawn, Steven J., Arlington, VA, UNITED STATES
 LaVallee, Theresa M., Rockville, MD, UNITED STATES
 Sidor, Carolyn F., Chapel Hill, NC, UNITED STATES
 Fogler, William E., Rockville, MD, UNITED STATES
 Treston, Anthony M., Rockville, MD, UNITED STATES

PI US 20070185069 A1 20070809

AI US 2006-599997 A1 20061114 (11)

PRAI US 2005-736220P 20051114 (60)
 US 2006-788354P 20060331 (60)

DT Utility

FS APPLICATION

LN.CNT 1366

INCL INCLM: 514/182.000
 INCLS: 514/506.000

NCL NCLM: 514/182.000
 NCLS: 514/506.000

IC IPCI A61K0031-56 [I,A]
 IPCR A61K0031-56 [I,C]; A61K0031-56 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 42 OF 152 USPATFULL on STN

Full Text

AN 2007:204468 USPATFULL

TI Aminopyrimidines useful as kinase inhibitors

IN Fraysse, Damien, Abingdon, UNITED KINGDOM
 Miller, Andrew, Upton, UNITED KINGDOM
 Robinson, Daniel, Abingdon, UNITED KINGDOM
 Pinder, Joanne, Abingdon, UNITED KINGDOM

PI US 20070179125 A1 20070802

AI US 2006-600588 A1 20061116 (11)

PRAI US 2005-737064P 20051116 (60)

DT Utility

FS APPLICATION

LN.CNT 2062

INCL INCLM: 514/210.200
 INCLS: 544/314.000

NCL NCLM: 514/210.200
 NCLS: 544/314.000

IC IPCI A61K0031-513 [I,A]; C07D0417-14 [I,A]; C07D0417-00 [I,C*]
 IPCR A61K0031-513 [I,C]; A61K0031-513 [I,A]; C07D0417-00 [I,C];
 C07D0417-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 43 OF 152 USPATFULL on STN

Full Text

AN 2007:177930 USPATFULL
TI NOVEL IMIDAZOPYRAZINES AS CYCLIN DEPENDENT KINASE INHIBITORS
IN PARUCH, KAMIL, Garwood, NJ, UNITED STATES
Guzi, Timothy J., Chatham, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20070155751 A1 20070705
AI US 2007-680929 A1 20070301 (11)
RLI Division of Ser. No. US 2003-666424, filed on 19 Sep 2003, GRANTED, Pat.
No. US 7186740
PRAI US 2002-412906P 20020923 (60)
DT Utility
FS APPLICATION
LN.CNT 1189
INCL INCLM: 514/249.000
INCLS: 544/350.000; 514/034.000; 514/027.000; 514/049.000; 514/283.000;
514/449.000; 514/251.000; 514/008.000; 514/171.000; 514/109.000;
514/365.000
NCL NCLM: 514/249.000
NCLS: 514/008.000; 514/027.000; 514/034.000; 514/049.000; 514/109.000;
514/171.000; 514/251.000; 514/283.000; 514/365.000; 514/449.000;
544/350.000
IC IPCI A61K0031-498 [I,A]; C07D0487-02 [I,A]; C07D0487-00 [I,C*]
IPCR A61K0031-498 [I,C]; A61K0031-498 [I,A]; C07D0487-00 [I,C];
C07D0487-02 [I,A]; C07D0487-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 44 OF 152 USPATFULL on STN

Full Text

AN 2007:177114 USPATFULL
TI Genes associate with progression and response in chronic myeloid
leukemia and uses thereof
IN Radich, Jerald P., Sammamish, WA, UNITED STATES
Dai, Hongyue, Kenmore, WA, UNITED STATES
Mao, Mao, Kirkland, WA, UNITED STATES
Schelter, Janell M., Bellevue, WA, UNITED STATES
Linsley, Peter S., Seattle, WA, UNITED STATES
PI US 20070154931 A1 20070705
AI US 2006-640517 A1 20061214 (11)
PRAI US 2005-751455P 20051215 (60)
DT Utility
FS APPLICATION
LN.CNT 29037
INCL INCLM: 435/006.000
INCLS: 702/020.000
NCL NCLM: 435/006.000
NCLS: 702/020.000
IC IPCI C12Q0001-68 [I,A]; G06F0019-00 [I,A]
IPCR C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; G06F0019-00 [I,C];
G06F0019-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 45 OF 152 USPATFULL on STN

Full Text

AN 2007:170821 USPATFULL
TI Six membered heteroaromatic inhibitors targeting resistant kinase
mutations
IN Noronha, Glenn, Oceanside, CA, UNITED STATES
Cao, Jianguo, San Diego, CA, UNITED STATES
Zeng, Binqi, San Diego, CA, UNITED STATES
Mak, Chi Ching, San Diego, CA, UNITED STATES
McPherson, Andrew, San Diego, CA, UNITED STATES
Renick, Joel, San Diego, CA, UNITED STATES
Pathak, Ved P., San Diego, CA, UNITED STATES
Chow, Chun, San Diego, CA, UNITED STATES
Palanki, Moorthy, Encinitas, CA, UNITED STATES
Soll, Richard M., San Diego, CA, UNITED STATES
Lohse, Daniel L., San Diego, CA, UNITED STATES
Hood, John D., San Diego, CA, UNITED STATES

Dneprovskaia, Elena, San Diego, CA, UNITED STATES
PA TargeGen, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20070149508 A1 20070628
AI US 2006-591076 A1 20061031 (11)
PRAI US 2005-733115P 20051102 (60)
DT Utility
FS APPLICATION
LN.CNT 9660
INCL INCLM: 514/218.000
INCLS: 514/242.000; 514/252.140; 514/256.000; 540/575.000; 544/295.000;
544/333.000; 544/182.000
NCL NCLM: 514/218.000
NCLS: 514/242.000; 514/252.140; 514/256.000; 540/575.000; 544/182.000;
544/295.000; 544/333.000
IC IPCI A61K0031-551 [I,A]; A61K0031-53 [I,A]; A61K0031-506 [I,A];
C07D0403-02 [I,A]; C07D0403-00 [I,C*]
IPCR A61K0031-551 [I,C]; A61K0031-551 [I,A]; A61K0031-506 [I,C];
A61K0031-506 [I,A]; A61K0031-53 [I,C]; A61K0031-53 [I,A];
C07D0403-00 [I,C]; C07D0403-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 46 OF 152 USPATFULL on STN

Full Text

AN 2007:170797 USPATFULL
TI NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES
IN Claus, Eckhard, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Seipelt, Irene, Offenbach, GERMANY, FEDERAL REPUBLIC OF
Guenther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
Polymeropoulos, Emmanuel, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Czech, Michael, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Schuster, Tilmann, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
PA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S.
corporation)
PI US 20070149484 A1 20070628
AI US 2006-558503 A1 20061110 (11)
PRAI US 2006-849761P 20061006 (60)
US 2005-735698P 20051111 (60)
DT Utility
FS APPLICATION
LN.CNT 15167
INCL INCLM: 514/081.000
INCLS: 514/249.000; 544/350.000; 544/337.000
NCL NCLM: 514/081.000
NCLS: 514/249.000; 544/337.000; 544/350.000
IC IPCI A61K0031-675 [I,A]; C07D0487-02 [I,A]; C07D0487-00 [I,C*];
A61K0031-498 [I,A]
IPCR A61K0031-675 [I,C]; A61K0031-675 [I,A]; A61K0031-498 [I,C];
A61K0031-498 [I,A]; C07D0487-00 [I,C]; C07D0487-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 47 OF 152 USPATFULL on STN

Full Text

AN 2007:141503 USPATFULL
TI PYRIDOPYRAZINE DERIVATIVES AND THEIR USE
IN SEIPELT, Irene, Offenbach, GERMANY, FEDERAL REPUBLIC OF
Claus, Eckhard, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Guenther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
Schuster, Tilmann, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Czech, Michael, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
Polymeropoulos, Emmanuel, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
PA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S.
corporation)
PI US 20070123494 A1 20070531
AI US 2006-558493 A1 20061110 (11)
PRAI US 2005-735707P 20051111 (60)
DT Utility
FS APPLICATION
LN.CNT 4048
INCL INCLM: 514/081.000
INCLS: 514/249.000; 544/350.000; 544/295.000; 544/237.000; 544/238.000;
514/224.800; 514/234.500; 544/125.000; 544/118.000; 544/051.000
NCL NCLM: 514/081.000

NCLS: 514/224.800; 514/234.500; 514/249.000; 544/051.000; 544/118.000;
 544/125.000; 544/237.000; 544/238.000; 544/295.000; 544/350.000
 IC IPCI A61K0031-5415 [I,A]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*];
 A61K0031-506 [I,A]; A61K0031-501 [I,A]; A61K0031-498 [I,A];
 C07D0487-02 [I,A]; C07D0487-00 [I,C*]
 IPCR A61K0031-5415 [I,C]; A61K0031-5415 [I,A]; A61K0031-498 [I,C];
 A61K0031-498 [I,A]; A61K0031-501 [I,C]; A61K0031-501 [I,A];
 A61K0031-506 [I,C]; A61K0031-506 [I,A]; A61K0031-5375 [I,C];
 A61K0031-5377 [I,A]; C07D0487-00 [I,C]; C07D0487-02 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 48 OF 152 USPATFULL on STN

Full Text

AN 2007:128647 USPATFULL
 TI 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of
 caspases and inducers of apoptosis and the use of thereof
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Zhang, Han-Zhong, San Diego, CA, UNITED STATES
 Kuemmerle, Jared D., Del Mar, CA, UNITED STATES
 Zhang, Hong, San Diego, CA, UNITED STATES
 Kemnitz, William E., San Diego, CA, UNITED STATES
 PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 20070112003 A1 20070517
 US 7317029 B2 20080108
 AI US 2006-593030 A1 20061106 (11)
 RLI Division of Ser. No. US 2003-737865, filed on 18 Dec 2003, GRANTED, Pat.
 No. US 7144876
 PRAI US 2002-433953P 20021218 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2614
 INCL INCLM: 514/235.500
 INCLS: 514/254.030; 514/364.000; 514/326.000; 544/138.000; 544/367.000;
 546/209.000; 548/136.000
 NCL NCLM: 514/364.000; 514/235.500
 NCLS: 548/131.000; 514/254.030; 514/326.000; 544/138.000; 544/367.000;
 546/209.000; 548/136.000
 IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-496 [I,A];
 A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4245 [I,A];
 C07D0413-14 [I,A]; C07D0413-00 [I,C*]
 IPCI-2 A61K0031-41 [I,A]; C07D0271-06 [I,A]; C07D0271-00 [I,C*]
 IPCR A61K0031-41 [I,C]; A61K0031-41 [I,A]; A61K0031-4245 [I,C*];
 A61K0031-4245 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
 C07D0271-00 [I,C]; C07D0271-06 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 49 OF 152 USPATFULL on STN

Full Text

AN 2007:128627 USPATFULL
 TI Fasudil in combination therapies for the treatment of pulmonary arterial
 hypertension
 IN Fong, Benson M., San Francisco, CA, UNITED STATES
 PI US 20070111983 A1 20070517
 AI US 2006-588185 A1 20061025 (11)
 PRAI US 2005-730273P 20051026 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 983
 INCL INCLM: 514/211.070
 INCLS: 514/573.000; 514/355.000; 514/423.000; 514/548.000; 514/460.000;
 514/650.000; 514/649.000; 514/218.000
 NCL NCLM: 514/211.070
 NCLS: 514/218.000; 514/355.000; 514/423.000; 514/460.000; 514/548.000;
 514/573.000; 514/649.000; 514/650.000
 IC IPCI A61K0031-554 [I,A]; A61K0031-551 [I,A]; A61K0031-353 [I,A];
 A61K0031-352 [I,C*]; A61K0031-366 [I,A]; A61K0031-22 [I,A];
 A61K0031-21 [I,C*]; A61K0031-137 [I,A]; A61K0031-401 [I,A];
 A61K0031-455 [I,A]
 IPCR A61K0031-554 [I,C]; A61K0031-554 [I,A]; A61K0031-137 [I,C];
 A61K0031-137 [I,A]; A61K0031-21 [I,C]; A61K0031-22 [I,A];
 A61K0031-352 [I,C]; A61K0031-353 [I,A]; A61K0031-366 [I,C];
 A61K0031-366 [I,A]; A61K0031-401 [I,C]; A61K0031-401 [I,A];

A61K0031-455 [I,C]; A61K0031-455 [I,A]; A61K0031-551 [I,C];
A61K0031-551 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 50 OF 152 USPATFULL on STN

Full Text

AN 2007:127908 USPATFULL
TI IMPROVED PROTEIN EXPRESSION COMPARISON ASSAY RESULTS AND APPLICATIONS
IN Kohne, David E., 4845 Tarantella Lane, San Diego, CA, UNITED STATES
92130
PI US 20070111257 A1 20070517
AI US 2006-456170 A1 20060707 (11)
PRAI US 2005-697118P 20050707 (60)
DT Utility
FS APPLICATION
LN.CNT 3989
INCL INCLM: 435/007.100
INCLS: 702/019.000
NCL NCLM: 435/007.100
NCLS: 702/019.000
IC IPCI G01N0033-53 [I,A]; G06F0019-00 [I,A]
IPCR G01N0033-53 [I,C]; G01N0033-53 [I,A]; G06F0019-00 [I,C];
G06F0019-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 51 OF 152 USPATFULL on STN

Full Text

AN 2007:114867 USPATFULL
TI N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of
caspases and inducers of apoptosis and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Kemnitzer, William E., San Diego, CA, UNITED STATES
Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20070099941 A1 20070503
AI US 2006-591531 A1 20061102 (11)
PRAI US 2005-732139P 20051102 (60)
DT Utility
FS APPLICATION
LN.CNT 1909
INCL INCLM: 514/260.100
INCLS: 544/278.000
NCL NCLM: 514/260.100
NCLS: 544/278.000
IC IPCI A61K0031-519 [I,A]; C07D0498-02 [I,A]; C07D0498-00 [I,C*]
IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; C07D0498-00 [I,C];
C07D0498-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 52 OF 152 USPATFULL on STN

Full Text

AN 2007:114803 USPATFULL
TI N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases
and inducers of apoptosis and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Kemnitzer, William E., San Diego, CA, UNITED STATES
Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 20070099877 A1 20070503
AI US 2006-591532 A1 20061102 (11)
PRAI US 2005-732140P 20051102 (60)
DT Utility
FS APPLICATION
LN.CNT 2682
INCL INCLM: 514/151.000
INCLS: 514/260.100; 544/278.000
NCL NCLM: 514/151.000
NCLS: 514/260.100; 544/278.000
IC IPCI A61K0031-655 [I,A]; A61K0031-519 [I,A]; C07D0498-02 [I,A];
C07D0498-00 [I,C*]

IPCR A61K0031-655 [I,C]; A61K0031-655 [I,A]; A61K0031-519 [I,C];
A61K0031-519 [I,A]; C07D0498-00 [I,C]; C07D0498-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 53 OF 152 USPATFULL on STN

Full Text

AN 2007:107483 USPATFULL
TI Derivatives of gambogic acid and analogs as activators of caspases and
inducers of apoptosis
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Jiang, Songchun, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
PI US 20070093456 A1 20070426
AI US 2004-580263 A1 20041217 (10)
WO 2004-US42292 20041217
20060525 PCT 371 date
PRAI US 2003-530256P 20031218 (60)
DT Utility
FS APPLICATION
LN.CNT 1379
INCL INCLM: 514/151.000
INCLS: 514/254.110; 514/232.800; 514/453.000
NCL NCLM: 514/151.000
NCLS: 514/232.800; 514/254.110; 514/453.000
IC IPCI A61K0031-655 [I,A]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*];
A61K0031-366 [I,A]
IPCR A61K0031-655 [I,C]; A61K0031-655 [I,A]; A61K0031-366 [I,C];
A61K0031-366 [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 54 OF 152 USPATFULL on STN

Full Text

AN 2007:95342 USPATFULL
TI Pyrazolopyrimidines as protein kinase inhibitors
IN Paruch, Kamil, Garwood, NJ, UNITED STATES
Guzi, Timothy J., Chatham, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Alvarez, Carmen S., Livingston, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20070083044 A1 20070412
AI US 2006-542921 A1 20061004 (11)
PRAI US 2005-724197P 20051006 (60)
DT Utility
FS APPLICATION
LN.CNT 3776
INCL INCLM: 540/575.000
INCLS: 544/114.000; 544/230.000; 544/281.000
NCL NCLM: 540/575.000
NCLS: 544/114.000; 544/230.000; 544/281.000
IC IPCI C07D0487-12 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR C07D0487-00 [I,C]; C07D0487-12 [I,A]; C07D0487-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 55 OF 152 USPATFULL on STN

Full Text

AN 2007:95200 USPATFULL
TI Pyrazolopyrimidines as protein kinase inhibitors
IN Paruch, Kamil, Garwood, NJ, UNITED STATES
Guzi, Timothy J., Chatham, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20070082902 A1 20070412
AI US 2006-542902 A1 20061004 (11)
PRAI US 2005-724159P 20051006 (60)
DT Utility
FS APPLICATION
LN.CNT 2309
INCL INCLM: 514/234.500
INCLS: 514/259.300; 514/252.160; 544/114.000; 544/281.000; 544/230.000
NCL NCLM: 514/234.500
NCLS: 514/252.160; 514/259.300; 544/114.000; 544/230.000; 544/281.000
IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-519 [I,A];

C07D0487-10 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-519 [I,C];
A61K0031-519 [I,A]; C07D0487-00 [I,C]; C07D0487-04 [I,A];
C07D0487-10 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 56 OF 152 USPATFULL on STN

Full Text

AN 2007:95199 USPATFULL
TI Pyrazolopyrimidines as protein kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20070082901 A1 20070412
AI US 2006-542852 A1 20061004 (11)
PRAI US 2005-724123P 20051006 (60)
DT Utility
FS APPLICATION
LN.CNT 2170
INCL INCLM: 514/234.500
INCLS: 514/252.160; 514/259.300; 544/060.000; 544/114.000; 544/281.000
NCL NCLM: 514/234.500
NCLS: 514/252.160; 514/259.300; 544/060.000; 544/114.000; 544/281.000
IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-519 [I,A];
C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-519 [I,C];
A61K0031-519 [I,A]; C07D0487-00 [I,C]; C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 57 OF 152 USPATFULL on STN

Full Text

AN 2007:95198 USPATFULL
TI Methods for inhibiting protein kinases
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Parry, David A., Mountain View, CA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20070082900 A1 20070412
AI US 2006-542801 A1 20061004 (11)
PRAI US 2005-724158P 20051006 (60)
DT Utility
FS APPLICATION
LN.CNT 11060
INCL INCLM: 514/234.500
INCLS: 514/252.160; 514/259.300
NCL NCLM: 514/234.500
NCLS: 514/252.160; 514/259.300
IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-519 [I,A]
IPCR A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-519 [I,C];
A61K0031-519 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 58 OF 152 USPATFULL on STN

Full Text

AN 2007:83463 USPATFULL
TI Use of tyrosine kinase inhibitor to treat **diabetes**
IN Hagerkvist, Robert Per, Höganasgatan 7B, Uppsala, SWEDEN 75330
Welsh, Nils Richard, Uppsala, SWEDEN
PI US 20070072932 A1 20070329
AI US 2004-556984 A1 20040526 (10)
WO 2004-EP5679 20040526
20060622 PCT 371 date
PRAI GB 2003-12086 20030527
GB 2004-2682 20040206
DT Utility
FS APPLICATION
LN.CNT 857
INCL INCLM: 514/414.000
NCL NCLM: 514/414.000
IC IPCI A61K0031-40 [I,A]

IPCR A61K0031-40 [I,C]; A61K0031-40 [I,A]; A61K0031-403 [I,C*];
A61K0031-404 [I,A]; A61K0031-42 [I,C*]; A61K0031-42 [I,A];
A61K0031-4353 [I,C*]; A61K0031-437 [I,A]; A61K0031-47 [I,C*];
A61K0031-47 [I,A]; A61K0031-498 [I,C*]; A61K0031-498 [I,A];
A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-517 [I,C*];
A61K0031-517 [I,A]; A61K0031-519 [I,C*]; A61K0031-519 [I,A];
A61P0003-00 [I,C*]; A61P0003-10 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 59 OF 152 USPATFULL on STN

Full Text

AN 2007:83413 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Siddiqui, M. Arshad, Newton, MA, UNITED STATES
Reddy, Panduranga Adulla P., Walpole, MA, UNITED STATES
Belanger, David B., Cambridge, MA, UNITED STATES
Hamann, Blake, Cambridge, MA, UNITED STATES
Curran, Patrick J., Winthrop, MA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20070072882 A1 20070329
AI US 2006-543182 A1 20061004 (11)
RLI Continuation-in-part of Ser. No. US 2005-244776, filed on 6 Oct 2005,
PENDING Continuation-in-part of Ser. No. US 2003-654157, filed on 3 Sep
2003, GRANTED, Pat. No. US 7078525
PRAI US 2002-408030P 20020904 (60)
DT Utility
FS APPLICATION
LN.CNT 2147
INCL INCLM: 514/259.300
INCLS: 544/281.000
NCL NCLM: 514/259.300
NCLS: 544/281.000
IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 60 OF 152 USPATFULL on STN

Full Text

AN 2007:83412 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Labroli, Marc, Mount Laurel, NJ, UNITED STATES
Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20070072881 A1 20070329
AI US 2006-542920 A1 20061004 (11)
RLI Continuation-in-part of Ser. No. US 2005-245401, filed on 6 Oct 2005,
PENDING Continuation-in-part of Ser. No. US 2004-776988, filed on 11 Feb
2004, GRANTED, Pat. No. US 7119200 Continuation-in-part of Ser. No. US
2003-654546, filed on 3 Sep 2003, GRANTED, Pat. No. US 7161003
PRAI US 2002-408027P 20020904 (60)
US 2002-421959P 20021029 (60)
DT Utility
FS APPLICATION
LN.CNT 4000
INCL INCLM: 514/259.300
INCLS: 544/281.000
NCL NCLM: 514/259.300
NCLS: 544/281.000
IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 61 OF 152 USPATFULL on STN

Full Text

AN 2007:83411 USPATFULL
 TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 PI US 20070072880 A1 20070329
 AI US 2006-542833 A1 20061004 (11)
 RLI Continuation-in-part of Ser. No. US 2005-244772, filed on 6 Oct 2005,
 PENDING Continuation-in-part of Ser. No. US 2003-653776, filed on 3 Sep
 2003, GRANTED, Pat. No. US 7067661
 PRAI US 2002-408029P 20020904 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1325
 INCL INCLM: 514/259.300
 INCLS: 544/281.000
 NCL NCLM: 514/259.300
 NCLS: 544/281.000
 IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; C07D0487-00 [I,C];
 C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 62 OF 152 USPATFULL on STN

Full Text

AN 2007:83394 USPATFULL
 TI Bis-aryl amide compounds and methods of use
 IN Dimauro, Erin F., Cambridge, MA, UNITED STATES
 Bemis, Jean E., Arlington, MA, UNITED STATES
 Chaffee, Stuart C., Philadelphia, PA, UNITED STATES
 Chen, Ning, Thousand Oaks, CA, UNITED STATES
 Hu, Essu, Camarillo, CA, UNITED STATES
 Kunz, Roxanne, Santa Monica, CA, UNITED STATES
 Martin, Matthew W., Cambridge, MA, UNITED STATES
 McGowan, David C., Woluwe St. Pierre, BELGIUM
 Rumfelt, Shannon, Camarillo, CA, UNITED STATES
 PI US 20070072862 A1 20070329
 AI US 2006-503551 A1 20060811 (11)
 PRAI US 2005-708720P 20050815 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 6229
 INCL INCLM: 514/248.000
 INCLS: 514/252.030; 514/252.050; 514/249.000; 514/255.050; 514/256.000;
 514/300.000; 514/314.000; 544/237.000; 544/238.000; 544/333.000;
 544/405.000; 544/353.000; 546/122.000; 546/169.000
 NCL NCLM: 514/248.000
 NCLS: 514/249.000; 514/252.030; 514/252.050; 514/255.050; 514/256.000;
 514/300.000; 514/314.000; 544/237.000; 544/238.000; 544/333.000;
 544/353.000; 544/405.000; 546/122.000; 546/169.000
 IC IPCI A61K0031-506 [I,A]; A61K0031-502 [I,A]; A61K0031-501 [I,A];
 A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-498 [I,A];
 A61K0031-4745 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4709 [I,A]
 IPCR A61K0031-506 [I,C]; A61K0031-506 [I,A]; A61K0031-4709 [I,C];
 A61K0031-4709 [I,A]; A61K0031-4738 [I,C]; A61K0031-4745 [I,A];
 A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-498 [I,C];
 A61K0031-498 [I,A]; A61K0031-501 [I,C]; A61K0031-501 [I,A];
 A61K0031-502 [I,C]; A61K0031-502 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 63 OF 152 USPATFULL on STN

Full Text

AN 2007:76268 USPATFULL
 TI Novel 4-cyano, 4-amino, and 4-aminomethyl derivatives of
 pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2h-indazole
 compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of
 imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent
 kinase inhibitors
 IN Mallams, Alan K., Hackettstown, NJ, UNITED STATES
 Madison, Vincent, Moutain Lakes, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES

PI US 20070066621 A1 20070322
 AI US 2006-514548 A1 20060831 (11)
 PRAI US 2005-715621P 20050909 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2199
 INCL INCLM: 514/252.160
 INCLS: 514/259.300; 514/303.000; 544/281.000; 544/362.000; 546/118.000
 NCL NCLM: 514/252.160
 NCLS: 514/259.300; 514/303.000; 544/281.000; 544/362.000; 546/118.000
 IC IPCI A61K0031-519 [I,A]; A61K0031-496 [I,A]; C07D0487-04 [I,A];
 C07D0487-00 [I,C*]; C07D0471-02 [I,A]; C07D0471-00 [I,C*];
 A61K0031-4745 [I,A]; A61K0031-4738 [I,C*]
 IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61K0031-4738 [I,C];
 A61K0031-4745 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A];
 C07D0471-00 [I,C]; C07D0471-02 [I,A]; C07D0487-00 [I,C];
 C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 64 OF 152 USPATFULL on STN

Full Text

AN 2007:62126 USPATFULL
 TI PHARMACODYNAMIC ASSAYS
 IN Trepel, Jane, Bethesda, MD, UNITED STATES
 Chung, Eun Joo, Rockville, MD, UNITED STATES
 PI US 20070054260 A1 20070308
 AI US 2006-467080 A1 20060824 (11)
 RLI Continuation of Ser. No. WO 2005-US6236, filed on 25 Feb 2005, PENDING
 PRAI US 2004-548794P 20040227 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1502
 INCL INCLM: 435/004.000
 INCLS: 435/018.000
 NCL NCLM: 435/004.000
 NCLS: 435/018.000
 IC IPCI C12Q0001-00 [I,A]; C12Q0001-34 [I,A]
 IPCR C12Q0001-00 [I,C]; C12Q0001-00 [I,A]; C12Q0001-34 [I,C];
 C12Q0001-34 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 65 OF 152 USPATFULL on STN

Full Text

AN 2007:49250 USPATFULL
 TI Substituted 2-arylmethylene-n-aryl-n'aryl-malonamides and analogs as
 activators of caspases and inducers of apoptosis
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Pervin, Azra, Murrieta, CA, UNITED STATES
 Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
 Nguyen, Bao Ngoc, San Diego, CA, UNITED STATES
 PI US 20070043076 A1 20070222
 AI US 2004-572910 A1 20041005 (10)
 WO 2004-US32570 20041005
 20060321 PCT 371 date
 PRAI US 2003-508290P 20031006 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3795
 INCL INCLM: 514/307.000
 INCLS: 514/313.000; 514/406.000; 514/332.000; 514/419.000; 514/397.000;
 514/471.000; 514/459.000; 514/616.000; 514/422.000
 NCL NCLM: 514/307.000
 NCLS: 514/313.000; 514/332.000; 514/397.000; 514/406.000; 514/419.000;
 514/422.000; 514/459.000; 514/471.000; 514/616.000
 IC IPCI A61K0031-4709 [I,A]; A61K0031-444 [I,A]; A61K0031-4427 [I,C*];
 A61K0031-416 [I,A]; A61K0031-4178 [I,A]; A61K0031-4164 [I,C*];
 A61K0031-405 [I,A]; A61K0031-403 [I,C*]; A61K0031-381 [I,A];
 A61K0031-4025 [I,A]; A61K0031-165 [I,A]
 IPCR A61K0031-4709 [I,C]; A61K0031-4709 [I,A]; A61K0031-165 [I,C];
 A61K0031-165 [I,A]; A61K0031-381 [I,C]; A61K0031-381 [I,A];
 A61K0031-4025 [I,C]; A61K0031-4025 [I,A]; A61K0031-403 [I,C];
 A61K0031-405 [I,A]; A61K0031-416 [I,C]; A61K0031-416 [I,A];

A61K0031-4164 [I,C]; A61K0031-4178 [I,A]; A61K0031-4427 [I,C];
A61K0031-444 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 66 OF 152 USPATFULL on STN

Full Text

AN 2007:49219 USPATFULL
TI Novel high affinity thiophene-based and furan-based kinase ligands
IN Deng, Yongqi, Newton, MA, UNITED STATES
Zhao, Lianyun, Burlington, MA, UNITED STATES
Shipps, Gerald W. JR., Stoneham, MA, UNITED STATES
Curran, Patrick J., Winthrop, MA, UNITED STATES
Siddiqui, M. Arshad, Newton, MA, UNITED STATES
Zhang, Rumin, Edison, NJ, UNITED STATES
McNemar, Charles W., High Bridge, NJ, UNITED STATES
Mayhood, Todd W., Randolph, NJ, UNITED STATES
Windsor, William T., East Brunswick, NJ, UNITED STATES
Lees, Emma M., Oakland, CA, UNITED STATES
Parry, David A., Mountain View, CA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20070043045 A1 20070222
AI US 2006-505263 A1 20060816 (11)
PRAI US 2005-709143P 20050817 (60)
DT Utility
FS APPLICATION
LN.CNT 2753
INCL INCLM: 514/235.200
INCLS: 514/422.000; 514/447.000; 514/471.000; 514/255.050; 514/326.000;
514/340.000; 514/383.000; 514/378.000; 514/362.000; 514/397.000;
514/406.000; 514/374.000; 514/314.000; 514/249.000; 514/367.000;
544/142.000; 544/146.000; 544/333.000; 544/405.000; 544/373.000;
546/176.000; 546/207.000; 546/276.400; 546/280.400; 548/154.000;
548/152.000; 548/266.200; 548/252.000; 548/242.000; 548/311.100;
548/527.000; 548/517.000
NCL NCLM: 514/235.200
NCLS: 514/249.000; 514/255.050; 514/314.000; 514/326.000; 514/340.000;
514/362.000; 514/367.000; 514/374.000; 514/378.000; 514/383.000;
514/397.000; 514/406.000; 514/422.000; 514/447.000; 514/471.000;
544/142.000; 544/146.000; 544/333.000; 544/373.000; 544/405.000;
546/176.000; 546/207.000; 546/276.400; 546/280.400; 548/152.000;
548/154.000; 548/242.000; 548/252.000; 548/266.200; 548/311.100;
548/517.000; 548/527.000
IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-497 [I,A];
A61K0031-4965 [I,C*]; A61K0031-496 [I,A]; A61K0031-4439 [I,A];
A61K0031-4427 [I,C*]; A61K0031-4709 [I,A]; A61K0031-428 [I,A];
A61K0031-42 [I,A]; A61K0031-4196 [I,A]; A61K0031-4178 [I,A];
A61K0031-4164 [I,C*]; A61K0031-4025 [I,A]; A61K0031-416 [I,A];
C07D0413-02 [I,A]; C07D0413-00 [I,C*]; C07D0405-02 [I,A];
C07D0405-00 [I,C*]; C07D0409-02 [I,A]; C07D0409-00 [I,C*];
C07D0417-02 [I,A]; C07D0417-00 [I,C*]
IPCR A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-4025 [I,C];
A61K0031-4025 [I,A]; A61K0031-416 [I,C]; A61K0031-416 [I,A];
A61K0031-4164 [I,C]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C];
A61K0031-4196 [I,A]; A61K0031-42 [I,C]; A61K0031-42 [I,A];
A61K0031-428 [I,C]; A61K0031-428 [I,A]; A61K0031-4427 [I,C];
A61K0031-4439 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709 [I,A];
A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C];
A61K0031-497 [I,A]; C07D0405-00 [I,C]; C07D0405-02 [I,A];
C07D0409-00 [I,C]; C07D0409-02 [I,A]; C07D0413-00 [I,C];
C07D0413-02 [I,A]; C07D0417-00 [I,C]; C07D0417-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 67 OF 152 USPATFULL on STN

Full Text

AN 2007:36955 USPATFULL
TI Pyrazolotriazines as kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
PI US 20070032495 A1 20070208
US 7354921 B2 20080408
AI US 2006-546766 A1 20061012 (11)
RLI Division of Ser. No. US 2006-335383, filed on 19 Jan 2006, PENDING

Division of Ser. No. US 2005-64044, filed on 23 Feb 2005, GRANTED, Pat.
 No. US 7038045
 PRAI US 2004-547685P 20040225 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1459
 INCL INCLM: 514/246.000
 INCLS: 544/180.000
 NCL NCLM: 514/246.000
 NCLS: 544/194.000; 544/206.000; 544/207.000; 544/180.000
 IC IPCI A61K0031-53 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCI-2 A61K0031-53 [I,A]; A61P0035-00 [I,A]; A61P0019-02 [N,A];
 A61P0019-00 [N,C*]; C07D0251-72 [N,A]; C07D0251-00 [N,C*]
 IPCR A61K0031-53 [I,C]; A61K0031-53 [I,A]; C07D0487-00 [I,C];
 C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 68 OF 152 USPATFULL on STN

Full Text

AN 2007:36890 USPATFULL
 TI Peptides and peptide mimetics to treat pathologies characterized by an
 inflammatory response
 IN Fogelman, Alan M., Beverly Hills, CA, UNITED STATES
 Navab, Mohamad, Los Angeles, CA, UNITED STATES
 PA The Regents of the University of California (U.S. corporation)
 PI US 20070032430 A1 20070208
 AI US 2006-407390 A1 20060418 (11)
 RLI Continuation-in-part of Ser. No. US 2003-423830, filed on 25 Apr 2003,
 PENDING Continuation-in-part of Ser. No. US 2002-273386, filed on 16 Oct
 2002, PENDING Continuation-in-part of Ser. No. US 2002-187215, filed on
 28 Jun 2002, GRANTED, Pat. No. US 7144862 Continuation-in-part of Ser.
 No. US 2001-896841, filed on 29 Jun 2001, GRANTED, Pat. No. US 6933279
 Continuation-in-part of Ser. No. US 2000-645454, filed on 24 Aug 2000,
 GRANTED, Pat. No. US 6664230
 PRAI US 2005-697495P 20050707 (60)
 US 2005-676431P 20050429 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 10947
 INCL INCLM: 514/013.000
 INCLS: 530/326.000
 NCL NCLM: 514/013.000
 NCLS: 530/326.000
 IC IPCI A61K0038-10 [I,A]; C07K0007-08 [I,A]; C07K0007-00 [I,C*]
 IPCR A61K0038-10 [I,C]; A61K0038-10 [I,A]; C07K0007-00 [I,C];
 C07K0007-08 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 69 OF 152 USPATFULL on STN

Full Text

AN 2006:301047 USPATFULL
 TI Sensitizing cells for apoptosis by selectively blocking cytokines
 IN Stassi, Giorgio, Palermo, ITALY
 Todaro, Maltilde, Palermo, ITALY
 PI US 20060257401 A1 20061116
 AI US 2004-544794 A1 20040209 (10)
 WO 2004-EP1177 20040209
 20060508 PCT 371 date
 PRAI EP 2003-2603 20030207
 DT Utility
 FS APPLICATION
 LN.CNT 1861
 INCL INCLM: 424/144.100
 INCLS: 424/085.400; 424/155.100; 424/085.100; 424/649.000; 514/171.000;
 514/027.000; 514/456.000; 514/251.000; 514/454.000; 514/492.000;
 514/034.000; 514/012.000
 NCL NCLM: 424/144.100
 NCLS: 424/085.100; 424/085.400; 424/155.100; 424/649.000; 514/012.000;
 514/027.000; 514/034.000; 514/171.000; 514/251.000; 514/454.000;
 514/456.000; 514/492.000
 IC IPCI A61K0039-395 [I,A]; A61K0038-21 [I,A]; A61K0033-24 [I,A];
 A61K0031-7048 [I,A]; A61K0031-7042 [I,C*]; A61K0031-704 [I,A];

A61K0031-7028 [I,C*]; A61K0031-57 [I,A]
IPCR A61K0039-395 [I,C]; A61K0039-395 [I,A]; A61K0031-57 [I,C];
A61K0031-57 [I,A]; A61K0031-7028 [I,C]; A61K0031-704 [I,A];
A61K0031-7042 [I,C]; A61K0031-7048 [I,A]; A61K0033-24 [I,C];
A61K0033-24 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-19 [I,C*]; A61K0038-19 [I,A]; A61K0038-20 [I,C*];
A61K0038-20 [I,A]; A61K0038-21 [I,C]; A61K0038-21 [I,A];
A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0035-00 [I,C*];
A61P0035-00 [I,A]; A61P0037-00 [I,C*]; A61P0037-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 70 OF 152 USPATFULL on STN

Full Text

AN 2006:275228 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
Dillard, Lawrence W., Skillman, NJ, UNITED STATES
Tran, Vinh D., Fountain Valley, CA, UNITED STATES
He, Zhen Min, Princeton, NJ, UNITED STATES
James, Ray Anthony, Bristol, PA, UNITED STATES
Park, Haengsoon, Plainsboro, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20060235025 A1 20061019
AI US 2006-395974 A1 20060331 (11)
RLI Division of Ser. No. US 2003-654157, filed on 3 Sep 2003, PENDING
PRAI US 2002-408030P 20020904 (60)
DT Utility
FS APPLICATION
LN.CNT 1722
INCL INCLM: 514/252.160
INCLS: 544/281.000; 514/259.300
NCL NCLM: 514/252.160
NCLS: 514/259.300; 544/281.000
IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 71 OF 152 USPATFULL on STN

Full Text

AN 2006:262718 USPATFULL
TI Drug eluting structurally variable stent
IN Jayaraman, Swaminathan, Fremont, CA, UNITED STATES
PI US 20060224234 A1 20061005
AI US 2006-399304 A1 20060406 (11)
RLI Continuation-in-part of Ser. No. US 2003-696174, filed on 29 Oct 2003,
PENDING Continuation-in-part of Ser. No. US 2001-994253, filed on 26 Nov
2001, GRANTED, Pat. No. US 6641611 Continuation-in-part of Ser. No. US
2002-286805, filed on 4 Nov 2002, GRANTED, Pat. No. US 6746478
Continuation-in-part of Ser. No. US 2005-156992, filed on 20 Jun 2005,
PENDING Continuation-in-part of Ser. No. US 2001-941327, filed on 29 Aug
2001, GRANTED, Pat. No. US 6908480
DT Utility
FS APPLICATION
LN.CNT 2208
INCL INCLM: 623/001.160
INCLS: 623/001.420
NCL NCLM: 623/001.160
NCLS: 623/001.420
IC IPCI A61F0002-90 [I,A]; A61F0002-82 [I,C*]
IPCR A61F0002-82 [I,C]; A61F0002-90 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 72 OF 152 USPATFULL on STN

Full Text

AN 2006:209372 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES

Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Alvarez, Carmen S., Livingston, NJ, UNITED STATES
 Chan, Tin-Yau, Edison, NJ, UNITED STATES
 Knutson, Chad, Garwood, NJ, UNITED STATES
 Madison, Vincent, Mountain Lakes, NJ, UNITED STATES
 Fischmann, Thierry O., Scotch Plains, NJ, UNITED STATES
 Dillard, Lawrence W., Skillman, NJ, UNITED STATES
 Tran, Vinh D., Fountain Valle, CA, UNITED STATES
 He, Zhen Min, Princeton, NJ, UNITED STATES
 James, Ray Anthony, Bensalem, PA, UNITED STATES
 Park, Haengsoon, Plainsboro, NJ, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 Pahrmacopeia, Inc. (U.S. corporation)
 PI US 20060178371 A1 20060810
 AI US 2006-395676 A1 20060331 (11)
 RLI Division of Ser. No. US 2003-653776, filed on 3 Sep 2003, GRANTED, Pat.
 No. US 7067661
 PRAI US 2002-408029P 20020904 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1840
 INCL INCLM: 514/252.160
 INCLS: 544/281.000; 514/259.300; 514/251.000; 514/109.000; 514/034.000;
 514/283.000; 514/290.000; 514/027.000; 514/449.000; 514/492.000;
 600/001.000; 424/649.000
 NCL NCLM: 514/252.160
 NCLS: 424/649.000; 514/027.000; 514/034.000; 514/109.000; 514/251.000;
 514/259.300; 514/283.000; 514/290.000; 514/449.000; 514/492.000;
 544/281.000; 600/001.000
 IC IPCI A61K0031-519 [I,A]; A61K0031-7048 [I,A]; A61K0031-7042 [I,C*];
 A61K0031-704 [I,A]; A61K0031-7028 [I,C*]; A61K0031-525 [I,A];
 A61K0031-66 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 73 OF 152 USPATFULL on STN

Full Text

AN 2006:203131 USPATFULL
 TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Knutson, Chad, Garwood, NJ, UNITED STATES
 McKittrick, Brian, New Vernon, NJ, UNITED STATES
 Dillard, Lawrence W., Skillman, NJ, UNITED STATES
 Tran, Vinh D., Fountain Valley, CA, UNITED STATES
 He, Zhen Min, Princeton, NJ, UNITED STATES
 James, Ray Anthony, Bristol, PA, UNITED STATES
 Park, Haengsoon, Plainsboro, NJ, UNITED STATES
 PI US 20060173017 A1 20060803
 AI US 2006-395965 A1 20060331 (11)
 RLI Division of Ser. No. US 2003-654163, filed on 3 Sep 2003, PENDING
 PRAI US 2002-408182P 20020904 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1602
 INCL INCLM: 514/252.160
 INCLS: 544/281.000; 514/259.300
 NCL NCLM: 514/252.160
 NCLS: 514/259.300; 544/281.000
 IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 74 OF 152 USPATFULL on STN

Full Text

AN 2006:203130 USPATFULL
 TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES

Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Dillard, Lawrence W., Skillman, NJ, UNITED STATES
 Tran, Vinh D., Fountain Valle, CA, UNITED STATES
 He, Zhen Min, Princeton, NJ, UNITED STATES
 James, Ray Anthony, Bristol, PA, UNITED STATES
 Park, Haengsoon, Plainsboro, NJ, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 Pharmacopeia, Inc. (U.S. corporation)
 PI US 20060173016 A1 20060803
 US 7309705 B2 20071218
 AI US 2006-395824 A1 20060331 (11)
 RLI Division of Ser. No. US 2003-653868, filed on 3 Sep 2003, PENDING
 PRAI US 2002-407999P 20020904 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1663
 INCL INCLM: 514/252.160
 INCLS: 514/259.300; 544/281.000
 NCL NCLM: 514/259.310; 514/252.160
 NCLS: 544/281.000; 514/259.300
 IC IPCI A61K0031-517 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCI-2 A61K0031-519 [I,A]; A61P0035-00 [N,A]; C07D0484-04 [N,A]
 IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61P0035-00 [N,C];
 A61P0035-00 [N,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 75 OF 152 USPATFULL on STN

Full Text

AN 2006:188672 USPATFULL
 TI Harnessing network biology to improve drug discovery
 IN MacDonald, Marnie L., Pleasanton, CA, UNITED STATES
 Westwick, John K., San Ramon, CA, UNITED STATES
 Keon, Brigitte, Castro Valley, CA, UNITED STATES
 Lamerdin, Jane, Livermore, CA, UNITED STATES
 Michnick, Stephen W., Montreal, CANADA
 PA Odyssey Thera, Inc., San Ramon, CA, UNITED STATES (U.S. corporation)
 PI US 20060160109 A1 20060720
 AI US 2005-282745 A1 20051121 (11)
 PRAI US 2004-629558P 20041122 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4681
 INCL INCLM: 435/006.000
 INCLS: 435/007.100; 977/702.000; 977/926.000
 NCL NCLM: 435/006.000
 NCLS: 435/007.100; 977/702.000; 977/926.000
 IC IPCI C40B0040-08 [I,A]; C40B0040-10 [I,A]; C40B0040-04 [I,C*]
 IPCR C40B0040-04 [I,C]; C40B0040-08 [I,A]; C40B0040-10 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 76 OF 152 USPATFULL on STN

Full Text

AN 2006:152284 USPATFULL
 TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Labroli, Marc, Mount Laurel, NJ, UNITED STATES
 Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
 PA Schering Corporation (U.S. corporation)
 PI US 20060128725 A1 20060615
 US 7196078 B2 20070327
 AI US 2005-245401 A1 20051006 (11)
 RLI Continuation-in-part of Ser. No. US 2004-776988, filed on 11 Feb 2004,
 PENDING Continuation-in-part of Ser. No. US 2003-654546, filed on 3 Sep
 2003, PENDING
 PRAI US 2002-408027P 20020904 (60)
 US 2002-421959P 20021029 (60)
 DT Utility

FS APPLICATION
LN.CNT 11723
INCL INCLM: 514/259.300
INCLS: 544/281.000
NCL NCLM: 514/218.000; 514/259.300
NCLS: 514/228.500; 514/233.200; 514/259.300; 540/115.000; 540/575.000;
544/061.000; 544/117.000; 544/281.000
IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCI-2 A61K0031-5513 [I,A]; A61K0031-551 [I,C*]; A61K0031-5355 [I,A];
A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*];
C07D0413-04 [I,A]; C07D0417-04 [I,A]; C07D0417-00 [I,C*];
C07D0243-08 [I,A]; C07D0243-00 [I,C*]; A61K0031-541 [N,A];
A61P0019-02 [N,A]; A61P0019-00 [N,C*]; A61P0029-00 [N,A];
C07D0413-06 [N,A]; C07D0413-00 [N,C*]
IPCR A61K0031-519 [I,A]; A61K0031-519 [I,C]; C07D0487-00 [I,C];
C07D0487-04 [I,A]; A61K0031-551 [I,C]; A61K0031-5513 [I,A];
A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61K0031-5355 [I,C];
A61K0031-5355 [I,A]; A61K0031-541 [N,C]; A61K0031-541 [N,A];
A61P0019-00 [N,C]; A61P0019-02 [N,A]; A61P0029-00 [N,C];
A61P0029-00 [N,A]; C07D0243-00 [I,C]; C07D0243-08 [I,A];
C07D0413-00 [I,C]; C07D0413-04 [I,A]; C07D0413-06 [N,A];
C07D0417-00 [I,C]; C07D0417-04 [I,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 77 OF 152 USPATFULL on STN

Full Text

AN 2006:144869 USPATFULL
TI Pyrazolotriazines as kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20060122389 A1 20060608
US 7166602 B2 20070123
AI US 2006-335383 A1 20060119 (11)
RLI Division of Ser. No. US 2005-64044, filed on 23 Feb 2005, PENDING
PRAI US 2004-547685P 20040225 (60)
DT Utility
FS APPLICATION
LN.CNT 1549
INCL INCLM: 544/182.000
INCLS: 514/246.000
NCL NCLM: 514/245.000; 544/182.000
NCLS: 514/241.000; 544/194.000; 544/206.000; 544/207.000
IC IPCI A61K0031-53 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCI-2 A61K0031-53 [I,A]; A61P0019-02 [I,A]; A61P0019-00 [I,C*];
C07D0251-72 [N,A]; C07D0251-00 [N,C*]; C07D0487-04 [N,A];
C07D0487-00 [N,C*]
IPCR A61K0031-53 [I,A]; A61K0031-53 [I,C]; C07D0487-00 [I,C];
C07D0487-04 [I,A]; A61K0031-53 [I,C]; A61K0031-53 [I,A];
A61P0019-00 [I,C]; A61P0019-02 [I,A]; C07D0251-00 [N,C];
C07D0251-72 [N,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 78 OF 152 USPATFULL on STN

Full Text

AN 2006:137823 USPATFULL
TI Therapeutic target and uses thereof
IN Little, Peter James, Victoria, AUSTRALIA
PI US 20060116403 A1 20060601
AI US 2003-515393 A1 20030520 (10)
WO 2003-AU608 20030520
20051219 PCT 371 date
PRAI AU 2002-2430 20020520
DT Utility
FS APPLICATION
LN.CNT 1395
INCL INCLM: 514/352.000
NCL NCLM: 514/352.000
IC IPCI A61K0031-44 [I,A]
IPCR A61K0031-44 [I,A]; A61K0031-44 [I,C]; A61K0031-506 [I,C*];
A61K0031-506 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];

A61P0009-00 [I,C*]; A61P0009-10 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 79 OF 152 USPATFULL on STN

Full Text

AN 2006:131781 USPATFULL
TI Use of diindolylmethane-related indoles and growth factor receptor
inhibitors for the treatment of human cytomegalovirus-associated disease
IN Zeligs, Michael A., Boulder, CO, UNITED STATES
PI US 20060111423 A1 20060525
AI US 2005-260543 A1 20051026 (11)
PRAI US 2004-622333P 20041026 (60)
DT Utility
FS APPLICATION
LN.CNT 2738
INCL INCLM: 514/410.000
INCLS: 514/414.000; 514/151.000
NCL NCLM: 514/410.000
NCLS: 514/151.000; 514/414.000
IC IPCI A61K0031-655 [I,A]; A61K0031-405 [I,A]; A61K0031-403 [I,C*];
A61K0031-407 [I,A]
IPCR A61K0031-655 [I,A]; A61K0031-403 [I,C]; A61K0031-405 [I,A];
A61K0031-407 [I,C]; A61K0031-407 [I,A]; A61K0031-655 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 80 OF 152 USPATFULL on STN

Full Text

AN 2006:125288 USPATFULL
TI Novel imidazopyrazines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Zhao, Lianyun, Burlington, MA, UNITED STATES
Curran, Patrick J., Winthrop, MA, UNITED STATES
Belanger, David B., Cambridge, MA, UNITED STATES
Hamann, Blake, Cambridge, MA, UNITED STATES
Reddy, Panduranga A., Walpole, MA, UNITED STATES
Siddiqui, M. Arshad, Newton, MA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20060106023 A1 20060518
AI US 2005-272392 A1 20051110 (11)
RLI Continuation-in-part of Ser. No. US 2005-47524, filed on 31 Jan 2005,
PENDING Division of Ser. No. US 2003-665005, filed on 19 Sep 2003,
GRANTED, Pat. No. US 6919341
PRAI US 2002-412997P 20020923 (60)
DT Utility
FS APPLICATION
LN.CNT 3257
INCL INCLM: 514/249.000
INCLS: 544/295.000; 544/350.000
NCL NCLM: 514/249.000
NCLS: 544/295.000; 544/350.000
IC IPCI A61K0031-506 [I,A]; A61K0031-498 [I,A]; C07D0487-02 [I,A];
C07D0487-00 [I,C*]
IPCR A61K0031-506 [I,A]; A61K0031-498 [I,C]; A61K0031-498 [I,A];
A61K0031-506 [I,C]; C07D0487-00 [I,C]; C07D0487-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 81 OF 152 USPATFULL on STN

Full Text

AN 2006:111759 USPATFULL
TI Pyrazolopyrimidines as protein kinase inhibitors
IN Paruch, Kamil, Garwood, NJ, UNITED STATES
Guzi, Timothy J., Chatham, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Shipps, Gerald W. JR., Stoneham, MA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20060094706 A1 20060504
AI US 2005-244628 A1 20051006 (11)
RLI Continuation-in-part of Ser. No. US 2003-452400, filed on 2 Jun 2003,
PENDING
PRAI US 2002-385837P 20020604 (60)

DT Utility
FS APPLICATION
LN.CNT 5714
INCL INCLM: 514/211.150
INCLS: 514/218.000; 514/227.800; 514/234.500; 514/252.160; 514/259.300;
540/575.000; 540/060.000; 544/114.000; 544/281.000; 540/544.000;
544/230.000
NCL NCLM: 514/211.150
NCLS: 514/218.000; 514/227.800; 514/234.500; 514/252.160; 514/259.300;
540/060.000; 540/544.000; 540/575.000; 544/114.000; 544/230.000;
544/281.000
IC IPCI A61K0031-554 [I,A]; A61K0031-553 [I,A]; A61K0031-551 [I,A];
A61K0031-541 [I,A]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*];
A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR A61K0031-554 [I,A]; A61K0031-519 [I,C]; A61K0031-519 [I,A];
A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-541 [I,C];
A61K0031-541 [I,A]; A61K0031-551 [I,C]; A61K0031-551 [I,A];
A61K0031-553 [I,C]; A61K0031-553 [I,A]; A61K0031-554 [I,C];
C07D0487-00 [I,C]; C07D0487-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 82 OF 152 USPATFULL on STN

Full Text

AN 2006:73778 USPATFULL
TI Polycationic peptide coatings and methods of making the same
IN Simhambhatla, Murthy V., Sunnyvale, CA, UNITED STATES
Ding, Ni, San Jose, CA, UNITED STATES
Pacetti, Stephen D., San Jose, CA, UNITED STATES
PI US 20060062821 A1 20060323
AI US 2005-218654 A1 20050902 (11)
RLI Continuation-in-part of Ser. No. US 2002-177114, filed on 21 Jun 2002,
PENDING
DT Utility
FS APPLICATION
LN.CNT 1173
INCL INCLM: 424/422.000
NCL NCLM: 424/422.000
IC IPCI A61F0013-00 [I,A]
IPCR A61F0013-00 [I,A]; A61F0013-00 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 83 OF 152 USPATFULL on STN

Full Text

AN 2006:47656 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20060041131 A1 20060223
US 7205308 B2 20070417
AI US 2005-244772 A1 20051006 (11)
RLI Continuation-in-part of Ser. No. US 2003-653776, filed on 3 Sep 2003,
PENDING
PRAI US 2002-408029P 20020904 (60)
DT Utility
FS APPLICATION
LN.CNT 2477
INCL INCLM: 544/281.000
INCLS: 514/252.160; 514/259.300
NCL NCLM: 514/259.300; 544/281.000
NCLS: 544/281.000
IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCI-2 A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*];
A61P0037-00 [N,A]; A61P0019-02 [N,A]; A61P0019-00 [N,C*];
A61P0029-00 [N,A]
IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61P0019-00 [N,C];
A61P0019-02 [N,A]; A61P0029-00 [N,C]; A61P0029-00 [N,A];
A61P0037-00 [N,C]; A61P0037-00 [N,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 84 OF 152 USPATFULL on STN

Full Text

AN 2006:47484 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20060040958 A1 20060223
US 7196092 B2 20070327
AI US 2005-244776 A1 20051006 (11)
RLI Continuation-in-part of Ser. No. US 2003-654157, filed on 3 Sep 2003,
PENDING
PRAI US 2002-408030P 20020904 (60)
DT Utility
FS APPLICATION
LN.CNT 2103
INCL INCLM: 514/259.300
INCLS: 544/281.000
NCL NCLM: 514/259.300
NCLS: 544/281.000
IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCI-2 A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*];
A61P0037-00 [N,A]; A61P0019-02 [N,A]; A61P0019-00 [N,C*];
A61P0029-00 [N,A]
IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61P0019-00 [N,C];
A61P0019-02 [N,A]; A61P0029-00 [N,C]; A61P0029-00 [N,A];
A61P0037-00 [N,C]; A61P0037-00 [N,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 85 OF 152 USPATFULL on STN

Full Text

AN 2006:34781 USPATFULL
TI Novel imidazopyridines as cyclin dependent kinase inhibitors
IN Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20060030555 A1 20060209
AI US 2005-238597 A1 20050929 (11)
RLI Division of Ser. No. US 2003-664338, filed on 17 Sep 2003, PENDING
PRAI US 2002-412063P 20020919 (60)
DT Utility
FS APPLICATION
LN.CNT 2360
INCL INCLM: 514/217.070
INCLS: 514/253.040; 514/303.000; 544/362.000; 540/599.000; 546/118.000
NCL NCLM: 514/217.070
NCLS: 514/253.040; 514/303.000; 540/599.000; 544/362.000; 546/118.000
IC IPCI C07D0471-02 [I,A]; C07D0471-00 [I,C*]; A61K0031-55 [I,A];
A61K0031-496 [I,A]; A61K0031-4745 [I,A]; A61K0031-4738 [I,C*]
IPCR C07D0471-00 [I,C]; C07D0471-02 [I,A]; A61K0031-4738 [I,C];
A61K0031-4745 [I,A]; A61K0031-496 [I,C]; A61K0031-496 [I,A];
A61K0031-55 [I,C]; A61K0031-55 [I,A]; C07D0471-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 86 OF 152 USPATFULL on STN

Full Text

AN 2005:331495 USPATFULL
TI Design of poly(ester amides) for the control of agent-release from
polymeric compositions
IN DesNoyer, Jessica R., San Jose, CA, UNITED STATES
Pacetti, Stephen D., San Jose, CA, UNITED STATES
Kleiner, Lothar W., Los Altos, CA, UNITED STATES
Hossainy, Syed F.A., Fremont, CA, UNITED STATES
Chen, Yung-Ming, Cupertino, CA, UNITED STATES
Stewart, Gordon, San Francisco, CA, UNITED STATES
Zhang, Gina, Temecula, CA, UNITED STATES

PI US 20050288481 A1 20051229
 AI US 2005-187467 A1 20050722 (11)
 RLI Continuation-in-part of Ser. No. US 2004-835656, filed on 30 Apr 2004,
 PENDING Continuation-in-part of Ser. No. US 2004-855294, filed on 26 May
 2004, PENDING Continuation-in-part of Ser. No. US 2005-115631, filed on
 26 Apr 2005, PENDING Continuation-in-part of Ser. No. US 2005-119020,
 filed on 29 Apr 2005, PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 4020
 INCL INCLM: 528/310.000
 NCL NCLM: 528/310.000
 IC [7]
 ICM A61L002-00
 IPCI A61L0002-00 [ICM,7]
 IPCR A61L0002-00 [I,C*]; A61L0002-00 [I,A]; A61L0031-08 [I,C*];
 A61L0031-10 [I,A]; A61L0031-14 [I,C*]; A61L0031-16 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 87 OF 152 USPATFULL on STN

Full Text

AN 2005:331242 USPATFULL
 TI Use of thioredoxin measurements for diagnostics and treatments
 IN Marks, Paul A., Washington, CT, UNITED STATES
 Ungerstedt, Johanna, Stockholm, SWEDEN
 PI US 20050288227 A1 20051229
 AI US 2005-144301 A1 20050603 (11)
 RLI Continuation-in-part of Ser. No. US 2003-369094, filed on 14 Feb 2003,
 ABANDONED
 PRAI US 2004-577089P 20040604 (60)
 US 2002-357383P 20020215 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2218
 INCL INCLM: 514/012.000
 INCLS: 514/044.000
 NCL NCLM: 514/012.000
 NCLS: 514/044.000
 IC [7]
 ICM A61K038-00
 IPCI A61K0038-00 [ICM,7]
 IPCR A61K0038-00 [I,C*]; A61K0038-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 88 OF 152 USPATFULL on STN

Full Text

AN 2005:313052 USPATFULL
 TI Compositions comprising hepoxilin analogs and their use in the treatment
 of cancer
 IN Pace-Asciak, Cecil, Toronto, CANADA
 PI US 20050272671 A1 20051208
 AI US 2004-999195 A1 20041129 (10)
 RLI Continuation of Ser. No. WO 2003-CA780, filed on 28 May 2003, UNKNOWN
 PRAI US 2002-383134P 20020528 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1008
 INCL INCLM: 514/025.000
 NCL NCLM: 514/025.000
 IC [7]
 ICM A61K031-7024
 IPCI A61K0031-7024 [ICM,7]
 IPCR A61K0031-7024 [I,C*]; A61K0031-7024 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 89 OF 152 USPATFULL on STN

Full Text

AN 2005:255889 USPATFULL
 TI Smac-peptides as therapeutics against cancer and autoimmune diseases
 IN Debatin, Klaus Michael, Ulm, GERMANY, FEDERAL REPUBLIC OF
 Fulda, Simone, Ulm, GERMANY, FEDERAL REPUBLIC OF
 PA Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts

(non-U.S. corporation)

PI US 20050222387 A1 20051006
 AI US 2003-511037 A1 20030417 (10)
 WO 2003-EP4039 20030417
 20050119 PCT 371 date

PRAI EP 2002-8199 20020417
 EP 2003-2015499 20020712

DT Utility
 FS APPLICATION
 LN.CNT 914
 INCL INCLM: 530/350.000
 INCLS: 514/012.000
 NCL NCLM: 530/350.000
 IC [7]
 ICM A61K038-17
 ICS C07K014-16; C07K014-475; C07K014-705
 IPCI A61K0038-17 [ICM,7]; C07K0014-16 [ICS,7]; C07K0014-005
 [ICS,7,C*]; C07K0014-475 [ICS,7]; C07K0014-705 [ICS,7];
 C07K0014-435 [ICS,7,C*]
 IPCR C12N0015-09 [I,C*]; C12N0015-09 [I,A]; A61K0031-7028 [I,C*];
 A61K0031-704 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7048 [I,A];
 A61K0033-24 [I,C*]; A61K0033-24 [I,A]; A61K0038-00 [I,C*];
 A61K0038-00 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
 A61K0039-395 [I,C*]; A61K0039-395 [I,A]; A61K0045-00 [I,C*];
 A61K0045-00 [I,A]; A61K0047-42 [I,C*]; A61K0047-42 [I,A];
 A61K0047-48 [I,C*]; A61K0047-48 [I,A]; A61P0001-00 [I,C*];
 A61P0001-16 [I,A]; A61P0003-00 [I,C*]; A61P0003-10 [I,A];
 A61P0005-00 [I,C*]; A61P0005-14 [I,A]; A61P0005-40 [I,A];
 A61P0007-00 [I,C*]; A61P0007-00 [I,A]; A61P0007-06 [I,A];
 A61P0009-00 [I,C*]; A61P0009-00 [I,A]; A61P0009-14 [I,A];
 A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0015-00 [I,C*];
 A61P0015-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-00 [I,A];
 A61P0019-00 [I,C*]; A61P0019-02 [I,A]; A61P0021-00 [I,C*];
 A61P0021-00 [I,A]; A61P0021-04 [I,A]; A61P0025-00 [I,C*];
 A61P0025-00 [I,A]; A61P0025-28 [I,A]; A61P0027-00 [I,C*];
 A61P0027-02 [I,A]; A61P0029-00 [I,C*]; A61P0029-00 [I,A];
 A61P0031-00 [I,C*]; A61P0031-00 [I,A]; A61P0031-10 [I,A];
 A61P0031-18 [I,A]; A61P0033-00 [I,C*]; A61P0033-06 [I,A];
 A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A];
 A61P0037-00 [I,C*]; A61P0037-06 [I,A]; C07K0005-00 [I,C*];
 C07K0005-103 [I,A]; C07K0014-005 [I,C*]; C07K0014-11 [I,A];
 C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C07K0014-50 [I,A];
 C12N0015-12 [I,C*]; C12N0015-12 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 90 OF 152 USPATFULL on STN

Full Text

AN 2005:215543 USPATFULL
 TI Pyrazolotriazines as kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 PA SCHERING CORPORATION (U.S. corporation)
 PI US 20050187219 A1 20050825
 US 7038045 B2 20060502
 AI US 2005-64044 A1 20050223 (11)
 PRAI US 2004-547685P 20040225 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1554
 INCL INCLM: 514/246.000
 INCLS: 544/184.000
 NCL NCLM: 544/194.000; 514/246.000
 NCLS: 544/206.000; 544/207.000; 544/184.000
 IC [7]
 ICM A61K031-53
 ICS C07D487-04
 IPCI A61K0031-53 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
 IPCI-2 C07D0251-72 [I,A]; C07D0251-00 [I,C*]; A61K0311-53 [I,A];
 A61P0019-02 [I,A]; A61P0019-00 [I,C*]
 IPCR A61K0031-53 [I,C*]; A61K0031-53 [I,A]; C07D0487-00 [I,C*];
 C07D0487-04 [I,A]; A61K0031-53 [I,C]; A61P0019-00 [I,C];
 A61P0019-02 [I,A]; C07D0251-00 [I,C]; C07D0251-72 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 91 OF 152 USPATFULL on STN

Full Text

AN 2005:190137 USPATFULL
TI Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and
analogs as activators of caspases and inducers of apoptosis and the use
thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
Drewe, John, Carlsbad, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
PA Cytovia, Inc. (U.S. corporation)
PI US 20050165053 A1 20050728
AI US 2003-477953 A1 20020604 (10)
WO 2002-US17486 20020604
PRAI US 2001-295007P 20010604 (60)
DT Utility
FS APPLICATION
LN.CNT 1624
INCL INCLM: 514/312.000
INCLS: 546/156.000
NCL NCLM: 514/312.000
NCLS: 546/156.000
IC [7]
ICM A61K031-47
ICS C07D215-36
IPCI A61K0031-47 [ICM,7]; C07D0215-36 [ICS,7]; C07D0215-00 [ICS,7,C*]
IPCR A61K0031-4704 [I,C*]; A61K0031-4704 [I,A]; A61K0031-4709 [I,C*];
A61K0031-4709 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 92 OF 152 USPATFULL on STN

Full Text

AN 2005:177931 USPATFULL
TI Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators
of caspases and inducers of apoptosis and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Reddy, P. Sanjeeva, San Diego, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Kuemmerle, Jared Daniel, Del Mar, CA, UNITED STATES
Ollis, Kristin P., San Diego, CA, UNITED STATES
PI US 20050154012 A1 20050714
AI US 2005-74077 A1 20050308 (11)
RLI Division of Ser. No. US 2002-164705, filed on 10 Jun 2002, PENDING
PRAI US 2001-296479P 20010608 (60)
DT Utility
FS APPLICATION
LN.CNT 3607
INCL INCLM: 514/310.000
INCLS: 514/314.000; 514/340.000; 514/365.000; 514/374.000
NCL NCLM: 514/310.000
NCLS: 514/314.000; 514/340.000; 514/365.000; 514/374.000
IC [7]
ICM A61K031-4709
ICS A61K031-4439; A61K031-427; A61K031-422
IPCI A61K0031-4709 [ICM,7]; A61K0031-4439 [ICS,7]; A61K0031-4427
[ICS,7,C*]; A61K0031-427 [ICS,7]; A61K0031-422 [ICS,7]
IPCR A61K0031-335 [I,C*]; A61K0031-335 [I,A]; A61K0031-38 [I,C*];
A61K0031-38 [I,A]; A61K0031-395 [I,C*]; A61K0031-395 [I,A];
C07D0409-00 [I,C*]; C07D0409-04 [I,A]; C07D0409-14 [I,A];
C07D0413-00 [I,C*]; C07D0413-04 [I,A]; C07D0413-14 [I,A];
C07D0417-00 [I,C*]; C07D0417-14 [I,A]; C07D0471-00 [I,C*];
C07D0471-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 93 OF 152 USPATFULL on STN

Full Text

AN 2005:159003 USPATFULL
TI Compounds and therapeutical use thereof

IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
 Pervin, Azra, Escondido, CA, UNITED STATES
 Drewe, John A., Carlsbad, CA, UNITED STATES
 Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
 Jiang, Songchun, San Diego, CA, UNITED STATES
 Zhang, Hong, San Diego, CA, UNITED STATES
 Pleiman, Chris, Holladay, UT, UNITED STATES
 Baichwal, Vijay, Salt Lake City, UT, UNITED STATES
 Manfredi, John, Salt Lake City, UT, UNITED STATES
 Bhoite, Leena, Salt Lake City, UT, UNITED STATES
 PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S. corporation)
 PI US 20050137213 A1 20050623
 AI US 2004-885903 A1 20040706 (10)
 PRAI US 2003-484325P 20030703 (60)
 US 2003-493006P 20030807 (60)
 US 2004-557556P 20040329 (60)
 US 2004-571288P 20040514 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 9124
 INCL INCLM: 514/262.100
 INCLS: 514/264.110; 514/266.400
 NCL NCLM: 514/262.100
 NCLS: 514/264.110; 514/266.400
 IC [7]
 ICM A61K031-519
 ICS A61K031-517
 IPCI A61K0031-519 [ICM,7]; A61K0031-517 [ICS,7]
 IPCR A61K0031-517 [I,C*]; A61K0031-517 [I,A]; A61K0031-519 [I,C*];
 A61K0031-519 [I,A]; C07D0239-00 [I,C*]; C07D0239-94 [I,A];
 C07D0239-95 [I,A]; C07D0401-00 [I,C*]; C07D0401-12 [I,A];
 C07D0403-00 [I,C*]; C07D0403-04 [I,A]; C07D0403-12 [I,A];
 C07D0405-00 [I,C*]; C07D0405-12 [I,A]; C07D0487-00 [I,C*];
 C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 94 OF 152 USPATFULL on STN

Full Text

AN 2005:152066 USPATFULL
 TI Novel imidazopyrazines as cyclin dependent kinase inhibitors
 IN Paruch, Kamil, Garwood, NJ, UNITED STATES
 Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Mallams, Alan, Hackettstown, NJ, UNITED STATES
 PI US 20050130980 A1 20050616
 AI US 2005-47524 A1 20050131 (11)
 RLI Division of Ser. No. US 2003-665005, filed on 19 Sep 2003, PENDING
 PRAI US 2002-412997P 20020923 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1878
 INCL INCLM: 514/249.000
 INCLS: 544/350.000
 NCL NCLM: 514/249.000
 NCLS: 544/350.000
 IC [7]
 ICM A61K031-498
 ICS C07D487-04
 IPCI A61K0031-498 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
 IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 95 OF 152 USPATFULL on STN

Full Text

AN 2005:150785 USPATFULL
 TI Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
 IN Thorpe, Philip E., Dallas, TX, UNITED STATES

Ran, Sophia, Riverton, IL, UNITED STATES
 PI US 20050129696 A1 20050616
 AI US 2003-642065 A1 20030815 (10)
 RLI Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003,
 PENDING
 PRAI US 2002-396263P 20020715 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 13046
 INCL INCLM: 424/155.100
 INCLS: 424/178.100
 NCL NCLM: 424/155.100
 NCLS: 424/178.100
 IC [7]
 ICM A61K039-395
 IPCI A61K0039-395 [ICM,7]
 IPCR A61K0039-395 [I,C*]; A61K0039-395 [I,A]; C07K0016-18 [I,C*];
 C07K0016-28 [I,A]; C07K0016-44 [I,C*]; C07K0016-44 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 96 OF 152 USPATFULL on STN

Full Text

AN 2005:144884 USPATFULL
 TI 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-
 2-yl-amino)phenyl]-benzamide for threatening ang ii-mediated diseases
 IN Gilbert, Richard Ernest, Victoria, AUSTRALIA
 Kelly, Darren James, Victoria, AUSTRALIA
 Feldman, David Louis, Teaneck, NJ, UNITED STATES
 PI US 20050124624 A1 20050609
 AI US 2003-507642 A1 20030314 (10)
 WO 2003-EP2709 20030314
 PRAI GB 2002-216 20020315
 GB 2003-206217 20020315
 GB 2003-217505 20020729
 DT Utility
 FS APPLICATION
 LN.CNT 1641
 INCL INCLM: 514/252.180
 INCLS: 514/381.000; 514/423.000; 514/355.000; 514/223.500; 514/460.000;
 514/548.000
 NCL NCLM: 514/252.180
 NCLS: 514/223.500; 514/355.000; 514/381.000; 514/423.000; 514/460.000;
 514/548.000
 IC [7]
 ICM A61K031-549
 ICS A61K031-506; A61K031-4178; A61K031-401; A61K031-366
 IPCI A61K0031-549 [ICM,7]; A61K0031-506 [ICS,7]; A61K0031-4178
 [ICS,7]; A61K0031-4164 [ICS,7,C*]; A61K0031-401 [ICS,7];
 A61K0031-366 [ICS,7]
 IPCR C07D0401-00 [I,C*]; C07D0401-04 [I,A]; A61K0031-00 [I,C*];
 A61K0031-00 [I,A]; A61K0031-41 [I,C*]; A61K0031-41 [I,A];
 A61K0031-505 [I,C*]; A61K0031-505 [I,A]; A61K0031-506 [I,C*];
 A61K0031-506 [I,A]; A61K0031-549 [I,C*]; A61K0031-549 [I,A];
 A61K0045-00 [I,C*]; A61K0045-06 [I,A]; A61P0009-00 [I,C*];
 A61P0009-00 [I,A]; A61P0009-04 [I,A]; A61P0009-10 [I,A];
 A61P0009-12 [I,A]; A61P0011-00 [I,C*]; A61P0011-00 [I,A];
 A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0043-00 [I,C*];
 A61P0043-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 97 OF 152 USPATFULL on STN

Full Text

AN 2005:44347 USPATFULL
 TI Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and
 prevention of diseases and conditions
 IN Boyer, Stephen, Hilden, GERMANY, FEDERAL REPUBLIC OF
 Dumas, Jacques, Bethany, CT, UNITED STATES
 Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
 Wilhelm, Scott, Orange, CT, UNITED STATES
 PI US 20050038080 A1 20050217
 AI US 2004-895985 A1 20040722 (10)
 PRAI US 2003-489102P 20030723 (60)

US 2004-540326P 20040202 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2492
 INCL INCLM: 514/350.000
 INCLS: 546/298.000
 NCL NCLM: 514/350.000
 NCLS: 546/298.000
 IC [7]
 ICM A61K031-675
 ICS C07D213-78; A61K031-4415
 IPCI A61K0031-675 [ICM,7]; C07D0213-78 [ICS,7]; C07D0213-00
 [ICS,7,C*]; A61K0031-4415 [ICS,7]
 IPCR A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4415 [I,C*];
 A61K0031-4415 [I,A]; A61K0031-675 [I,C*]; A61K0031-675 [I,A];
 A61P0035-00 [I,C*]; A61P0035-00 [I,A]; C07D0213-00 [I,C*];
 C07D0213-78 [I,A]; C07D0213-81 [I,A]; C07D0213-00 [I,C*]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 98 OF 152 USPATFULL on STN

Full Text

AN 2005:38145 USPATFULL
 TI Phosphorus-containing compounds and uses thereof
 IN Metcalf, Chester A., III, Needham, MA, UNITED STATES
 Rozamus, Leonard W., Bedford, MA, UNITED STATES
 Wang, Yihan, Newton, MA, UNITED STATES
 Berstein, David L., Waban, MA, UNITED STATES
 PI US 20050032825 A1 20050210
 US 7091213 B2 20060815
 AI US 2004-862149 A1 20040604 (10)
 RLI Continuation-in-part of Ser. No. US 2003-635054, filed on 6 Aug 2003,
 PENDING Continuation-in-part of Ser. No. US 2003-357152, filed on 3 Feb
 2003, PENDING
 PRAI US 2002-353252P 20020201 (60)
 US 2002-426928P 20021115 (60)
 US 2002-428383P 20021122 (60)
 US 2002-433930P 20021217 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3716
 INCL INCLM: 514/291.000
 INCLS: 540/456.000; 514/080.000
 NCL NCLM: 514/291.000
 NCLS: 540/456.000; 514/080.000
 IC [7]
 ICM A61K031-675
 ICS A61K031-4745
 IPCI A61K0031-675 [ICM,7]; A61K0031-4745 [ICS,7]; A61K0031-4738
 [ICS,7,C*]
 IPCI-2 C07D0491-06 [I,A]; C07D0491-00 [I,C*]; A61K0031-395 [I,A];
 A61P0035-00 [I,A]; A61P0035-02 [I,A]
 IPCR A61L0027-00 [I,C*]; A61L0027-00 [I,A]; A61F0002-82 [I,C*];
 A61F0002-84 [I,A]; A61K0031-661 [I,C*]; A61K0031-661 [I,A];
 A61K0031-662 [I,C*]; A61K0031-662 [I,A]; A61K0031-664 [I,C*];
 A61K0031-664 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
 A61K0045-06 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A];
 A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*];
 A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0011-00 [I,C*];
 A61P0011-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-02 [I,A];
 A61P0017-04 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C*];
 A61P0019-02 [I,A]; A61P0021-00 [I,C*]; A61P0021-04 [I,A];
 A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-28 [I,A];
 A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*];
 A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-10 [I,A];
 A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A];
 A61P0037-00 [I,C*]; A61P0037-00 [I,A]; C07D0498-00 [I,C*];
 C07D0498-18 [I,A]; C07F0009-00 [I,C*]; C07F0009-09 [I,A];
 C07F0009-22 [I,A]; C07F0009-32 [I,A]; C07F0009-36 [I,A];
 C07F0009-40 [I,A]; C07F0009-44 [I,A]; C07F0009-46 [I,A];
 C07F0009-53 [I,A]; C07F0009-6561 [I,A]; C07D0491-00 [I,C];
 C07D0491-06 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A];
 A61P0035-00 [I,C]; A61P0035-00 [I,A]; A61P0035-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 99 OF 152 USPATFULL on STN

Full Text

AN 2005:36945 USPATFULL
TI Combined cancer treatment methods using selected antibodies to
aminophospholipids
IN Thorpe, Philip E., Dallas, TX, UNITED STATES
Huang, Xianming, Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES
PI US 20050031620 A1 20050210
AI US 2003-642058 A1 20030815 (10)
RLI Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003,
PENDING
PRAI US 2002-396263P 20020715 (60)
DT Utility
FS APPLICATION
LN.CNT 13439
INCL INCLM: 424/155.100
NCL NCLM: 424/155.100
IC [7]
ICM A61K039-395
IPCI A61K0039-395 [ICM,7]
IPCR A61K0039-395 [I,C*]; A61K0039-395 [I,A]; C07K0016-18 [I,C*];
C07K0016-28 [I,A]; C07K0016-44 [I,C*]; C07K0016-44 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 100 OF 152 USPATFULL on STN

Full Text

AN 2005:17357 USPATFULL
TI Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as
activators of caspases and inducers of apoptosis
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Jiang, Sungchun, San Diego, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Kuemmerle, Jared Daniel, Del Mar, CA, UNITED STATES
Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
PA Cytovia, Inc. (U.S. corporation)
PI US 20050014759 A1 20050120
US 7135480 B2 20061114
AI US 2003-733229 A1 20031212 (10)
PRAI US 2002-432608P 20021212 (60)
DT Utility
FS APPLICATION
LN.CNT 3018
INCL INCLM: 514/250.000
INCLS: 514/291.000
NCL NCLM: 514/294.000; 514/250.000
NCLS: 514/233.200; 514/250.000; 544/126.000; 544/361.000; 546/094.000;
514/291.000
IC [7]
ICM A61K031-498
ICS A61K031-4745
IPCI A61K0031-498 [ICM,7]; A61K0031-4745 [ICS,7]; A61K0031-4738
[ICS,7,C*]
IPCI-2 A61K0031-4745 [I,A]; A61K0031-4738 [I,C*]; C07D0471-02 [I,A];
C07D0471-00 [I,C*]
IPCR A61K0031-4738 [I,C]; A61K0031-4745 [I,A]; A61K0031-496 [I,C*];
A61K0031-496 [I,A]; A61K0031-4985 [I,C*]; A61K0031-4985 [I,A];
C07D0471-00 [I,C]; C07D0471-02 [I,A]; C07D0471-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 101 OF 152 USPATFULL on STN

Full Text

AN 2005:3839 USPATFULL
TI Combinations and kits for cancer treatment using selected antibodies to
aminophospholipids
IN Thorpe, Philip E., Dallas, TX, UNITED STATES
Huang, Xianming, Dallas, TX, UNITED STATES
Ran, Sophia, Riverton, IL, UNITED STATES

PA Board of Regents, The University of Texas System (U.S. corporation)
 PI US 20050002941 A1 20050106
 AI US 2003-642116 A1 20030815 (10)
 RLI Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003,
 PENDING
 PRAI US 2002-396263P 20020715 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 13468
 INCL INCLM: 424/178.100
 INCLS: 530/388.800; 530/391.100
 NCL NCLM: 424/178.100
 NCLS: 530/388.800; 530/391.100
 IC [7]
 ICM A61K039-395
 ICS C07K016-46; C07K016-30
 IPCI A61K0039-395 [ICM,7]; C07K0016-46 [ICS,7]; C07K0016-30 [ICS,7];
 C07K0016-18 [ICS,7,C*]
 IPCR A61K0039-395 [I,C*]; A61K0039-395 [I,A]; C07K0016-18 [I,C*];
 C07K0016-28 [I,A]; C07K0016-44 [I,C*]; C07K0016-44 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 102 OF 152 USPATFULL on STN

Full Text

AN 2004:326927 USPATFULL
 TI Tumor-targeted drug delivery systems and uses thereof
 IN Ponzoni, Mirco, Genoa, ITALY
 Corti, Angelo, Bergamo, ITALY
 Allen, Theresa M., Edmonton, CANADA
 PI US 20040258747 A1 20041223
 AI US 2004-853895 A1 20040526 (10)
 PRAI GB 2003-12309 20030529
 DT Utility
 FS APPLICATION
 LN.CNT 2801
 INCL INCLM: 424/450.000
 INCLS: 424/093.200
 NCL NCLM: 424/450.000
 NCLS: 424/093.200
 IC [7]
 ICM A61K009-127
 ICS A61K048-00
 IPCI A61K0009-127 [ICM,7]; A61K0048-00 [ICS,7]
 IPCR A61K0009-127 [I,C*]; A61K0009-127 [I,A]; A61K0031-00 [I,C*];
 A61K0031-00 [I,A]; A61K0031-7028 [I,C*]; A61K0031-704 [I,A];
 A61K0038-08 [I,C*]; A61K0038-08 [I,A]; A61K0038-10 [I,C*];
 A61K0038-10 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 103 OF 152 USPATFULL on STN

Full Text

AN 2004:279855 USPATFULL
 TI Selected immunoconjugates for binding to aminophospholipids
 IN Thorpe, Philip E., Dallas, TX, UNITED STATES
 Ran, Sophia, Riverton, IL, UNITED STATES
 PI US 20040219155 A1 20041104
 AI US 2003-642099 A1 20030815 (10)
 RLI Continuation-in-part of Ser. No. US 2003-621269, filed on 15 Jul 2003,
 PENDING
 PRAI US 2002-396263P 20020715 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 13474
 INCL INCLM: 424/178.100
 INCLS: 530/391.100
 NCL NCLM: 424/178.100
 NCLS: 530/391.100
 IC [7]
 ICM A61K039-395
 ICS C07K016-46
 IPCI A61K0039-395 [ICM,7]; C07K0016-46 [ICS,7]
 IPCR A61K0039-395 [I,C*]; A61K0039-395 [I,A]; C07K0016-18 [I,C*];

C07K0016-28 [I,A]; C07K0016-44 [I,C*]; C07K0016-44 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 104 OF 152 USPATFULL on STN

Full Text

AN 2004:268335 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
Mallams, Alan, Hackettstown, NJ, UNITED STATES
Alvarez, Carmen S., Livingston, NJ, UNITED STATES
Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
Rivera, Jocelyn, Monmouth Junction, NJ, UNITED STATES
Chan, Tin-Yau, Edison, NJ, UNITED STATES
Madison, Vincent, Mountain Lakes, NJ, UNITED STATES
Fischmann, Thierry O., Scotch Plains, NJ, UNITED STATES
Dillard, Lawrence W., Skillman, NJ, UNITED STATES
Tran, Vinh D., Fountain Valley, CA, UNITED STATES
He, Zhen Min, Princeton, NJ, UNITED STATES
James, Ray Anthony, Bristol, PA, UNITED STATES
Park, Haengsoon, Plainsboro, NJ, UNITED STATES
Paradkar, Vidyadhar M., Somerville, NJ, UNITED STATES
Hobbs, Douglas Walsh, Yardley, PA, UNITED STATES
PA Schering Corporation and Pharmacoepia, Inc. (U.S. corporation)
PI US 20040209878 A1 20041021
US 7119200 B2 20061010
AI US 2004-776988 A1 20040211 (10)
RLI Continuation-in-part of Ser. No. US 2003-654546, filed on 3 Sep 2003,
PENDING
PRAI US 2002-408027P 20020904 (60)
US 2002-421959P 20021029 (60)
DT Utility
FS APPLICATION
LN.CNT 10644
INCL INCLM: 514/234.500
INCLS: 514/252.160; 514/259.300; 544/117.000; 544/280.000
NCL NCLM: 544/281.000; 514/234.500
NCLS: 514/252.160; 514/259.300; 544/117.000; 544/280.000
IC [7]
ICM A61K031-5377
ICS A61K031-519; C07D487-04
IPCI A61K0031-5377 [ICM,7]; A61K0031-5375 [ICM,7,C*]; A61K0031-519
[ICS,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCI-2 C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR C07D0487-00 [I,C]; C07D0487-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 105 OF 152 USPATFULL on STN

Full Text

AN 2004:177787 USPATFULL
TI Death domain containing receptor 5
IN Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner L., Belo Horizonte, BRAZIL
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 20040136951 A1 20040715
AI US 2003-648825 A1 20030827 (10)
RLI Continuation-in-part of Ser. No. US 2000-565009, filed on 4 May 2000,
PENDING Continuation-in-part of Ser. No. US 1998-42583, filed on 17 Mar
1998, PENDING
PRAI US 2002-413747P 20020927 (60)
US 2002-406307P 20020828 (60)
US 1999-148939P 19990813 (60)
US 1999-133238P 19990507 (60)
US 1999-132498P 19990504 (60)
US 1997-54021P 19970729 (60)
US 1997-40846P 19970317 (60)
DT Utility

FS APPLICATION
LN.CNT 12832
INCL INCLM: 424/085.100
INCLS: 424/131.100
NCL NCLM: 424/085.100
NCLS: 424/131.100
IC [7]
ICM A61K038-19
ICS A61K039-395
IPCI A61K0038-19 [ICM,7]; A61K0039-395 [ICS,7]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0039-395 [I,C*];
A61K0039-395 [I,A]; C07K0014-435 [I,C*]; C07K0014-705 [I,A];
C07K0014-715 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 106 OF 152 USPATFULL on STN

Full Text

AN 2004:177786 USPATFULL
TI Death domain containing receptor 4
IN Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Gentz, Reiner L., Belo-Horizonte, BRAZIL
PA Human Genome Sciences, Inc. (U.S. corporation)
The Regents of the University of Michigan (U.S. corporation)
PI US 20040136950 A1 20040715
US 20050112090 A9 20050526
AI US 2003-648786 A1 20030827 (10)
RLI Continuation-in-part of Ser. No. US 2000-565918, filed on 5 May 2000,
GRANTED, Pat. No. US 6433147 Continuation-in-part of Ser. No. US
1998-13895, filed on 27 Jan 1998, GRANTED, Pat. No. US 6342363
PRAI US 2002-413861P 20020927 (60)
US 2002-406922P 20020830 (60)
US 1999-132922P 19990506 (60)
US 1997-37829P 19970205 (60)
US 1997-35722P 19970128 (60)
DT Utility
FS APPLICATION
LN.CNT 13407
INCL INCLM: 424/085.100
INCLS: 424/144.100
NCL NCLM: 424/085.100
NCLS: 424/144.100
IC [7]
ICM A61K038-19
ICS A61K039-395
IPCI A61K0038-19 [ICM,7]; A61K0039-395 [ICS,7]
IPCI-2 A61K0038-19 [ICM,7]; A61K0039-395 [ICS,7]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0039-395 [I,C*];
A61K0039-395 [I,A]; C07K0014-435 [I,C*]; C07K0014-705 [I,A];
C07K0014-715 [I,A]; C07K0016-18 [I,C*]; C07K0016-28 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 107 OF 152 USPATFULL on STN

Full Text

AN 2004:166031 USPATFULL
TI 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of
caspases and inducers of apoptosis and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
Kuemmerle, Jared D., Del Mar, CA, UNITED STATES
Zhang, Hong, San Diego, CA, UNITED STATES
Kemnitzer, William E., Irvine, CA, UNITED STATES
PA Cytovia, Inc. (U.S. corporation)
PI US 20040127521 A1 20040701
US 7144876 B2 20061205
AI US 2003-737865 A1 20031218 (10)
PRAI US 2002-433953P 20021218 (60)
DT Utility
FS APPLICATION
LN.CNT 2946
INCL INCLM: 514/341.000
INCLS: 514/364.000

NCL NCLM: 514/171.000; 514/341.000
 NCLS: 546/048.000; 548/131.000; 549/323.000; 549/510.000; 514/364.000
 IC [7]
 ICM A61K031-4439
 ICS A61K031-4245
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0031-4245 [ICS,7]
 IPCI-2 A61K0031-56 [I,A]; C07D0471-00 [I,A]; C07D0271-06 [I,A]; C07D0271-00 [I,C*]; C07D0233-38 [I,A]; C07D0233-00 [I,C*]
 IPCR A61K0031-56 [I,C]; A61K0031-56 [I,A]; A61K0031-4245 [I,C*]; A61K0031-4245 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A]; C07D0233-00 [I,C]; C07D0233-38 [I,A]; C07D0271-00 [I,C]; C07D0271-06 [I,A]; C07D0471-00 [I,C]; C07D0471-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 108 OF 152 USPATFULL on STN

Full Text

AN 2004:152220 USPATFULL
 TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parisippany, NJ, UNITED STATES
 Dillard, Lawrence W., Skillman, NJ, UNITED STATES
 Tran, Vinh D., Fountain Valley, CA, UNITED STATES
 He, Zhen Min, Princeton, NJ, UNITED STATES
 James, Ray Anthony, Bristol, PA, UNITED STATES
 Park, Haengsoon, Plainsboro, NJ, UNITED STATES
 PI US 20040116442 A1 20040617
 US 7074924 B2 20060711
 AI US 2003-653868 A1 20030903 (10)
 PRAI US 2002-407999P 20020904 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1697
 INCL INCLM: 514/252.160
 INCLS: 514/259.300; 544/281.000
 NCL NCLM: 544/281.000; 514/252.160
 NCLS: 514/259.300
 IC [7]
 ICM A61K031-519
 ICS C07D487-02
 IPCI A61K0031-519 [ICM,7]; C07D0487-02 [ICS,7]; C07D0487-00 [ICS,7,C*]
 IPCI-2 C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0487-00 [I,C]; C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 109 OF 152 USPATFULL on STN

Full Text

AN 2004:139486 USPATFULL
 TI Use of the disorazoles and their derivatives for the treatment of benign and malignant oncoses
 IN Irschik, Herbert, Wolfenbuttel, GERMANY, FEDERAL REPUBLIC OF
 Jansen, Rolf, Braunschweig, GERMANY, FEDERAL REPUBLIC OF
 Sasse, Florenz, Braunschweig, GERMANY, FEDERAL REPUBLIC OF
 Baasner, Silke, Schoneck, GERMANY, FEDERAL REPUBLIC OF
 Schmidt, Peter, Schoneck, GERMANY, FEDERAL REPUBLIC OF
 Gunther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
 PI US 20040106662 A1 20040603
 AI US 2003-646904 A1 20030822 (10)
 PRAI US 2002-405594P 20020824 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 578
 INCL INCLM: 514/375.000
 NCL NCLM: 514/375.000
 IC [7]
 ICM A61K031-424
 IPCI A61K0031-424 [ICM,7]
 IPCR A61K0031-424 [I,C*]; A61K0031-424 [I,A]; C07D0498-00 [I,C*];

C07D0498-18 [I,A]; C07D0498-22 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 110 OF 152 USPATFULL on STN

Full Text

AN 2004:139448 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
Alvarez, Carmen S., Livingston, NJ, UNITED STATES
Chan, Tin-Yau, Edison, NJ, UNITED STATES
Knutson, Chad, Garwood, NJ, UNITED STATES
Madison, Vincent, Mountain Lakes, NJ, UNITED STATES
Fischmann, Thierry O., Scotch Plains, NJ, UNITED STATES
Dillard, Lawrence W., Skillman, NJ, UNITED STATES
Tran, Vinh D., Fountain Valley, CA, UNITED STATES
He, Zhen Min, Princeton, NJ, UNITED STATES
James, Ray Anthony, Bristol, PA, UNITED STATES
Park, Haengsoon, Plainsboro, NJ, UNITED STATES
PI US 20040106624 A1 20040603
US 7067661 B2 20060627
AI US 2003-653776 A1 20030903 (10)
PRAI US 2002-408029P 20020904 (60)
DT Utility
FS APPLICATION
LN.CNT 1889
INCL INCLM: 514/252.160
INCLS: 514/259.300; 544/281.000
NCL NCLM: 544/281.000; 514/252.160
NCLS: 514/259.300
IC [7]
ICM A61K031-519
ICS C07D487-04
IPCI A61K0031-519 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCI-2 C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 111 OF 152 USPATFULL on STN

Full Text

AN 2004:133915 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
Knutson, Chad, Garwood, NJ, UNITED STATES
McKittrick, Brian, New Vernon, NJ, UNITED STATES
Dillard, Lawrence W., Skillman, NJ, UNITED STATES
Tran, Vinh D., Fountain Valley, CA, UNITED STATES
He, Zhen Min, Princeton, NJ, UNITED STATES
James, Ray Anthony, Bristol, PA, UNITED STATES
Park, Haengsoon, Plainsboro, NJ, UNITED STATES
PA Schering Corporation and Pharmacopeia, Inc. (U.S. corporation)
PI US 20040102452 A1 20040527
US 7084271 B2 20060801
AI US 2003-654163 A1 20030903 (10)
PRAI US 2002-408182P 20020904 (60)
DT Utility
FS APPLICATION
LN.CNT 1678
INCL INCLM: 514/252.160
INCLS: 514/259.300; 544/281.000
NCL NCLM: 544/281.000; 514/252.160
NCLS: 514/259.300
IC [7]
ICM A61K031-519

ICS C07D487-02
IPCI A61K0031-519 [ICM,7]; C07D0487-02 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCI-2 C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 112 OF 152 USPATFULL on STN

Full Text

AN 2004:133914 USPATFULL
TI Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
Dillard, Lawrence W., Skillman, NJ, UNITED STATES
Tran, Vinh D., Fountain Valley, CA, UNITED STATES
He, Zhen Min, Princeton, NJ, UNITED STATES
James, Ray Anthony, Bristol, PA, UNITED STATES
Park, Haengsoon, Plainsboro, NJ, UNITED STATES
PA Schering Corporation and Pharmacoepia, Inc. (U.S. corporation)
PI US 20040102451 A1 20040527
US 7078525 B2 20060718
AI US 2003-654157 A1 20030903 (10)
PRAI US 2002-408030P 20020904 (60)
DT Utility
FS APPLICATION
LN.CNT 1816
INCL INCLM: 514/252.160
INCLS: 514/259.300; 544/281.000
NCL NCLM: 544/281.000; 514/252.160
NCLS: 514/259.300
IC [7]
ICM A61K031-519
ICS C07D487-02
IPCI A61K0031-519 [ICM,7]; C07D0487-02 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCI-2 C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 113 OF 152 USPATFULL on STN

Full Text

AN 2004:127533 USPATFULL
TI Novel imidazopyridines as cyclin dependent kinase inhibitors
IN Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20040097517 A1 20040520
US 6992080 B2 20060131
AI US 2003-664338 A1 20030917 (10)
PRAI US 2002-412063P 20020919 (60)
DT Utility
FS APPLICATION
LN.CNT 1855
INCL INCLM: 514/253.040
INCLS: 514/303.000; 544/362.000; 546/113.000
NCL NCLM: 514/217.070; 514/253.040
NCLS: 514/253.040; 514/256.000; 514/300.000; 514/303.000; 544/333.000;
544/362.000; 546/113.000; 546/121.000
IC [7]
ICM C07D471-02
ICS A61K031-496; A61K031-4745
IPCI C07D0471-02 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-496
[ICS,7]; A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*]
IPCI-2 A61K0031-435 [I,A]; A61K0031-505 [I,A]; A61K0031-44 [I,A];
C07D0471-02 [I,A]; C07D0471-00 [I,C*]; C07D0401-14 [I,A];

C07D0401-00 [I,C*]
 IPCR C07D0471-00 [I,C*]; C07D0471-04 [I,A]; A61K0031-435 [I,A];
 A61K0031-435 [I,C]; A61K0031-44 [I,C]; A61K0031-44 [I,A];
 A61K0031-505 [I,C]; A61K0031-505 [I,A]; C07D0401-00 [I,C];
 C07D0401-14 [I,A]; C07D0471-00 [I,C]; C07D0471-02 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 114 OF 152 USPATFULL on STN

Full Text

AN 2004:127532 USPATFULL
 TI Novel pyrazolopyridines as cyclin dependent kinase inhibitors
 IN Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 PA Schering Corporation (non-U.S. corporation)
 PI US 20040097516 A1 20040520
 US 7151104 B2 20061219
 AI US 2003-664337 A1 20030917 (10)
 PRAI US 2002-412138P 20020919 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1735
 INCL INCLM: 514/253.040
 INCLS: 514/303.000; 544/362.000; 546/113.000
 NCL NCLM: 514/259.100; 514/253.040
 NCLS: 514/359.000; 546/112.000; 546/113.000; 546/119.000; 546/121.000;
 548/100.000; 548/125.000; 548/126.000; 514/303.000; 544/362.000
 IC [7]
 ICM A61K031-496
 ICS A61K031-4745; C07D471-02
 IPCI A61K0031-496 [ICM,7]; A61K0031-4745 [ICS,7]; A61K0031-4738
 [ICS,7,C*]; C07D0471-02 [ICS,7]; C07D0471-00 [ICS,7,C*]
 IPCI-2 C07D0271-00 [I,A]; C07D0221-02 [I,A]; C07D0221-00 [I,C*];
 A01N0043-90 [I,A]
 IPCR C07D0271-00 [I,C]; C07D0271-00 [I,A]; A01N0043-90 [I,C];
 A01N0043-90 [I,A]; C07D0221-00 [I,C]; C07D0221-02 [I,A];
 C07D0471-00 [I,C*]; C07D0471-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 115 OF 152 USPATFULL on STN

Full Text

AN 2004:126458 USPATFULL
 TI Methods for inhibiting protein kinases in cancer cells
 IN Carson, Dennis A., Del Mar, CA, UNITED STATES
 Rosenbach, Michael D., San Diego, CA, UNITED STATES
 Carrera, Carlos J., San Diego, CA, UNITED STATES
 Leoni, Lorenzo M., San Diego, CA, UNITED STATES
 PA REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (U.S. corporation)
 SALMEDIX, INC., San Deigo, CA (U.S. corporation)
 PI US 20040096436 A1 20040520
 AI US 2003-632592 A1 20030801 (10)
 PRAI US 2002-400568P 20020802 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2382
 INCL INCLM: 424/094.400
 INCLS: 514/043.000; 514/456.000; 514/469.000; 424/146.100
 NCL NCLM: 424/094.400
 NCLS: 424/146.100; 514/043.000; 514/456.000; 514/469.000
 IC [7]
 ICM A61K031-7056
 ICS A61K031-365; A61K031-353; A61K038-44; A61K039-395
 IPCI A61K0031-7056 [ICM,7]; A61K0031-7042 [ICM,7,C*]; A61K0031-365
 [ICS,7]; A61K0031-353 [ICS,7]; A61K0031-352 [ICS,7,C*];
 A61K0038-44 [ICS,7]; A61K0038-43 [ICS,7,C*]; A61K0039-395 [ICS,7]
 IPCR A61K0031-352 [I,C*]; A61K0031-353 [I,A]; A61K0031-365 [I,C*];
 A61K0031-365 [I,A]; A61K0031-7042 [I,C*]; A61K0031-7056 [I,A];
 A61K0038-43 [I,C*]; A61K0038-44 [I,A]; A61K0039-395 [I,C*];
 A61K0039-395 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 116 OF 152 USPATFULL on STN

Full Text

AN 2004:107666 USPATFULL
TI Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Ollis, Kristin P., San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Tseng, Ben, San Diego, CA, UNITED STATES
Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
PA Cytovia, Inc. (U.S. corporation)
PI US 20040082066 A1 20040429
US 7176234 B2 20070213
AI US 2003-609670 A1 20030701 (10)
PRAI US 2002-392358P 20020701 (60)
US 2002-413649P 20020926 (60)
DT Utility
FS APPLICATION
LN.CNT 2606
INCL INCLM: 435/375.000
NCL NCLM: 514/450.000; 435/375.000
NCLS: 549/268.000
IC [7]
ICM C12N005-00
ICS C12N005-02
IPCI C12N005-00 [ICM,7]; C12N005-02 [ICS,7]
IPCI-2 A61K0031-352 [I,A]; C07D0313-06 [I,A]; C07D0313-00 [I,C*]
IPCR A61K0031-352 [I,C]; A61K0031-352 [I,A]; C07D0313-00 [I,C];
C07D0313-06 [I,A]; C07D0493-00 [I,C*]; C07D0493-20 [I,A];
C12N005-02 [I,C*]; C12N005-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 117 OF 152 USPATFULL on STN

Full Text

AN 2004:95380 USPATFULL
TI Novel imidazopyrazines as cyclin dependent kinase inhibitors
IN Paruch, Kamil, Garwood, NJ, UNITED STATES
Guzi, Timothy J., Chatham, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
PA SCHERING CORPORATION (U.S. corporation)
PI US 20040072835 A1 20040415
US 7186740 B2 20070306
AI US 2003-666424 A1 20030919 (10)
PRAI US 2002-412906P 20020923 (60)
DT Utility
FS APPLICATION
LN.CNT 1213
INCL INCLM: 514/249.000
INCLS: 544/350.000
NCL NCLM: 514/396.000; 514/249.000
NCLS: 514/359.000; 514/385.000; 514/393.000; 548/300.100; 548/302.700;
548/303.100; 544/350.000
IC [7]
ICM A61K031-498
ICS C07D487-04
IPCI A61K0031-498 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCI-2 A01N0043-50 [I,A]; A01N0043-48 [I,C*]; C07D0403-02 [I,A];
C07D0403-00 [I,C*]; C07D0235-02 [I,A]; C07D0235-00 [I,C*]
IPCR A01N0043-48 [I,C]; A01N0043-50 [I,A]; C07D0235-00 [I,C];
C07D0235-02 [I,A]; C07D0403-00 [I,C]; C07D0403-02 [I,A];
C07D0487-00 [I,C*]; C07D0487-04 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 118 OF 152 USPATFULL on STN

Full Text

AN 2004:83259 USPATFULL

TI Novel imidazopyrazines as cyclin dependent kinase inhibitors
 IN Paruch, Kamil, Garwood, NJ, UNITED STATES
 Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Mallams, Alan, Hackettstown, NJ, UNITED STATES
 PA SCHERING CORPORATION (U.S. corporation)
 PI US 20040063715 A1 20040401
 US 6919341 B2 20050719
 AI US 2003-665005 A1 20030919 (10)
 PRAI US 2002-412997P 20020923 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1716
 INCL INCLM: 514/249.000
 INCLS: 544/350.000
 NCL NCLM: 514/249.000
 NCLS: 544/350.000
 IC [7]
 ICM A61K031-498
 ICS C07D487-04
 IPCI A61K0031-498 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
 IPCI-2 C07D0487-04 [ICM,7]; C07D0487-00 [ICM,7,C*]; A61K0031-495 [ICS,7]
 IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 119 OF 152 USPATFULL on STN

Full Text

AN 2004:69982 USPATFULL
 TI Detection and evaluation of topoisomerase inhibitors using optophoretic analysis
 IN Kariv, Ilona A., Carlsbad, CA, UNITED STATES
 Lykstad, Kristie L., San Diego, CA, UNITED STATES
 Chung, Thomas D.Y., Carlsbad, CA, UNITED STATES
 PA Genoptix, Inc (U.S. corporation)
 PI US 20040053209 A1 20040318
 AI US 2002-326885 A1 20021219 (10)
 RLI Continuation-in-part of Ser. No. US 2002-243611, filed on 12 Sep 2002, PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 4070
 INCL INCLM: 435/004.000
 NCL NCLM: 435/004.000
 IC [7]
 ICM C12Q001-00
 ICS A61K009-14
 IPCI C12Q0001-00 [ICM,7]; A61K0009-14 [ICS,7]
 IPCR G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G21K0001-00 [I,C*]; G21K0001-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 120 OF 152 USPATFULL on STN

Full Text

AN 2004:59037 USPATFULL
 TI Oncokine fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
 IN Briesewitz, Roger, Mountain View, CA, UNITED STATES
 Griffin, John H., Atherton, CA, UNITED STATES
 PI US 20040045044 A1 20040304
 US 7195876 B2 20070327
 AI US 2003-637356 A1 20030808 (10)
 PRAI US 2002-402330P 20020809 (60)
 US 2003-440491P 20030116 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3564
 INCL INCLM: 800/008.000
 INCLS: 435/194.000
 NCL NCLM: 435/006.000; 800/008.000

NCLS: 435/015.000; 435/194.000; 536/023.200
 IC [7]
 ICM A01K067-00
 ICS C12N009-12
 IPCI A01K0067-00 [ICM,7]; C12N0009-12 [ICS,7]
 IPCI-2 C12Q0001-68 [I,A]; C12Q0001-48 [I,A]; C12N0009-12 [I,A];
 C07H0021-04 [I,A]; C07H0021-00 [I,C*]
 IPCR C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; C07H0021-00 [I,C];
 C07H0021-04 [I,A]; C07K0014-435 [I,C*]; C07K0014-71 [I,A];
 C12N0009-12 [I,C]; C12N0009-12 [I,A]; C12Q0001-48 [I,C];
 C12Q0001-48 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 121 OF 152 USPATFULL on STN

Full Text

AN 2004:31171 USPATFULL
 TI Quantitative determination of protein kinase C activation using
 optophoretic analysis
 IN Kariv, Ilona, Carlsbad, CA, UNITED STATES
 Lykstad, Kristie Lynn, San Diego, CA, UNITED STATES
 Chung, Thomas D.Y., Carlsbad, CA, UNITED STATES
 PA Genoptix, Inc (U.S. corporation)
 PI US 20040023310 A1 20040205
 AI US 2002-326568 A1 20021219 (10)
 RLI Continuation-in-part of Ser. No. US 2002-243611, filed on 12 Sep 2002,
 PENDING Continuation-in-part of Ser. No. US 2001-993377, filed on 14 Nov
 2001, PENDING Continuation-in-part of Ser. No. US 2001-845245, filed on
 27 Apr 2001, PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 4076
 INCL INCLM: 435/007.200
 INCLS: 435/040.500
 NCL NCLM: 435/007.200
 NCLS: 435/040.500

IC [7]
 ICM C12Q001-68
 ICS G01N033-53; G01N033-567; G01N001-30; G01N033-48
 IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-567 [ICS,7];
 G01N0001-30 [ICS,7]; G01N0033-48 [ICS,7]
 IPCR B07C0005-34 [I,C*]; B07C0005-34 [I,A]; G01N0015-14 [I,C*];
 G01N0015-14 [I,A]; G01N0030-00 [N,C*]; G01N0030-02 [N,A];
 G01N0033-50 [I,C*]; G01N0033-50 [I,A]; G21K0001-00 [I,C*];
 G21K0001-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 122 OF 152 USPATFULL on STN

Full Text

AN 2003:276730 USPATFULL
 TI Early detection of apoptotic events and apoptosis using optophoretic
 analysis
 IN Schnabel, Catherine A., La Jolla, CA, UNITED STATES
 Hall, Jeffrey M., Carlsbad, CA, UNITED STATES
 Lykstad, Kristie L., San Diego, CA, UNITED STATES
 PA Genoptix, Inc. (U.S. corporation)
 PI US 20030194755 A1 20031016
 AI US 2002-326796 A1 20021219 (10)
 RLI Continuation-in-part of Ser. No. US 2002-243611, filed on 12 Sep 2002,
 PENDING Continuation-in-part of Ser. No. US 2001-993377, filed on 14 Nov
 2001, PENDING Continuation-in-part of Ser. No. US 2001-845245, filed on
 27 Apr 2001, PENDING
 PRAI US 2002-377145P 20020501 (60)
 US 2002-399931P 20020730 (60)
 US 2002-400936P 20020801 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4096
 INCL INCLM: 435/007.230
 NCL NCLM: 435/007.230
 IC [7]
 ICM G01N033-574
 IPCI G01N0033-574 [ICM,7]

IPCR B07C0005-34 [I,C*]; B07C0005-34 [I,A]; G01N0015-14 [I,C*];
G01N0015-14 [I,A]; G01N0030-00 [N,C*]; G01N0030-02 [N,A];
G21K0001-00 [I,C*]; G21K0001-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 123 OF 152 USPATFULL on STN

Full Text

AN 2003:265960 USPATFULL
TI Use of pdgf receptor tyrosine kinase inhibitors for the treatment of
diabetic nephropathy
IN Atkins, Robert Charles, Canterbury, AUSTRALIA
Chadban, Steven James, Blackrock, AUSTRALIA
Cooper, Mark Emmanuel, East Prahran, AUSTRALIA
Gilbert, Richard Ernest, West St Kilda, AUSTRALIA
Hill, Prudence Ann, Canterbury, AUSTRALIA
Kelly, Darren James, Wonga Park, AUSTRALIA
Nikolic-Paterson, David John, Pearcedale, AUSTRALIA
PI US 20030186977 A1 20031002
US 7087608 B2 20060808
AI US 2003-220214 A1 20030415 (10)
WO 2001-EP2340 20010103
PRAI EP 2000-810181 20000303
DT Utility
FS APPLICATION
LN.CNT 692
INCL INCLM: 514/234.500
INCLS: 514/252.160; 514/255.050; 514/260.100; 514/263.400; 514/275.000
NCL NCLM: 514/252.180; 514/234.500
NCLS: 514/252.140; 514/269.000; 514/272.000; 514/252.160; 514/255.050;
514/260.100; 514/263.400; 514/275.000
IC [7]
ICM A61K031-5377
ICS A61K031-519; A61K031-52; A61K031-506
IPCI A61K0031-5377 [ICM,7]; A61K0031-5375 [ICM,7,C*]; A61K0031-519
[ICS,7]; A61K0031-52 [ICS,7]; A61K0031-519 [ICS,7,C*];
A61K0031-506 [ICS,7]
IPCI-2 A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-505 [I,A]
IPCR C07D0401-00 [I,C*]; C07D0401-14 [I,A]; A61K0031-00 [I,C*];
A61K0031-00 [I,A]; A61K0031-505 [I,C*]; A61K0031-505 [I,A];
A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-5375 [I,C*];
A61K0031-5377 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0043-00 [I,C*];
A61P0043-00 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 124 OF 152 USPATFULL on STN

Full Text

AN 2003:214312 USPATFULL
TI Soluble tumor necrosis factor receptor treatment of medical disorders
IN Pluenneke, John D., Parkville, MO, UNITED STATES
PI US 20030148955 A1 20030807
AI US 2002-314618 A1 20021209 (10)
RLI Continuation-in-part of Ser. No. US 2001-778403, filed on 7 Feb 2001,
ABANDONED Continuation-in-part of Ser. No. US 2000-726781, filed on 29
Nov 2000, PENDING Continuation-in-part of Ser. No. US 2000-602351, filed
on 23 Jun 2000, PENDING Continuation-in-part of Ser. No. WO
2000-US10565, filed on 19 Apr 2000, PENDING Continuation-in-part of Ser.
No. US 1999-373828, filed on 13 Aug 1999, ABANDONED
PRAI US 2000-184864P 20000225 (60)
US 1999-164676P 19991110 (60)
US 1999-148234P 19990811 (60)
US 1999-143959P 19990715 (60)
US 1999-134320P 19990514 (60)
US 1999-130074P 19990419 (60)
DT Utility
FS APPLICATION
LN.CNT 1458
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]
ICM A61K038-17
IPCI A61K0038-17 [ICM,7]

IPCR A61K0038-17 [I,C*]; A61K0038-17 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 125 OF 152 USPATFULL on STN

Full Text

AN 2003:65457 USPATFULL
TI 4-substituted-1- (arylmethylidene) thiosemicarbazide, 4-substituted-1-
(arylcarbonyl) thiosemicarbazide and analogs as activators of caspases
and inducers of apoptosis and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Nguyen, Bao Ngoc, San Diego, CA, UNITED STATES
Drewe, John, Carlsbad, CA, UNITED STATES
Reddy, P. Sanjeeva, San Diego, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Pervin, Azra, San Diego, CA, UNITED STATES
PI US 20030045581 A1 20030306
US 6794400 B2 20040921
AI US 2002-158827 A1 20020603 (10)
PRAI US 2001-294641P 20010601 (60)
DT Utility
FS APPLICATION
LN.CNT 2665
INCL INCLM: 514/582.000
INCLS: 514/590.000; 514/255.060; 514/353.000
NCL NCLM: 514/357.000; 514/582.000
NCLS: 514/406.000; 514/471.000; 514/255.060; 514/353.000; 514/590.000
IC [7]
ICM A61K031-175
ICS A61K031-4965; A61K031-44
IPCI A61K0031-175 [ICM,7]; A61K0031-17 [ICM,7,C*]; A61K0031-4965
[ICS,7]; A61K0031-44 [ICS,7]
IPCI-2 A61K0031-44 [ICM,7]; A61K0031-415 [ICS,7]; A61K0031-34 [ICS,7]
IPCR A61K0031-17 [I,C*]; A61K0031-175 [I,A]; A61K0031-435 [I,C*];
A61K0031-435 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A];
A61K0031-4965 [I,C*]; A61K0031-4965 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 126 OF 152 USPATFULL on STN

Full Text

AN 2003:65422 USPATFULL
TI Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators
of caspases and inducers of apoptosis and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Reddy, P. Sanjeeva, San Diego, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Kuemmerle, Jared Daniel, Del Mar, CA, UNITED STATES
Ollis, Kristin P., San Diego, CA, UNITED STATES
PI US 20030045546 A1 20030306
US 7041685 B2 20060509
AI US 2002-164705 A1 20020610 (10)
PRAI US 2001-296479P 20010608 (60)
DT Utility
FS APPLICATION
LN.CNT 4296
INCL INCLM: 514/307.000
INCLS: 514/314.000; 514/336.000; 514/340.000; 514/362.000; 514/365.000;
514/374.000; 514/397.000; 514/378.000
NCL NCLM: 514/340.000; 514/307.000
NCLS: 514/364.000; 544/138.000; 544/242.000; 544/336.000; 546/135.000;
546/139.000; 546/269.400; 548/131.000; 514/314.000; 514/336.000;
514/362.000; 514/365.000; 514/374.000; 514/378.000; 514/397.000
IC [7]
ICM A61K031-4709
ICS A61K031-427; A61K031-4168
IPCI A61K0031-4709 [ICM,7]; A61K0031-427 [ICS,7]; A61K0031-4168
[ICS,7]; A61K0031-4164 [ICS,7,C*]
IPCI-2 A61K0031-44 [I,A]; C07D0413-14 [I,A]; C07D0413-00 [I,C*]
IPCR A61K0031-335 [I,C*]; A61K0031-335 [I,A]; A61K0031-38 [I,C*];
A61K0031-38 [I,A]; A61K0031-395 [I,C*]; A61K0031-395 [I,A];
C07D0409-00 [I,C*]; C07D0409-04 [I,A]; C07D0409-14 [I,A];

C07D0413-00 [I,C*]; C07D0413-04 [I,A]; C07D0413-14 [I,A];
C07D0417-00 [I,C*]; C07D0417-14 [I,A]; C07D0471-00 [I,C*];
C07D0471-04 [I,A]; A61K0031-44 [I,A]; A61K0031-44 [I,C];
C07D0413-00 [I,C]; C07D0413-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 127 OF 152 USPAT2 on STN

Full Text

AN 2007:128647 USPAT2
TI 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of
caspases and inducers of apoptosis and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
Kuemmerle, Jared D., Del Mar, CA, UNITED STATES
Zhang, Hong, San Diego, CA, UNITED STATES
Kemnitzer, William E., San Diego, CA, UNITED STATES
PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 7317029 B2 20080108
AI US 2006-593030 20061106 (11)
RLI Division of Ser. No. US 2003-737865, filed on 18 Dec 2003, Pat. No. US
7144876
PRAI US 2002-433953P 20021218 (60)
DT Utility
FS GRANTED
LN.CNT 2682
INCL INCLM: 514/364.000
INCLS: 548/131.000
NCL NCLM: 514/364.000; 514/235.500
NCLS: 548/131.000; 514/254.030; 514/326.000; 544/138.000; 544/367.000;
546/209.000; 548/136.000
IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-496 [I,A];
A61K0031-454 [I,A]; A61K0031-4523 [I,C*]; A61K0031-4245 [I,A];
C07D0413-14 [I,A]; C07D0413-00 [I,C*]
IPCI-2 A61K0031-41 [I,A]; C07D0271-06 [I,A]; C07D0271-00 [I,C*]
IPCR A61K0031-41 [I,C]; A61K0031-41 [I,A]; A61K0031-4245 [I,C*];
A61K0031-4245 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
C07D0271-00 [I,C]; C07D0271-06 [I,A]
EXF 514/364; 548/131
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 128 OF 152 USPAT2 on STN

Full Text

AN 2007:36955 USPAT2
TI Pyrazolotriazines as kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
PI US 7354921 B2 20080408
AI US 2006-546766 20061012 (11)
RLI Division of Ser. No. US 2006-335383, filed on 19 Jan 2006, Pat. No. US
7166602 Division of Ser. No. US 2005-64044, filed on 23 Feb 2005, Pat.
No. US 7038045
PRAI US 2004-547685P 20040225 (60)
DT Utility
FS GRANTED
LN.CNT 1487
INCL INCLM: 514/246.000
INCLS: 544/194.000; 544/206.000; 544/207.000
NCL NCLM: 514/246.000
NCLS: 544/194.000; 544/206.000; 544/207.000; 544/180.000
IC IPCI A61K0031-53 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCI-2 A61K0031-53 [I,A]; A61P0035-00 [I,A]; A61P0019-02 [N,A];
A61P0019-00 [N,C*]; C07D0251-72 [N,A]; C07D0251-00 [N,C*]
IPCR A61K0031-53 [I,C]; A61K0031-53 [I,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]
EXF 514/245; 514/246; 544/245
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 129 OF 152 USPAT2 on STN

Full Text

AN 2006:203130 USPAT2
TI Pyrazolopyrimidines as cyclin dependent kinase inhibitors

IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Dillard, Lawrence W., Skillman, NJ, UNITED STATES
 Tran, Vinh D., Fountain Valley, CA, UNITED STATES
 He, Zhen Min, Princeton, NJ, UNITED STATES
 James, Ray Anthony, Bristol, PA, UNITED STATES
 Park, Haengsoon, Plainsboro, NJ, UNITED STATES
 PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
 PI US 7309705 B2 20071218
 AI US 2006-395824 20060331 (11)
 RLI Division of Ser. No. US 2003-653868, filed on 3 Sep 2003, Pat. No. US 7074924
 PRAI US 2002-407999P 20020904 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1627
 INCL INCLM: 514/259.310
 INCLS: 544/281.000
 NCL NCLM: 514/259.310; 514/252.160
 NCLS: 544/281.000; 514/259.300
 IC IPCI A61K0031-517 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCI-2 A61K0031-519 [I,A]; A61P0035-00 [N,A]; C07D0484-04 [N,A]
 IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61P0035-00 [N,C];
 A61P0035-00 [N,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]
 EXF 544/281; 514/259.31
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 L10 ANSWER 130 OF 152 USPAT2 on STN
Full Text
 AN 2006:152284 USPAT2
 TI Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Labroli, Marc, Mount Laurel, NJ, UNITED STATES
 Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
 PA Schering Corpoartion, Kenilworth, NJ, UNITED STATES (U.S. corporation)
 PI US 7196078 B2 20070327
 AI US 2005-245401 20051006 (11)
 RLI Continuation-in-part of Ser. No. US 2004-776988, filed on 11 Feb 2004, Pat. No. US 7119200 Continuation-in-part of Ser. No. US 2003-654546, filed on 3 Sep 2003, Pat. No. US 7161003
 PRAI US 2002-408027P 20020904 (60)
 US 2002-421959P 20021029 (60)
 DT Utility
 FS GRANTED
 LN.CNT 11677
 INCL INCLM: 514/218.000
 INCLS: 540/575.000; 540/115.000; 514/233.200; 514/228.500; 514/259.300; 544/281.000; 544/117.000; 544/061.000
 NCL NCLM: 514/218.000; 514/259.300
 NCLS: 514/228.500; 514/233.200; 514/259.300; 540/115.000; 540/575.000; 544/061.000; 544/117.000; 544/281.000
 IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCI-2 A61K0031-5513 [I,A]; A61K0031-551 [I,C*]; A61K0031-5355 [I,A]; A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]; C07D0413-04 [I,A]; C07D0417-04 [I,A]; C07D0417-00 [I,C*]; C07D0243-08 [I,A]; C07D0243-00 [I,C*]; A61K0031-541 [N,A]; A61P0019-02 [N,A]; A61P0019-00 [N,C*]; A61P0029-00 [N,A]; C07D0413-06 [N,A]; C07D0413-00 [N,C*]
 IPCR A61K0031-519 [I,A]; A61K0031-519 [I,C]; C07D0487-00 [I,C]; C07D0487-04 [I,A]; A61K0031-551 [I,C]; A61K0031-5513 [I,A]; A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61K0031-5355 [I,C]; A61K0031-5355 [I,A]; A61K0031-541 [N,C]; A61K0031-541 [N,A]; A61P0019-00 [N,C]; A61P0019-02 [N,A]; A61P0029-00 [N,C]; A61P0029-00 [N,A]; C07D0243-00 [I,C]; C07D0243-08 [I,A]; C07D0413-00 [I,C]; C07D0413-04 [I,A]; C07D0413-06 [N,A]; C07D0417-00 [I,C]; C07D0417-04 [I,A]; C07D0487-00 [I,C];

C07D0487-04 [I,A]
 EXF 544/281; 544/117; 544/61; 544/231; 544/287; 514/259.3; 514/218;
 514/233.2; 514/228.5; 540/575
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 131 OF 152 USPAT2 on STN
Full Text
 AN 2006:144869 USPAT2
 TI Pyrazolotriazines as kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
 PI US 7166602 B2 20070123
 AI US 2006-335383 20060119 (11)
 RLI Division of Ser. No. US 2005-64044, filed on 23 Feb 2005, Pat. No. US
 7038045
 PRAI US 2004-547685P 20040225 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1454
 INCL INCLM: 514/245.000
 INCLS: 514/241.000; 544/194.000; 544/206.000; 544/207.000
 NCL NCLM: 514/245.000; 544/182.000
 NCLS: 514/241.000; 544/194.000; 544/206.000; 544/207.000
 IC IPCI A61K0031-53 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCI-2 A61K0031-53 [I,A]; A61P0019-02 [I,A]; A61P0019-00 [I,C*];
 C07D0251-72 [N,A]; C07D0251-00 [N,C*]; C07D0487-04 [N,A];
 C07D0487-00 [N,C*]
 IPCR A61K0031-53 [I,A]; A61K0031-53 [I,C]; C07D0487-00 [I,C];
 C07D0487-04 [I,A]; A61K0031-53 [I,C]; A61K0031-53 [I,A];
 A61P0019-00 [I,C]; A61P0019-02 [I,A]; C07D0251-00 [N,C];
 C07D0251-72 [N,A]; C07D0487-00 [I,C*]; C07D0487-04 [I,A]
 EXF 514/245; 544/194; 544/206; 544/207
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 132 OF 152 USPAT2 on STN
Full Text
 AN 2006:47656 USPAT2
 TI Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase
 inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
 PI US 7205308 B2 20070417
 AI US 2005-244772 20051006 (11)
 RLI Continuation-in-part of Ser. No. US 2003-653776, filed on 3 Sep 2003,
 Pat. No. US 7067661
 PRAI US 2002-408029P 20020904 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2442
 INCL INCLM: 514/259.300
 INCLS: 544/281.000
 NCL NCLM: 514/259.300; 544/281.000
 NCLS: 544/281.000
 IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCI-2 A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*];
 A61P0037-00 [N,A]; A61P0019-02 [N,A]; A61P0019-00 [N,C*];
 A61P0029-00 [N,A]
 IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61P0019-00 [N,C];
 A61P0019-02 [N,A]; A61P0029-00 [N,C]; A61P0029-00 [N,A];
 A61P0037-00 [N,C]; A61P0037-00 [N,A]; C07D0487-00 [I,C];
 C07D0487-04 [I,A]
 EXF 544/259.3; 544/281; 514/281; 514/259.3
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 133 OF 152 USPAT2 on STN
Full Text
 AN 2006:47484 USPAT2
 TI N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES

Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
PI US 7196092 B2 20070327
AI US 2005-244776 20051006 (11)
RLI Continuation-in-part of Ser. No. US 2003-654157, filed on 3 Sep 2003,
Pat. No. US 7078525
PRAI US 2002-408030P 20020904 (60)
DT Utility
FS GRANTED
LN.CNT 2017
INCL INCLM: 514/259.300
INCLS: 544/281.000
NCL NCLM: 514/259.300
NCLS: 544/281.000
IC IPCI A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCI-2 A61K0031-519 [I,A]; C07D0487-04 [I,A]; C07D0487-00 [I,C*];
A61P0037-00 [N,A]; A61P0019-02 [N,A]; A61P0019-00 [N,C*];
A61P0029-00 [N,A]
IPCR A61K0031-519 [I,C]; A61K0031-519 [I,A]; A61P0019-00 [N,C];
A61P0019-02 [N,A]; A61P0029-00 [N,C]; A61P0029-00 [N,A];
A61P0037-00 [N,C]; A61P0037-00 [N,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]
EXF 514/259.31; 514/259.3; 544/281
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 134 OF 152 USPAT2 on STN

Full Text

AN 2005:215543 USPAT2
TI Pyrazolotriazines as kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
PI US 7038045 B2 20060502
AI US 2005-64044 20050223 (11)
PRAI US 2004-547685P 20040225 (60)
DT Utility
FS GRANTED
LN.CNT 1481
INCL INCLM: 544/194.000
INCLS: 544/206.000; 544/207.000; 514/241.000
NCL NCLM: 544/194.000; 514/246.000
NCLS: 544/206.000; 544/207.000; 544/184.000
IC IPCI A61K0031-53 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCI-2 C07D0251-72 [I,A]; C07D0251-00 [I,C*]; A61K0311-53 [I,A];
A61P0019-02 [I,A]; A61P0019-00 [I,C*]
IPCR A61K0031-53 [I,C*]; A61K0031-53 [I,A]; C07D0487-00 [I,C*];
C07D0487-04 [I,A]; A61K0031-53 [I,C]; A61P0019-00 [I,C];
A61P0019-02 [I,A]; C07D0251-00 [I,C]; C07D0251-72 [I,A]
EXF 544/194; 544/206; 544/207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 135 OF 152 USPAT2 on STN

Full Text

AN 2005:38145 USPAT2
TI Phosphorus-containing compounds and uses thereof
IN Metcalf, lll, Chester A., Needham, MA, UNITED STATES
Rozamus, Leonard W., Bedford, MA, UNITED STATES
Wang, Yihan, Newton, MA, UNITED STATES
Berstein, David L., Waban, MA, UNITED STATES
PA ARIAD Gene Therapeutics, Inc., Cambridge, MA, UNITED STATES (U.S.
corporation)
PI US 7091213 B2 20060815
AI US 2004-862149 20040604 (10)
RLI Continuation-in-part of Ser. No. US 2003-635054, filed on 6 Aug 2003,
ABANDONED Continuation-in-part of Ser. No. US 2003-357152, filed on 3
Feb 2003, ABANDONED
PRAI US 2002-433930P 20021217 (60)
US 2002-428383P 20021122 (60)
US 2002-426928P 20021115 (60)
US 2002-353252P 20020201 (60)
DT Utility
FS GRANTED

LN.CNT 3763
INCL INCLM: 514/291.000
INCLS: 540/456.000
NCL NCLM: 514/291.000
NCLS: 540/456.000; 514/080.000
IC IPCI A61K0031-675 [ICM,7]; A61K0031-4745 [ICS,7]; A61K0031-4738
[ICS,7,C*]
IPCI-2 C07D0491-06 [I,A]; C07D0491-00 [I,C*]; A61K0031-395 [I,A];
A61P0035-00 [I,A]; A61P0035-02 [I,A]
IPCR A61L0027-00 [I,C*]; A61L0027-00 [I,A]; A61F0002-82 [I,C*];
A61F0002-84 [I,A]; A61K0031-661 [I,C*]; A61K0031-661 [I,A];
A61K0031-662 [I,C*]; A61K0031-662 [I,A]; A61K0031-664 [I,C*];
A61K0031-664 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
A61K0045-06 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A];
A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*];
A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0011-00 [I,C*];
A61P0011-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-02 [I,A];
A61P0017-04 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C*];
A61P0019-02 [I,A]; A61P0021-00 [I,C*]; A61P0021-04 [I,A];
A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-28 [I,A];
A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*];
A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-10 [I,A];
A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A];
A61P0037-00 [I,C*]; A61P0037-00 [I,A]; C07D0498-00 [I,C*];
C07D0498-18 [I,A]; C07F0009-00 [I,C*]; C07F0009-09 [I,A];
C07F0009-22 [I,A]; C07F0009-32 [I,A]; C07F0009-36 [I,A];
C07F0009-40 [I,A]; C07F0009-44 [I,A]; C07F0009-46 [I,A];
C07F0009-53 [I,A]; C07F0009-6561 [I,A]; C07D0491-00 [I,C];
C07D0491-06 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A];
A61P0035-00 [I,C]; A61P0035-00 [I,A]; A61P0035-02 [I,A]
EXF 540/456; 514/291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 136 OF 152 USPAT2 on STN

Full Text

AN 2005:17357 USPAT2
TI Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as
activators of caspases and inducers of apoptosis
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Drewe, John A, Carlsbad, CA, UNITED STATES
Jiang, Sungchun, San Diego, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Kuemmerle, Jared Daniel, Del Mar, CA, UNITED STATES
Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 7135480 B2 20061114
AI US 2003-733229 20031212 (10)
PRAI US 2002-432608P 20021212 (60)
DT Utility
FS GRANTED
LN.CNT 2581
INCL INCLM: 514/294.000
INCLS: 546/094.000; 544/126.000; 544/361.000; 514/233.200; 514/253.000
NCL NCLM: 514/294.000; 514/250.000
NCLS: 514/233.200; 514/250.000; 544/126.000; 544/361.000; 546/094.000;
514/291.000
IC IPCI A61K0031-498 [ICM,7]; A61K0031-4745 [ICS,7]; A61K0031-4738
[ICS,7,C*]
IPCI-2 A61K0031-4745 [I,A]; A61K0031-4738 [I,C*]; C07D0471-02 [I,A];
C07D0471-00 [I,C*]
IPCR A61K0031-4738 [I,C]; A61K0031-4745 [I,A]; A61K0031-496 [I,C*];
A61K0031-496 [I,A]; A61K0031-4985 [I,C*]; A61K0031-4985 [I,A];
C07D0471-00 [I,C]; C07D0471-02 [I,A]; C07D0471-04 [I,A]
EXF 514/294; 514/233.2; 514/253; 546/94; 544/126; 544/361
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 137 OF 152 USPAT2 on STN

Full Text

AN 2004:268335 USPAT2
TI Pyrazolopyrimidines as cyclin dependent kinase inhibitors

IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Mallams, Alan, Hackettstown, NJ, UNITED STATES
 Alvarez, Carmen S., Livingston, NJ, UNITED STATES
 Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
 Rivera, Jocelyn, Monmouth Junction, NJ, UNITED STATES
 Chan, Tin-Yau, Edison, NJ, UNITED STATES
 Madison, Vincent, Mountain Lakes, NJ, UNITED STATES
 Fischmann, Thierry O., Scotch Plains, NJ, UNITED STATES
 Dillard, Lawrence W., Skillman, NJ, UNITED STATES
 Tran, Vinh D., Fountain Valley, CA, UNITED STATES
 He, Zhen Min, Princeton, NJ, UNITED STATES
 James, Ray Anthony, Bristol, PA, UNITED STATES
 Park, Haengsoon, Plainsboro, NJ, UNITED STATES
 Hobbs, Vidyadhar M., Somerville, NJ, UNITED STATES
 Hobbs, Douglas Walsh, Yardley, PA, UNITED STATES
 PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
 Pharmacoepia Drug Discovery, Inc., Cranbury, NJ, UNITED STATES (U.S. corporation)
 PI US 7119200 B2 20061010
 AI US 2004-776988 20040211 (10)
 RLI Continuation-in-part of Ser. No. US 2003-654546, filed on 3 Sep 2003, PENDING
 PRAI US 2002-421959P 20021029 (60)
 US 2002-408027P 20020904 (60)
 DT Utility
 FS GRANTED
 LN.CNT 10223
 INCL INCLM: 544/281.000
 NCL NCLM: 544/281.000; 514/234.500
 NCLS: 514/252.160; 514/259.300; 544/117.000; 544/280.000
 IC IPCI A61K0031-5377 [ICM,7]; A61K0031-5375 [ICM,7,C*]; A61K0031-519 [ICS,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
 IPCI-2 C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCR C07D0487-00 [I,C]; C07D0487-04 [I,A]
 EXF 514/259.31; 544/281
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 138 OF 152 USPAT2 on STN

Full Text

AN 2004:177786 USPAT2
 TI Death domain containing receptor 4
 IN Ni, Jian, Germantown, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Gentz, Reiner L., Belo-Horizonte, BRAZIL
 PA Human Genome Sciences, Inc. (U.S. corporation)
 The Regents of the University of Michigan (U.S. corporation)
 PI US 20050112090 A9 20050526
 AI US 2003-648786 A1 20030827 (10)
 RLI Continuation-in-part of Ser. No. US 2000-565918, filed on 5 May 2000, GRANTED, Pat. No. US 6433147 Continuation-in-part of Ser. No. US 1998-13895, filed on 27 Jan 1998, GRANTED, Pat. No. US 6342363
 PRAI US 2002-413861P 20020927 (60)
 US 2002-406922P 20020830 (60)
 US 1999-132922P 19990506 (60)
 US 1997-37829P 19970205 (60)
 US 1997-35722P 19970128 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 13753
 INCL INCLM: 424/085.100
 INCLS: 424/144.100
 NCL NCLM: 424/085.100
 NCLS: 424/144.100
 IC [7]
 ICM A61K038-19
 ICS A61K039-395
 IPCI A61K0038-19 [ICM,7]; A61K0039-395 [ICS,7]
 IPCI-2 A61K0038-19 [ICM,7]; A61K0039-395 [ICS,7]

IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0039-395 [I,C*];
A61K0039-395 [I,A]; C07K0014-435 [I,C*]; C07K0014-705 [I,A];
C07K0014-715 [I,A]; C07K0016-18 [I,C*]; C07K0016-28 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 139 OF 152 USPAT2 on STN

Full Text

AN 2004:166031 USPAT2
TI 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of
caspases and inducers of apoptosis and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
Kuemmerle, Jared D, Del Mar, CA, UNITED STATES
Zhang, Hong, San Diego, CA, UNITED STATES
Kemnitzner, William E, Irvine, CA, UNITED STATES
PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 7144876 B2 20061205
AI US 2003-737865 20031218 (10)
PRAI US 2002-433953P 20021218 (60)
DT Utility
FS GRANTED
LN.CNT 2852
INCL INCLM: 514/171.000
INCLS: 546/048.000; 548/131.000; 549/323.000; 549/510.000
NCL NCLM: 514/171.000; 514/341.000
NCLS: 546/048.000; 548/131.000; 549/323.000; 549/510.000; 514/364.000
IC IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0031-4245
[ICS,7]
IPCI-2 A61K0031-56 [I,A]; C07D0471-00 [I,A]; C07D0271-06 [I,A];
C07D0271-00 [I,C*]; C07D0233-38 [I,A]; C07D0233-00 [I,C*]
IPCR A61K0031-56 [I,C]; A61K0031-56 [I,A]; A61K0031-4245 [I,C*];
A61K0031-4245 [I,A]; A61K0031-4427 [I,C*]; A61K0031-4439 [I,A];
C07D0233-00 [I,C]; C07D0233-38 [I,A]; C07D0271-00 [I,C];
C07D0271-06 [I,A]; C07D0471-00 [I,C]; C07D0471-00 [I,A]
EXF 548/131; 514/171; 546/48; 549/510; 549/323
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 140 OF 152 USPAT2 on STN

Full Text

AN 2004:152220 USPAT2
TI Pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
Dillard, Lawrence W., Skillman, NJ, UNITED STATES
Tran, Vinh D., Fountain Valley, CA, UNITED STATES
He, Zhen Min, Princeton, NJ, UNITED STATES
James, Ray Anthony, Bristol, PA, UNITED STATES
Park, Haengsoon, Plainsboro, NJ, UNITED STATES
PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
Pharmacoepia Drug Discovery, Inc., Cranbury, NJ, UNITED STATES (U.S.
corporation)
PI US 7074924 B2 20060711
AI US 2003-653868 20030903 (10)
PRAI US 2002-407999P 20020904 (60)
DT Utility
FS GRANTED
LN.CNT 1624
INCL INCLM: 544/281.000
NCL NCLM: 544/281.000; 514/252.160
NCLS: 514/259.300
IC IPCI A61K0031-519 [ICM,7]; C07D0487-02 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCI-2 C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]
EXF 514/259.31; 544/281
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 141 OF 152 USPAT2 on STN

Full Text

AN 2004:139448 USPAT2
 TI Pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Alvarez, Carmen S., Livingston, NJ, UNITED STATES
 Chan, Tin-Yau, Edison, NJ, UNITED STATES
 Knutson, Chad, Garwood, NJ, UNITED STATES
 Madison, Vincent, Mountain Lakes, NJ, UNITED STATES
 Fischmann, Thierry O., Scotch Plains, NJ, UNITED STATES
 Dillard, Lawrence W., Skillman, NJ, UNITED STATES
 Tran, Vinh D., Fountain Valley, CA, UNITED STATES
 He, Zhen Min, Princeton, NJ, UNITED STATES
 James, Ray Anthony, Bristol, PA, UNITED STATES
 Park, Haengsoon, Plainsboro, NJ, UNITED STATES
 PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
 Pharmacoepia Drug Discovery, Inc., Crambury, NJ, UNITED STATES (U.S. corporation)
 PI US 7067661 B2 20060627
 AI US 2003-653776 20030903 (10)
 PRAI US 2002-408029P 20020904 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1798
 INCL INCLM: 544/281.000
 NCL NCLM: 544/281.000; 514/252.160
 NCLS: 514/259.300
 IC IPCI A61K0031-519 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
 IPCI-2 C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0487-00 [I,C];
 C07D0487-04 [I,A]
 EXF 514/259.31; 544/281
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 142 OF 152 USPAT2 on STN

Full Text

AN 2004:133915 USPAT2
 TI Pyrazolopyrimidines as cyclin dependent kinase inhibitors
 IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Knutson, Chad, Garwood, NJ, UNITED STATES
 McKittrick, Brian, New Vernon, NJ, UNITED STATES
 Dillard, Lawrence W., Skillman, NJ, UNITED STATES
 Tran, Vinh D., Fountain Valley, CA, UNITED STATES
 He, Zhen Min, Princeton, NJ, UNITED STATES
 James, Ray Anthony, Bristol, PA, UNITED STATES
 Park, Haengsoon, Plainsboro, NJ, UNITED STATES
 PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
 Pharmacoepia Drug Discovery, Inc., Princeton, NJ, UNITED STATES (U.S. corporation)
 PI US 7084271 B2 20060801
 AI US 2003-654163 20030903 (10)
 PRAI US 2002-408182P 20020904 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1598
 INCL INCLM: 544/281.000
 NCL NCLM: 544/281.000; 514/252.160
 NCLS: 514/259.300
 IC IPCI A61K0031-519 [ICM,7]; C07D0487-02 [ICS,7]; C07D0487-00 [ICS,7,C*]
 IPCI-2 C07D0487-04 [I,A]; C07D0487-00 [I,C*]
 IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0487-00 [I,C];
 C07D0487-04 [I,A]
 EXF 514/259.31; 544/281
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 143 OF 152 USPAT2 on STN

Full Text

AN 2004:133914 USPAT2
TI Pyrazolopyrimidines as cyclin dependent kinase inhibitors
IN Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
Dillard, Lawrence W., Skillman, NJ, UNITED STATES
Tran, Vinh D., Fountain Valley, CA, UNITED STATES
He, Zhen Min, Princeton, NJ, UNITED STATES
James, Ray Anthony, Bristol, PA, UNITED STATES
Park, Haengsoon, Plainsboro, NJ, UNITED STATES
PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
Pharmacoepia Drug Discovery, Inc., Cranbury, NJ, UNITED STATES (U.S. corporation)
PI US 7078525 B2 20060718
AI US 2003-654157 20030903 (10)
PRAI US 2002-408030P 20020904 (60)
DT Utility
FS GRANTED
LN.CNT 1736
INCL INCLM: 544/281.000
NCL NCLM: 544/281.000; 514/252.160
NCLS: 514/259.300
IC IPCI A61K0031-519 [ICM,7]; C07D0487-02 [ICS,7]; C07D0487-00 [ICS,7,C*]
IPCI-2 C07D0487-04 [I,A]; C07D0487-00 [I,C*]
IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]; C07D0487-00 [I,C];
C07D0487-04 [I,A]
EXF 514/259.31; 544/281
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 144 OF 152 USPAT2 on STN

Full Text

AN 2004:127533 USPAT2
TI Imidazopyridines as cyclin dependent kinase inhibitors
IN Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
Guzi, Timothy J., Chatham, NJ, UNITED STATES
Paruch, Kamil, Garwood, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
PI US 6992080 B2 20060131
AI US 2003-664338 20030917 (10)
PRAI US 2002-412063P 20020919 (60)
DT Utility
FS GRANTED
LN.CNT 1637
INCL INCLM: 514/217.070
INCLS: 514/303.000; 514/300.000; 514/253.040; 514/256.000; 544/362.000;
544/333.000; 546/121.000; 546/113.000
NCL NCLM: 514/217.070; 514/253.040
NCLS: 514/253.040; 514/256.000; 514/300.000; 514/303.000; 544/333.000;
544/362.000; 546/113.000; 546/121.000
IC IPCI C07D0471-02 [ICM,7]; C07D0471-00 [ICM,7,C*]; A61K0031-496
[ICS,7]; A61K0031-4745 [ICS,7]; A61K0031-4738 [ICS,7,C*]
IPCI-2 A61K0031-435 [I,A]; A61K0031-505 [I,A]; A61K0031-44 [I,A];
C07D0471-02 [I,A]; C07D0471-00 [I,C*]; C07D0401-14 [I,A];
C07D0401-00 [I,C*]
IPCR C07D0471-00 [I,C*]; C07D0471-04 [I,A]; A61K0031-435 [I,A];
A61K0031-435 [I,C]; A61K0031-44 [I,C]; A61K0031-44 [I,A];
A61K0031-505 [I,C]; A61K0031-505 [I,A]; C07D0401-00 [I,C];
C07D0401-14 [I,A]; C07D0471-00 [I,C]; C07D0471-02 [I,A]
EXF 546/121; 546/113; 544/333; 544/362; 540/597; 514/300; 514/303; 514/256;
514/253.04; 514/217.07
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 145 OF 152 USPAT2 on STN

Full Text

AN 2004:127532 USPAT2
TI Pyrazolopyridines as cyclin dependent kinase inhibitors

IN Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Paruch, Kamil, Garwood, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Keertikar, Kartik M., East Windsor, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
 PI US 7151104 B2 20061219
 AI US 2003-664337 20030917 (10)
 PRAI US 2002-412138P 20020919 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1633
 INCL INCLM: 514/259.100
 INCLS: 514/359.000; 546/112.000; 546/113.000; 546/119.000; 546/121.000;
 548/100.000; 548/125.000; 548/126.000
 NCL NCLM: 514/259.100; 514/253.040
 NCLS: 514/359.000; 546/112.000; 546/113.000; 546/119.000; 546/121.000;
 548/100.000; 548/125.000; 548/126.000; 514/303.000; 544/362.000
 IC IPCI A61K0031-496 [ICM,7]; A61K0031-4745 [ICS,7]; A61K0031-4738
 [ICS,7,C*]; C07D0471-02 [ICS,7]; C07D0471-00 [ICS,7,C*]
 IPCI-2 C07D0271-00 [I,A]; C07D0221-02 [I,A]; C07D0221-00 [I,C*];
 A01N0043-90 [I,A]
 IPCR C07D0271-00 [I,C]; C07D0271-00 [I,A]; A01N0043-90 [I,C];
 A01N0043-90 [I,A]; C07D0221-00 [I,C]; C07D0221-02 [I,A];
 C07D0471-00 [I,C*]; C07D0471-04 [I,A]
 EXF 548/100; 548/125; 548/126; 546/112; 546/113; 546/119; 546/121;
 514/259.1; 514/359
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 146 OF 152 USPAT2 on STN

Full Text

AN 2004:107666 USPAT2
 TI Derivatives of gambogic acid and analogs as activators of caspases and
 inducers of apoptosis
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
 Ollis, Kristin P., San Diego, CA, UNITED STATES
 Zhang, Han-Zhong, San Diego, CA, UNITED STATES
 Drewe, John A., Carlsbad, CA, UNITED STATES
 Tseng, Ben, San Diego, CA, UNITED STATES
 Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
 PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 7176234 B2 20070213
 AI US 2003-609670 20030701 (10)
 PRAI US 2002-413649P 20020926 (60)
 US 2002-392358P 20020701 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2753
 INCL INCLM: 514/450.000
 INCLS: 549/268.000
 NCL NCLM: 514/450.000; 435/375.000
 NCLS: 549/268.000
 IC IPCI C12N0005-00 [ICM,7]; C12N0005-02 [ICS,7]
 IPCI-2 A61K0031-352 [I,A]; C07D0313-06 [I,A]; C07D0313-00 [I,C*]
 IPCR A61K0031-352 [I,C]; A61K0031-352 [I,A]; C07D0313-00 [I,C];
 C07D0313-06 [I,A]; C07D0493-00 [I,C*]; C07D0493-20 [I,A];
 C12N0005-02 [I,C*]; C12N0005-02 [I,A]
 EXF 514/450; 549/268
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 147 OF 152 USPAT2 on STN

Full Text

AN 2004:95380 USPAT2
 TI Imidazopyrazines as cyclin dependent kinase inhibitors
 IN Paruch, Kamil, Garwood, NJ, UNITED STATES
 Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)

PI US 7186740 B2 20070306
 AI US 2003-666424 20030919 (10)
 PRAI US 2002-412906P 20020923 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1153
 INCL INCLM: 514/396.000
 INCLS: 514/359.000; 514/385.000; 514/393.000; 548/300.100; 548/302.700;
 548/303.100
 NCL NCLM: 514/396.000; 514/249.000
 NCLS: 514/359.000; 514/385.000; 514/393.000; 548/300.100; 548/302.700;
 548/303.100; 544/350.000
 IC IPCI A61K0031-498 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
 IPCI-2 A01N0043-50 [I,A]; A01N0043-48 [I,C*]; C07D0403-02 [I,A];
 C07D0403-00 [I,C*]; C07D0235-02 [I,A]; C07D0235-00 [I,C*]
 IPCR A01N0043-48 [I,C]; A01N0043-50 [I,A]; C07D0235-00 [I,C];
 C07D0235-02 [I,A]; C07D0403-00 [I,C]; C07D0403-02 [I,A];
 C07D0487-00 [I,C*]; C07D0487-04 [I,A]
 EXF 548/300; 548/302.7; 548/303.1; 514/359; 514/385; 514/393; 514/396
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 148 OF 152 USPAT2 on STN

Full Text

AN 2004:83259 USPAT2
 TI Imidazopyrazines as cyclin dependent kinase inhibitors
 IN Paruch, Kamil, Garwood, NJ, UNITED STATES
 Guzi, Timothy J., Chatham, NJ, UNITED STATES
 Dwyer, Michael P., Scotch Plains, NJ, UNITED STATES
 Doll, Ronald J., Convent Station, NJ, UNITED STATES
 Girijavallabhan, Viyyoor M., Parsippany, NJ, UNITED STATES
 Mallams, Alan, Hackettstown, NJ, UNITED STATES
 PA Schering Corporation, Kenilworth, NJ, UNITED STATES (U.S. corporation)
 PI US 6919341 B2 20050719
 AI US 2003-665005 20030919 (10)
 PRAI US 2002-412997P 20020923 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1692
 INCL INCLM: 514/249.000
 INCLS: 544/350.000
 NCL NCLM: 514/249.000
 NCLS: 544/350.000
 IC [7]
 ICM C07D487-04
 ICS A61K031-495
 IPCI A61K0031-498 [ICM,7]; C07D0487-04 [ICS,7]; C07D0487-00 [ICS,7,C*]
 IPCI-2 C07D0487-04 [ICM,7]; C07D0487-00 [ICM,7,C*]; A61K0031-495 [ICS,7]
 IPCR C07D0487-00 [I,C*]; C07D0487-04 [I,A]
 EXF 544/350; 514/249
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 149 OF 152 USPAT2 on STN

Full Text

AN 2004:59037 USPAT2
 TI Oncokinase fusion polypeptides associated with hyperproliferative and
 related disorders, nucleic acids encoding the same and methods for
 detecting and identifying the same
 IN Briesewitz, Roger, Mountain View, CA, UNITED STATES
 Griffin, John H., Atherton, CA, UNITED STATES
 PA Theravance, Inc., South San Francisco, CA, UNITED STATES (U.S.
 corporation)
 PI US 7195876 B2 20070327
 AI US 2003-637356 20030808 (10)
 PRAI US 2002-402330P 20020809 (60)
 US 2003-440491P 20030116 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3478
 INCL INCLM: 435/006.000
 INCLS: 435/015.000; 435/194.000; 536/023.200
 NCL NCLM: 435/006.000; 800/008.000
 NCLS: 435/015.000; 435/194.000; 536/023.200

IC IPCI A01K0067-00 [ICM,7]; C12N0009-12 [ICS,7]
 IPCI-2 C12Q0001-68 [I,A]; C12Q0001-48 [I,A]; C12N0009-12 [I,A];
 C07H0021-04 [I,A]; C07H0021-00 [I,C*]
 IPCR C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; C07H0021-00 [I,C];
 C07H0021-04 [I,A]; C07K0014-435 [I,C*]; C07K0014-71 [I,A];
 C12N0009-12 [I,C]; C12N0009-12 [I,A]; C12Q0001-48 [I,C];
 C12Q0001-48 [I,A]
 EXF 435/6; 435/15; 435/194; 536/23.2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 150 OF 152 USPAT2 on STN
Full Text
 AN 2003:265960 USPAT2
 TI Use of PDGF receptor tyrosine kinase inhibitors for the treatment of
 diabetic nephropathy
 IN Atkins, Robert Charles, 7 Wentworth Avenue, Canterbury, Victoria 3126,
 AUSTRALIA
 Chadban, Steven James, 73 Ardoyne Street, Blackrock, Victoria 3193,
 AUSTRALIA
 Cooper, Mark Emmanuel, 60 Chatsworth Road, East Prahran, Victoria 3181,
 AUSTRALIA
 Gilbert, Richard Ernest, 16 Mary Street, West St. Kilda, Victoria 3182,
 AUSTRALIA
 Hill, Prudence Ann, 7 Wentworth Avenue, Canterbury, Victoria 3126,
 AUSTRALIA
 Kelly, Darren James, 1 Commerford Place, Chirnside Village, Victoria
 3116, AUSTRALIA
 Nikolic-Paterson, David John, 170 Mt Grantview Road, Pearcedale,
 Victoria 3912, AUSTRALIA
 PI US 7087608 B2 20060808
 WO 2001064200 20010907
 AI US 2001-220214 20010103 (10)
 WO 2001-EP2340 20010103
 20030415 PCT 371 date
 PRAI EP 2000-810181 20000303
 DT Utility
 FS GRANTED
 LN.CNT 628
 INCL INCLM: 514/252.180
 INCLS: 514/252.140; 514/269.000; 514/272.000
 NCL NCLM: 514/252.180; 514/234.500
 NCLS: 514/252.140; 514/269.000; 514/272.000; 514/252.160; 514/255.050;
 514/260.100; 514/263.400; 514/275.000
 IC IPCI A61K0031-5377 [ICM,7]; A61K0031-5375 [ICM,7,C*]; A61K0031-519
 [ICS,7]; A61K0031-52 [ICS,7]; A61K0031-519 [ICS,7,C*];
 A61K0031-506 [ICS,7]
 IPCI-2 A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-505 [I,A]
 IPCR C07D0401-00 [I,C*]; C07D0401-14 [I,A]; A61K0031-00 [I,C*];
 A61K0031-00 [I,A]; A61K0031-505 [I,C*]; A61K0031-505 [I,A];
 A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-5375 [I,C*];
 A61K0031-5377 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
 A61P0013-00 [I,C*]; A61P0013-12 [I,A]; A61P0043-00 [I,C*];
 A61P0043-00 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 151 OF 152 USPAT2 on STN
Full Text
 AN 2003:65457 USPAT2
 TI 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-
 (arylcarbonyl)thiosemicarbazide and analogs as activators of caspases
 and inducers of apoptosis and the use thereof
 IN Cai, Sui Xiong, San Diego, CA, United States
 Nguyen, Bao Ngoc, San Diego, CA, United States
 Drewe, John, Carlsbad, CA, United States
 Reddy, P. Sanjeeva, San Diego, CA, United States
 Kasibhatla, Shailaja, San Diego, CA, United States
 Pervin, Azra, San Diego, CA, United States
 PA Cytovia, Inc., San Diego, CA, United States (U.S. corporation)
 PI US 6794400 B2 20040921
 AI US 2002-158827 20020603 (10)
 PRAI US 2001-294641P 20010601 (60)
 DT Utility

FS GRANTED
LN.CNT 2453
INCL INCLM: 514/357.000
INCLS: 514/406.000; 514/471.000
NCL NCLM: 514/357.000; 514/582.000
NCLS: 514/406.000; 514/471.000; 514/255.060; 514/353.000; 514/590.000
IC [7]
ICM A61K031-44
ICS A61K031-415; A61K031-34
IPCI A61K0031-175 [ICM,7]; A61K0031-17 [ICM,7,C*]; A61K0031-4965
[ICS,7]; A61K0031-44 [ICS,7]
IPCI-2 A61K0031-44 [ICM,7]; A61K0031-415 [ICS,7]; A61K0031-34 [ICS,7]
IPCR A61K0031-17 [I,C*]; A61K0031-175 [I,A]; A61K0031-435 [I,C*];
A61K0031-435 [I,A]; A61K0031-44 [I,C*]; A61K0031-44 [I,A];
A61K0031-4965 [I,C*]; A61K0031-4965 [I,A]
EXF 514/357; 514/406; 514/471
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 152 OF 152 USPAT2 on STN

Full Text

AN 2003:65422 USPAT2
TI Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators
of caspases and inducers of apoptosis and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Zhang, Han-Zhong, San Diego, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Reddy, P. Sanjeeva, San Diego, CA, UNITED STATES
Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
Kuemmerle, Jared Daniel, Del Mar, CA, UNITED STATES
Ollis, Kristin P., San Diego, CA, UNITED STATES
PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
PI US 7041685 B2 20060509
AI US 2002-164705 20020610 (10)
PRAI US 2001-296479P 20010608 (60)
DT Utility
FS GRANTED
LN.CNT 3588
INCL INCLM: 514/340.000
INCLS: 544/138.000; 544/242.000; 544/336.000; 546/135.000; 546/139.000;
546/269.400; 548/131.000; 514/364.000
NCL NCLM: 514/340.000; 514/307.000
NCLS: 514/364.000; 544/138.000; 544/242.000; 544/336.000; 546/135.000;
546/139.000; 546/269.400; 548/131.000; 514/314.000; 514/336.000;
514/362.000; 514/365.000; 514/374.000; 514/378.000; 514/397.000
IC IPCI A61K0031-4709 [ICM,7]; A61K0031-427 [ICS,7]; A61K0031-4168
[ICS,7]; A61K0031-4164 [ICS,7,C*]
IPCI-2 A61K0031-44 [I,A]; C07D0413-14 [I,A]; C07D0413-00 [I,C*]
IPCR A61K0031-335 [I,C*]; A61K0031-335 [I,A]; A61K0031-38 [I,C*];
A61K0031-38 [I,A]; A61K0031-395 [I,C*]; A61K0031-395 [I,A];
C07D0409-00 [I,C*]; C07D0409-04 [I,A]; C07D0409-14 [I,A];
C07D0413-00 [I,C*]; C07D0413-04 [I,A]; C07D0413-14 [I,A];
C07D0417-00 [I,C*]; C07D0417-14 [I,A]; C07D0471-00 [I,C*];
C07D0471-04 [I,A]; A61K0031-44 [I,A]; A61K0031-44 [I,C];
C07D0413-00 [I,C]; C07D0413-14 [I,A]
EXF 548/131; 546/269.4; 546/135; 546/139; 514/340; 514/364; 544/242;
544/138; 544/336
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> his

HIS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 01:39:32 ON 15 AUG 2008)

FILE 'REGISTRY' ENTERED AT 01:44:03 ON 15 AUG 2008

E CGP57148B/CN

E CGP 57148B/CN

L1 1 S E3

FILE 'MRCK' ENTERED AT 01:45:00 ON 15 AUG 2008

L2 1 S L1

FILE 'CA' ENTERED AT 01:45:53 ON 15 AUG 2008

L3 2285 S L1

L4 136470 S (DIABETE?)/AB,BI

L5 41 S L3 AND L4

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 01:47:44 ON 15 AUG 2008

L6 472 S L1

L7 78627 S (DIABETE?)

L8 14871 S (DIABETE?)/CLM

L9 152 S L6 AND L7

L10 152 S L6 AND L9

=> s 16 and 18

L11 18 L6 AND L8

=> d 1-18

L11 ANSWER 1 OF 18 USPATFULL on STN

Full Text

AN 2008:158973 USPATFULL

TI Methods, treatments, and compositions for modulating Hedgehog pathways

IN Jennings-Spring, Barbara L., Jupiter, FL, UNITED STATES

PI US 20080138379 A1 20080612

AI US 2007-1869 A1 20071213 (12)

RLI Continuation-in-part of Ser. No. US 2006-591398, filed on 1 Nov 2006, PENDING

DT Utility

FS APPLICATION

LN.CNT 6011

INCL INCLM: 424/423.000

INCLS: 514/129.000; 514/738.000; 424/484.000; 435/375.000; 424/400.000

NCL NCLM: 424/423.000

NCLS: 424/400.000; 424/484.000; 435/375.000; 514/129.000; 514/738.000

IC IPCI A61K0009-00 [I,A]; A61K0031-66 [I,A]; C12N0005-06 [I,A]; A61P0035-00 [I,A]; A61K0031-047 [I,A]; A61K0031-045 [I,C*]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 18 USPATFULL on STN

Full Text

AN 2008:80791 USPATFULL

TI Combination of Organic Compounds

IN Burkey, Bryan, Winchester, MA, UNITED STATES

Hughes, Thomas, Concord, MA, UNITED STATES

PI US 20080070922 A1 20080320

AI US 2005-576860 A1 20051006 (11)

WO 2005-US35917 20051006

20070406 PCT 371 date

PRAI US 2004-617201P 20041008 (60)

DT Utility

FS APPLICATION

LN.CNT 1392

INCL INCLM: 514/252.180

INCLS: 514/423.000

NCL NCLM: 514/252.180

NCLS: 514/423.000

IC IPCI A61K0031-496 [I,A]; A61K0031-40 [I,A]; A61P0015-00 [I,A]; A61P0017-00 [I,A]; A61P0027-02 [I,A]; A61P0027-00 [I,C*]; A61P0003-04 [I,A]; A61P0003-08 [I,A]; A61P0003-10 [I,A]; A61P0003-00 [I,C*]; A61P0005-00 [I,A]; A61P0009-00 [I,A]

IPCR A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-40 [I,C]; A61K0031-40 [I,A]; A61P0003-00 [I,C]; A61P0003-04 [I,A]; A61P0003-08 [I,A]; A61P0003-10 [I,A]; A61P0005-00 [I,C]; A61P0005-00 [I,A]; A61P0009-00 [I,C]; A61P0009-00 [I,A]; A61P0015-00 [I,C]; A61P0015-00 [I,A]; A61P0017-00 [I,C]; A61P0017-00 [I,A]; A61P0027-00 [I,C]; A61P0027-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 18 USPATFULL on STN

Full Text

AN 2008:51812 USPATFULL
TI Novel high affinity quinoline-based kinase ligands
IN Deng, Yongqi, Newton, MA, UNITED STATES
Curran, Patrick J., Winthrop, MA, UNITED STATES
Shipps, Gerald W., Stoneham, MA, UNITED STATES
Zhao, Lianyun, Burlington, MA, UNITED STATES
Siddiqui, M. Arshad, Newton, MA, UNITED STATES
Popovici-Muller, Janeta, Waltham, MA, UNITED STATES
Duca, Jose S., Cranford, NJ, UNITED STATES
Hruza, Alan W., Hackettstown, NJ, UNITED STATES
Fischmann, Thierry O., Scotch Plains, NJ, UNITED STATES
Madison, Vincent S., Mountain Lakes, NJ, UNITED STATES
Zhang, Rumin, Edison, NJ, UNITED STATES
McNemar, Charles W., High Bridge, NJ, UNITED STATES
Mayhood, Todd W., Randolph, NJ, UNITED STATES
Windsor, William T., East Brunswick, NJ, UNITED STATES
Lees, Emma M., Oakland, CA, UNITED STATES
Parry, David A., Mountain View, CA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20080045568 A1 20080221
AI US 2006-504869 A1 20060816 (11)
DT Utility
FS APPLICATION
LN.CNT 4013
INCL INCLM: 514/312.000
INCLS: 546/156.000; 546/159.000; 546/169.000; 514/313.000; 514/314.000
NCL NCLM: 514/312.000
NCLS: 514/313.000; 514/314.000; 546/156.000; 546/159.000; 546/169.000
IC IPCI A61K0031-4709 [I,A]; A61K0031-4706 [I,A]; C07D0215-38 [I,A];
C07D0215-00 [I,C*]
IPCR A61K0031-4709 [I,C]; A61K0031-4709 [I,A]; A61K0031-4706 [I,C];
A61K0031-4706 [I,A]; C07D0215-00 [I,C]; C07D0215-38 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 18 USPATFULL on STN

Full Text

AN 2007:285091 USPATFULL
TI Substituted CIS- and trans-stilbenes as therapeutic agents
IN Vander Jagt, David L., Albuquerque, NM, UNITED STATES
Deck, Lorraine M., Albuquerque, NM, UNITED STATES
PI US 20070249647 A1 20071025
AI US 2007-789583 A1 20070425 (11)
PRAI US 2006-794765P 20060425 (60)
DT Utility
FS APPLICATION
LN.CNT 2051
INCL INCLM: 514/277.000
INCLS: 514/438.000; 514/733.000; 514/720.000; 514/034.000; 514/492.000;
514/109.000; 514/027.000; 514/049.000; 514/262.100; 514 8;
514/406.000; 424/623.000; 514/283.000; 424/094.630; 514/559.000;
424/085.700; 514/251.000; 514/651.000; 546/339.000; 549/078.000
NCL NCLM: 514/277.000
NCLS: 424/085.700; 424/094.630; 424/623.000; 514/008.000; 514/027.000;
514/034.000; 514/049.000; 514/109.000; 514/251.000; 514/262.100;
514/283.000; 514/406.000; 514/438.000; 514/492.000; 514/559.000;
514/651.000; 514/720.000; 514/733.000; 546/339.000; 549/078.000
IC IPCI A61K0031-44 [I,A]; A61K0031-381 [I,A]; C07D0333-16 [I,A];
C07D0333-00 [I,C*]; A61K0038-48 [I,A]; A61K0038-43 [I,C*];
A61K0038-21 [I,A]; A61K0031-66 [I,A]; A61K0031-525 [I,A];
A61K0031-519 [I,C*]
IPCR A61K0031-44 [I,C]; A61K0031-44 [I,A]; A61K0031-381 [I,C];
A61K0031-381 [I,A]; A61K0031-519 [I,C]; A61K0031-525 [I,A];
A61K0031-66 [I,C]; A61K0031-66 [I,A]; A61K0038-21 [I,C];
A61K0038-21 [I,A]; A61K0038-43 [I,C]; A61K0038-48 [I,A];
C07D0333-00 [I,C]; C07D0333-16 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 18 USPATFULL on STN

Full Text

AN 2007:256682 USPATFULL

TI Site-specific enzymatic deposition of metal in situ
 IN Hainfeld, James F., Shoreham, NY, UNITED STATES
 Liu, Wenqiu, Miller Place, NY, UNITED STATES
 PI US 20070224625 A1 20070927
 AI US 2007-714682 A1 20070305 (11)
 RLI Continuation-in-part of Ser. No. US 2007-627735, filed on 26 Jan 2007,
 PENDING Division of Ser. No. US 2003-658609, filed on 8 Sep 2003,
 GRANTED, Pat. No. US 7183072 Continuation-in-part of Ser. No. US
 2001-822131, filed on 30 Mar 2001, GRANTED, Pat. No. US 6670113
 DT Utility
 FS APPLICATION
 LN.CNT 2966
 INCL INCLM: 435/006.000
 INCLS: 435/183.000; 435/007.940
 NCL NCLM: 435/006.000
 NCLS: 435/007.940; 435/183.000
 IC IPCI G01N0033-53 [I,A]; C12N0009-00 [I,A]; C12Q0001-68 [I,A]
 IPCR G01N0033-53 [I,C]; G01N0033-53 [I,A]; C12N0009-00 [I,C];
 C12N0009-00 [I,A]; C12Q0001-68 [I,C]; C12Q0001-68 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 18 USPATFULL on STN

Full Text

AN 2007:170821 USPATFULL
 TI Six membered heteroaromatic inhibitors targeting resistant kinase
 mutations
 IN Noronha, Glenn, Oceanside, CA, UNITED STATES
 Cao, Jianguo, San Diego, CA, UNITED STATES
 Zeng, Binqi, San Diego, CA, UNITED STATES
 Mak, Chi Ching, San Diego, CA, UNITED STATES
 McPherson, Andrew, San Diego, CA, UNITED STATES
 Renick, Joel, San Diego, CA, UNITED STATES
 Pathak, Ved P., San Diego, CA, UNITED STATES
 Chow, Chun, San Diego, CA, UNITED STATES
 Palanki, Moorthy, Encinitas, CA, UNITED STATES
 Soll, Richard M., San Diego, CA, UNITED STATES
 Lohse, Daniel L., San Diego, CA, UNITED STATES
 Hood, John D., San Diego, CA, UNITED STATES
 Dneprovskaia, Elena, San Diego, CA, UNITED STATES
 PA TargeGen, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 20070149508 A1 20070628
 AI US 2006-591076 A1 20061031 (11)
 PRAI US 2005-733115P 20051102 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 9660
 INCL INCLM: 514/218.000
 INCLS: 514/242.000; 514/252.140; 514/256.000; 540/575.000; 544/295.000;
 544/333.000; 544/182.000
 NCL NCLM: 514/218.000
 NCLS: 514/242.000; 514/252.140; 514/256.000; 540/575.000; 544/182.000;
 544/295.000; 544/333.000
 IC IPCI A61K0031-551 [I,A]; A61K0031-53 [I,A]; A61K0031-506 [I,A];
 C07D0403-02 [I,A]; C07D0403-00 [I,C*]
 IPCR A61K0031-551 [I,C]; A61K0031-551 [I,A]; A61K0031-506 [I,C];
 A61K0031-506 [I,A]; A61K0031-53 [I,C]; A61K0031-53 [I,A];
 C07D0403-00 [I,C]; C07D0403-02 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 18 USPATFULL on STN

Full Text

AN 2007:170797 USPATFULL
 TI NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES
 IN Claus, Eckhard, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 Seipelt, Irene, Offenbach, GERMANY, FEDERAL REPUBLIC OF
 Guenther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
 Polymeropoulos, Emmanuel, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 Czech, Michael, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 Schuster, Tilmann, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 PA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S.
 corporation)
 PI US 20070149484 A1 20070628

AI US 2006-558503 A1 20061110 (11)
 PRAI US 2006-849761P 20061006 (60)
 US 2005-735698P 20051111 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 15167
 INCL INCLM: 514/081.000
 INCLS: 514/249.000; 544/350.000; 544/337.000
 NCL NCLM: 514/081.000
 NCLS: 514/249.000; 544/337.000; 544/350.000
 IC IPCI A61K0031-675 [I,A]; C07D0487-02 [I,A]; C07D0487-00 [I,C*];
 A61K0031-498 [I,A]
 IPCR A61K0031-675 [I,C]; A61K0031-675 [I,A]; A61K0031-498 [I,C];
 A61K0031-498 [I,A]; C07D0487-00 [I,C]; C07D0487-02 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 18 USPATFULL on STN

Full Text

AN 2007:141503 USPATFULL
 TI PYRIDOPYRAZINE DERIVATIVES AND THEIR USE
 IN SEIPELT, Irene, Offenbach, GERMANY, FEDERAL REPUBLIC OF
 Claus, Eckhard, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 Guenther, Eckhard, Maintal, GERMANY, FEDERAL REPUBLIC OF
 Schuster, Tilmann, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 Czech, Michael, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 Polymeropoulos, Emmanuel, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 PA ZENTARIS GmbH, Frankfurt, GERMANY, FEDERAL REPUBLIC OF (non-U.S.
 corporation)
 PI US 20070123494 A1 20070531
 AI US 2006-558493 A1 20061110 (11)
 PRAI US 2005-735707P 20051111 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4048
 INCL INCLM: 514/081.000
 INCLS: 514/249.000; 544/350.000; 544/295.000; 544/237.000; 544/238.000;
 514/224.800; 514/234.500; 544/125.000; 544/118.000; 544/051.000
 NCL NCLM: 514/081.000
 NCLS: 514/224.800; 514/234.500; 514/249.000; 544/051.000; 544/118.000;
 544/125.000; 544/237.000; 544/238.000; 544/295.000; 544/350.000
 IC IPCI A61K0031-5415 [I,A]; A61K0031-5377 [I,A]; A61K0031-5375 [I,C*];
 A61K0031-506 [I,A]; A61K0031-501 [I,A]; A61K0031-498 [I,A];
 C07D0487-02 [I,A]; C07D0487-00 [I,C*]
 IPCR A61K0031-5415 [I,C]; A61K0031-5415 [I,A]; A61K0031-498 [I,C];
 A61K0031-498 [I,A]; A61K0031-501 [I,C]; A61K0031-501 [I,A];
 A61K0031-506 [I,C]; A61K0031-506 [I,A]; A61K0031-5375 [I,C];
 A61K0031-5377 [I,A]; C07D0487-00 [I,C]; C07D0487-02 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 18 USPATFULL on STN

Full Text

AN 2007:83463 USPATFULL
 TI Use of tyrosine kinase inhibitor to treat diabetes
 IN Hagerkvist, Robert Per, Hoganasgatan 7B, Uppsala, SWEDEN 75330
 Welsh, Nils Richard, Uppsala, SWEDEN
 PI US 20070072932 A1 20070329
 AI US 2004-556984 A1 20040526 (10)
 WO 2004-EP5679 20040526
 20060622 PCT 371 date
 PRAI GB 2003-12086 20030527
 GB 2004-2682 20040206
 DT Utility
 FS APPLICATION
 LN.CNT 857
 INCL INCLM: 514/414.000
 NCL NCLM: 514/414.000
 IC IPCI A61K0031-40 [I,A]
 IPCR A61K0031-40 [I,C]; A61K0031-40 [I,A]; A61K0031-403 [I,C*];
 A61K0031-404 [I,A]; A61K0031-42 [I,C*]; A61K0031-42 [I,A];
 A61K0031-4353 [I,C*]; A61K0031-437 [I,A]; A61K0031-47 [I,C*];
 A61K0031-47 [I,A]; A61K0031-498 [I,C*]; A61K0031-498 [I,A];
 A61K0031-506 [I,C*]; A61K0031-506 [I,A]; A61K0031-517 [I,C*];

A61K0031-517 [I,A]; A61K0031-519 [I,C*]; A61K0031-519 [I,A];
A61P0003-00 [I,C*]; A61P0003-10 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 18 USPATFULL on STN

Full Text

AN 2007:83394 USPATFULL
TI Bis-aryl amide compounds and methods of use
IN Dimauro, Erin F., Cambridge, MA, UNITED STATES
Bemis, Jean E., Arlington, MA, UNITED STATES
Chaffee, Stuart C., Philadelphia, PA, UNITED STATES
Chen, Ning, Thousand Oaks, CA, UNITED STATES
Hu, Essu, Camarillo, CA, UNITED STATES
Kunz, Roxanne, Santa Monica, CA, UNITED STATES
Martin, Matthew W., Cambridge, MA, UNITED STATES
McGowan, David C., Woluwe St. Pierre, BELGIUM
Rumfelt, Shannon, Camarillo, CA, UNITED STATES
PI US 20070072862 A1 20070329
AI US 2006-503551 A1 20060811 (11)
PRAI US 2005-708720P 20050815 (60)
DT Utility
FS APPLICATION
LN.CNT 6229
INCL INCLM: 514/248.000
INCLS: 514/252.030; 514/252.050; 514/249.000; 514/255.050; 514/256.000;
514/300.000; 514/314.000; 544/237.000; 544/238.000; 544/333.000;
544/405.000; 544/353.000; 546/122.000; 546/169.000
NCL NCLM: 514/248.000
NCLS: 514/249.000; 514/252.030; 514/252.050; 514/255.050; 514/256.000;
514/300.000; 514/314.000; 544/237.000; 544/238.000; 544/333.000;
544/353.000; 544/405.000; 546/122.000; 546/169.000
IC IPCI A61K0031-506 [I,A]; A61K0031-502 [I,A]; A61K0031-501 [I,A];
A61K0031-497 [I,A]; A61K0031-4965 [I,C*]; A61K0031-498 [I,A];
A61K0031-4745 [I,A]; A61K0031-4738 [I,C*]; A61K0031-4709 [I,A]
IPCR A61K0031-506 [I,C]; A61K0031-506 [I,A]; A61K0031-4709 [I,C];
A61K0031-4709 [I,A]; A61K0031-4738 [I,C]; A61K0031-4745 [I,A];
A61K0031-4965 [I,C]; A61K0031-497 [I,A]; A61K0031-498 [I,C];
A61K0031-498 [I,A]; A61K0031-501 [I,C]; A61K0031-501 [I,A];
A61K0031-502 [I,C]; A61K0031-502 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 18 USPATFULL on STN

Full Text

AN 2007:49219 USPATFULL
TI Novel high affinity thiophene-based and furan-based kinase ligands
IN Deng, Yongqi, Newton, MA, UNITED STATES
Zhao, Lianyun, Burlington, MA, UNITED STATES
Shipp, Gerald W. JR., Stoneham, MA, UNITED STATES
Curran, Patrick J., Winthrop, MA, UNITED STATES
Siddiqui, M. Arshad, Newton, MA, UNITED STATES
Zhang, Rumin, Edison, NJ, UNITED STATES
McNemar, Charles W., High Bridge, NJ, UNITED STATES
Mayhood, Todd W., Randolph, NJ, UNITED STATES
Windsor, William T., East Brunswick, NJ, UNITED STATES
Lees, Emma M., Oakland, CA, UNITED STATES
Parry, David A., Mountain View, CA, UNITED STATES
PA Schering Corporation (U.S. corporation)
PI US 20070043045 A1 20070222
AI US 2006-505263 A1 20060816 (11)
PRAI US 2005-709143P 20050817 (60)
DT Utility
FS APPLICATION
LN.CNT 2753
INCL INCLM: 514/235.200
INCLS: 514/422.000; 514/447.000; 514/471.000; 514/255.050; 514/326.000;
514/340.000; 514/383.000; 514/378.000; 514/362.000; 514/397.000;
514/406.000; 514/374.000; 514/314.000; 514/249.000; 514/367.000;
544/142.000; 544/146.000; 544/333.000; 544/405.000; 544/373.000;
546/176.000; 546/207.000; 546/276.400; 546/280.400; 548/154.000;
548/152.000; 548/266.200; 548/252.000; 548/242.000; 548/311.100;
548/527.000; 548/517.000
NCL NCLM: 514/235.200

NCLS: 514/249.000; 514/255.050; 514/314.000; 514/326.000; 514/340.000;
514/362.000; 514/367.000; 514/374.000; 514/378.000; 514/383.000;
514/397.000; 514/406.000; 514/422.000; 514/447.000; 514/471.000;
544/142.000; 544/146.000; 544/333.000; 544/373.000; 544/405.000;
546/176.000; 546/207.000; 546/276.400; 546/280.400; 548/152.000;
548/154.000; 548/242.000; 548/252.000; 548/266.200; 548/311.100;
548/517.000; 548/527.000

IC IPCI A61K0031-5377 [I,A]; A61K0031-5375 [I,C*]; A61K0031-497 [I,A];
A61K0031-4965 [I,C*]; A61K0031-496 [I,A]; A61K0031-4439 [I,A];
A61K0031-4427 [I,C*]; A61K0031-4709 [I,A]; A61K0031-428 [I,A];
A61K0031-42 [I,A]; A61K0031-4196 [I,A]; A61K0031-4178 [I,A];
A61K0031-4164 [I,C*]; A61K0031-4025 [I,A]; A61K0031-416 [I,A];
C07D0413-02 [I,A]; C07D0413-00 [I,C*]; C07D0405-02 [I,A];
C07D0405-00 [I,C*]; C07D0409-02 [I,A]; C07D0409-00 [I,C*];
C07D0417-02 [I,A]; C07D0417-00 [I,C*]

IPCR A61K0031-5375 [I,C]; A61K0031-5377 [I,A]; A61K0031-4025 [I,C];
A61K0031-4025 [I,A]; A61K0031-416 [I,C]; A61K0031-416 [I,A];
A61K0031-4164 [I,C]; A61K0031-4178 [I,A]; A61K0031-4196 [I,C];
A61K0031-4196 [I,A]; A61K0031-42 [I,C]; A61K0031-42 [I,A];
A61K0031-428 [I,C]; A61K0031-428 [I,A]; A61K0031-4427 [I,C];
A61K0031-4439 [I,A]; A61K0031-4709 [I,C]; A61K0031-4709 [I,A];
A61K0031-496 [I,C]; A61K0031-496 [I,A]; A61K0031-4965 [I,C];
A61K0031-497 [I,A]; C07D0405-00 [I,C]; C07D0405-02 [I,A];
C07D0409-00 [I,C]; C07D0409-02 [I,A]; C07D0413-00 [I,C];
C07D0413-02 [I,A]; C07D0417-00 [I,C]; C07D0417-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 18 USPATFULL on STN

Full Text

AN 2007:36890 USPATFULL

TI Peptides and peptide mimetics to treat pathologies characterized by an
inflammatory response

IN Fogelman, Alan M., Beverly Hills, CA, UNITED STATES
Navab, Mohamad, Los Angeles, CA, UNITED STATES

PA The Regents of the University of California (U.S. corporation)

PI US 20070032430 A1 20070208

AI US 2006-407390 A1 20060418 (11)

RLI Continuation-in-part of Ser. No. US 2003-423830, filed on 25 Apr 2003,
PENDING Continuation-in-part of Ser. No. US 2002-273386, filed on 16 Oct
2002, PENDING Continuation-in-part of Ser. No. US 2002-187215, filed on
28 Jun 2002, GRANTED, Pat. No. US 7144862 Continuation-in-part of Ser.
No. US 2001-896841, filed on 29 Jun 2001, GRANTED, Pat. No. US 6933279
Continuation-in-part of Ser. No. US 2000-645454, filed on 24 Aug 2000,
GRANTED, Pat. No. US 6664230

PRAI US 2005-697495P 20050707 (60)
US 2005-676431P 20050429 (60)

DT Utility

FS APPLICATION

LN.CNT 10947

INCL INCLM: 514/013.000
INCLS: 530/326.000

NCL NCLM: 514/013.000
NCLS: 530/326.000

IC IPCI A61K0038-10 [I,A]; C07K0007-08 [I,A]; C07K0007-00 [I,C*]
IPCR A61K0038-10 [I,C]; A61K0038-10 [I,A]; C07K0007-00 [I,C];
C07K0007-08 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 18 USPATFULL on STN

Full Text

AN 2006:137823 USPATFULL

TI Therapeutic target and uses thereof

IN Little, Peter James, Victoria, AUSTRALIA

PI US 20060116403 A1 20060601

AI US 2003-515393 A1 20030520 (10)
WO 2003-AU608 20030520
20051219 PCT 371 date

PRAI AU 2002-2430 20020520

DT Utility

FS APPLICATION

LN.CNT 1395

INCL INCLM: 514/352.000

NCL NCLM: 514/352.000
IC IPCI A61K0031-44 [I,A]
IPCR A61K0031-44 [I,A]; A61K0031-44 [I,C]; A61K0031-506 [I,C*];
A61K0031-506 [I,A]; A61K0045-00 [I,C*]; A61K0045-06 [I,A];
A61P0009-00 [I,C*]; A61P0009-10 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 18 USPATFULL on STN

Full Text

AN 2006:131781 USPATFULL
TI Use of diindolylmethane-related indoles and growth factor receptor
inhibitors for the treatment of human cytomegalovirus-associated disease
IN Zeligs, Michael A., Boulder, CO, UNITED STATES
PI US 20060111423 A1 20060525
AI US 2005-260543 A1 20051026 (11)
PRAI US 2004-622333P 20041026 (60)
DT Utility
FS APPLICATION
LN.CNT 2738
INCL INCLM: 514/410.000
INCLS: 514/414.000; 514/151.000
NCL NCLM: 514/410.000
NCLS: 514/151.000; 514/414.000
IC IPCI A61K0031-655 [I,A]; A61K0031-405 [I,A]; A61K0031-403 [I,C*];
A61K0031-407 [I,A]
IPCR A61K0031-655 [I,A]; A61K0031-403 [I,C]; A61K0031-405 [I,A];
A61K0031-407 [I,C]; A61K0031-407 [I,A]; A61K0031-655 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 18 USPATFULL on STN

Full Text

AN 2005:44347 USPATFULL
TI Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and
prevention of diseases and conditions
IN Boyer, Stephen, Hilden, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Bethany, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Wilhelm, Scott, Orange, CT, UNITED STATES
PI US 20050038080 A1 20050217
AI US 2004-895985 A1 20040722 (10)
PRAI US 2003-489102P 20030723 (60)
US 2004-540326P 20040202 (60)
DT Utility
FS APPLICATION
LN.CNT 2492
INCL INCLM: 514/350.000
INCLS: 546/298.000
NCL NCLM: 514/350.000
NCLS: 546/298.000
IC [7]
ICM A61K031-675
ICS C07D213-78; A61K031-4415
IPCI A61K0031-675 [ICM,7]; C07D0213-78 [ICS,7]; C07D0213-00
[ICS,7,C*]; A61K0031-4415 [ICS,7]
IPCR A61K0031-44 [I,C*]; A61K0031-44 [I,A]; A61K0031-4415 [I,C*];
A61K0031-4415 [I,A]; A61K0031-675 [I,C*]; A61K0031-675 [I,A];
A61P0035-00 [I,C*]; A61P0035-00 [I,A]; C07D0213-00 [I,C*];
C07D0213-78 [I,A]; C07D0213-81 [I,A]; C07D0213-00 [I,C*]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 18 USPATFULL on STN

Full Text

AN 2005:38145 USPATFULL
TI Phosphorus-containing compounds and uses thereof
IN Metcalf, Chester A., III, Needham, MA, UNITED STATES
Rozamus, Leonard W., Bedford, MA, UNITED STATES
Wang, Yihan, Newton, MA, UNITED STATES
Bernstein, David L., Waban, MA, UNITED STATES
PI US 20050032825 A1 20050210
US 7091213 B2 20060815
AI US 2004-862149 A1 20040604 (10)
RLI Continuation-in-part of Ser. No. US 2003-635054, filed on 6 Aug 2003,

PENDING Continuation-in-part of Ser. No. US 2003-357152, filed on 3 Feb 2003, PENDING

PRAI US 2002-353252P 20020201 (60)
US 2002-426928P 20021115 (60)
US 2002-428383P 20021122 (60)
US 2002-433930P 20021217 (60)
DT Utility
FS APPLICATION
LN.CNT 3716
INCL INCLM: 514/291.000
INCLS: 540/456.000; 514/080.000
NCL NCLM: 514/291.000
NCLS: 540/456.000; 514/080.000
IC [7]
ICM A61K031-675
ICS A61K031-4745
IPCI A61K0031-675 [ICM,7]; A61K0031-4745 [ICS,7]; A61K0031-4738
[ICS,7,C*]
IPCI-2 C07D0491-06 [I,A]; C07D0491-00 [I,C*]; A61K0031-395 [I,A];
A61P0035-00 [I,A]; A61P0035-02 [I,A]
IPCR A61L0027-00 [I,C*]; A61L0027-00 [I,A]; A61F0002-82 [I,C*];
A61F0002-84 [I,A]; A61K0031-661 [I,C*]; A61K0031-661 [I,A];
A61K0031-662 [I,C*]; A61K0031-662 [I,A]; A61K0031-664 [I,C*];
A61K0031-664 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
A61K0045-06 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A];
A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*];
A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0011-00 [I,C*];
A61P0011-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-02 [I,A];
A61P0017-04 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C*];
A61P0019-02 [I,A]; A61P0021-00 [I,C*]; A61P0021-04 [I,A];
A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-28 [I,A];
A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*];
A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-10 [I,A];
A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A];
A61P0037-00 [I,C*]; A61P0037-00 [I,A]; C07D0498-00 [I,C*];
C07D0498-18 [I,A]; C07F0009-00 [I,C*]; C07F0009-09 [I,A];
C07F0009-22 [I,A]; C07F0009-32 [I,A]; C07F0009-36 [I,A];
C07F0009-40 [I,A]; C07F0009-44 [I,A]; C07F0009-46 [I,A];
C07F0009-53 [I,A]; C07F0009-6561 [I,A]; C07D0491-00 [I,C];
C07D0491-06 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A];
A61P0035-00 [I,C]; A61P0035-00 [I,A]; A61P0035-02 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 18 USPAT2 on STN

Full Text

AN 2005:38145 USPAT2
TI Phosphorus-containing compounds and uses thereof
IN Metcalf, lll, Chester A., Needham, MA, UNITED STATES
Rozamus, Leonard W., Bedford, MA, UNITED STATES
Wang, Yihan, Newton, MA, UNITED STATES
Bernstein, David L., Waban, MA, UNITED STATES
PA ARIAD Gene Therapeutics, Inc., Cambridge, MA, UNITED STATES (U.S.
corporation)
PI US 7091213 B2 20060815
AI US 2004-862149 20040604 (10)
RLI Continuation-in-part of Ser. No. US 2003-635054, filed on 6 Aug 2003,
ABANDONED Continuation-in-part of Ser. No. US 2003-357152, filed on 3
Feb 2003, ABANDONED
PRAI US 2002-433930P 20021217 (60)
US 2002-428383P 20021122 (60)
US 2002-426928P 20021115 (60)
US 2002-353252P 20020201 (60)
DT Utility
FS GRANTED
LN.CNT 3763
INCL INCLM: 514/291.000
INCLS: 540/456.000
NCL NCLM: 514/291.000
NCLS: 540/456.000; 514/080.000
IC IPCI A61K0031-675 [ICM,7]; A61K0031-4745 [ICS,7]; A61K0031-4738
[ICS,7,C*]
IPCI-2 C07D0491-06 [I,A]; C07D0491-00 [I,C*]; A61K0031-395 [I,A];

IPCR A61P0035-00 [I,A]; A61P0035-02 [I,A]
 A61L0027-00 [I,C*]; A61L0027-00 [I,A]; A61F0002-82 [I,C*];
 A61F0002-84 [I,A]; A61K0031-661 [I,C*]; A61K0031-661 [I,A];
 A61K0031-662 [I,C*]; A61K0031-662 [I,A]; A61K0031-664 [I,C*];
 A61K0031-664 [I,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A];
 A61K0045-06 [I,A]; A61P0001-00 [I,C*]; A61P0001-04 [I,A];
 A61P0003-00 [I,C*]; A61P0003-10 [I,A]; A61P0009-00 [I,C*];
 A61P0009-00 [I,A]; A61P0009-10 [I,A]; A61P0011-00 [I,C*];
 A61P0011-00 [I,A]; A61P0017-00 [I,C*]; A61P0017-02 [I,A];
 A61P0017-04 [I,A]; A61P0017-06 [I,A]; A61P0019-00 [I,C*];
 A61P0019-02 [I,A]; A61P0021-00 [I,C*]; A61P0021-04 [I,A];
 A61P0025-00 [I,C*]; A61P0025-00 [I,A]; A61P0025-28 [I,A];
 A61P0027-00 [I,C*]; A61P0027-02 [I,A]; A61P0029-00 [I,C*];
 A61P0029-00 [I,A]; A61P0031-00 [I,C*]; A61P0031-10 [I,A];
 A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A];
 A61P0037-00 [I,C*]; A61P0037-00 [I,A]; C07D0498-00 [I,C*];
 C07D0498-18 [I,A]; C07F0009-00 [I,C*]; C07F0009-09 [I,A];
 C07F0009-22 [I,A]; C07F0009-32 [I,A]; C07F0009-36 [I,A];
 C07F0009-40 [I,A]; C07F0009-44 [I,A]; C07F0009-46 [I,A];
 C07F0009-53 [I,A]; C07F0009-6561 [I,A]; C07D0491-00 [I,C];
 C07D0491-06 [I,A]; A61K0031-395 [I,C]; A61K0031-395 [I,A];
 A61P0035-00 [I,C]; A61P0035-00 [I,A]; A61P0035-02 [I,A]
 EXF 540/456; 514/291
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 18 USPAT2 on STN

Full Text

AN 2004:107666 USPAT2
 TI Derivatives of gambogic acid and analogs as activators of caspases and
 inducers of apoptosis
 IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Kasibhatla, Shailaja, San Diego, CA, UNITED STATES
 Ollis, Kristin P., San Diego, CA, UNITED STATES
 Zhang, Han-Zhong, San Diego, CA, UNITED STATES
 Drewe, John A., Carlsbad, CA, UNITED STATES
 Tseng, Ben, San Diego, CA, UNITED STATES
 Sirisoma, Nilantha Sudath, San Diego, CA, UNITED STATES
 PA Cytovia, Inc., San Diego, CA, UNITED STATES (U.S. corporation)
 PI US 7176234 B2 20070213
 AI US 2003-609670 20030701 (10)
 PRAI US 2002-413649P 20020926 (60)
 US 2002-392358P 20020701 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2753
 INCL INCLM: 514/450.000
 INCLS: 549/268.000
 NCL NCLM: 514/450.000; 435/375.000
 NCLS: 549/268.000
 IC IPCI C12N0005-00 [ICM,7]; C12N0005-02 [ICS,7]
 IPCI-2 A61K0031-352 [I,A]; C07D0313-06 [I,A]; C07D0313-00 [I,C*]
 IPCR A61K0031-352 [I,C]; A61K0031-352 [I,A]; C07D0313-00 [I,C];
 C07D0313-06 [I,A]; C07D0493-00 [I,C*]; C07D0493-20 [I,A];
 C12N0005-02 [I,C*]; C12N0005-02 [I,A]
 EXF 514/450; 549/268
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	189.06	254.56

STN INTERNATIONAL LOGOFF AT 01:51:28 ON 15 AUG 2008